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1Summary
The ms oncogene family has been implicated in the growth and 
development of a high percentage of human tumours. However, the 
biochemical role of p2 1  the protein encoded by this oncogene, is not 
well defined. Therefore, the effects of p21 ^  transformation of murine 
fibroblasts on cellular signal transduction were investigated. The study 
utilised a clone of NIH3T3 cells which overexpressed the p21 N-ras proto­
oncogene in the presence of a glucocorticoid inducer. Overexpression of 
p21 N-ras in this cell line results in uncontrolled cell proliferation and 
transformation. The effects of transformation on growth factor mediated 
signal transduction pathways were studied.
Data obtained from these studies indicate that p2 1  N-ras 
overexpression may have a direct role in cell proliferation by causing the 
amplification of growth factor stimulated inositol phosphate production 
without a change in the basal levels of inositol phosphates. Bombesin 
stimulated inositol phosphate production in p21 N-ras transformed NIH3T3 
cells occurs as a consequence of receptor mediated phosphoinositide 
specific phospholipase C activation. This results in the production of 
inositol 1,4,5 trisphosphate which acts as a calcium mobilising second 
messenger. This effect of p21 N-ras overexpression occurs at the post- 
receptor level, does not involve the guanine nucleotide binding proteins of 
the adenylate cyclase system and suggests that p2 1  N^ras may act as a 
coupling protein to mediate receptor activated phosphoinositide signal 
transduction in this cell line. Therefore, this evidence demonstrates that 
overexpressed p21 N-ras directly causes an amplification in growth factor 
stimulated inositol phosphate production which may act as an initial signal 
for cell proliferation.
This study also indicates that p21 N-ras overexpression results in 
reduced intracellular levels of cyclic AMP which are associated with rapidly 
proliferating cells. However, it is probable that this effect of p21 N-ras on 
the adenylate cyclase system is indirect and a consequence of protein kinase
2C activation upon p2 1  N-ras overexpression.
The results from this study are consistent with some reports in the 
literature on the function of p2 1  His in cen proliferation and transformation. 
It appears that p21 N-ras overexpression may induce rapid proliferation and 
consequent transformation of murine fibroblasts by the modulation of two 
major signal transduction pathways in this cell line.
3Chapter 1; Introduction
1. Malignant transformation and the cancer cell
A cancer cell is defined by certain characteristics that make it distinct 
from normal cells. Some of these are the morphological transformation of 
the cells and their ability to proliferate rapidly, their invasion of other 
surrounding tissue and their non-differentiated state. Some of these 
characteristics are associated with cells in the early stages of embryogenesis 
and are only transiendy expressed. The development of cancer then, may be 
associated with a loss of control over key events which influence normal 
cell proliferation.
The development of a transformed cell and therefore, cancer, is now 
recognised to be a multistage process involving genetic lesions and the 
deregulation of normal growth control pathways. (Spandidos, 1986; 
Ohlsson and Pfeiffer-Ohlsson, 1987)
A. Transformation as an effect of genetic changes.
The genetic changes associated with cellular transformation have 
been studied in detail (Marshall, 1985; Bishop, 1985) and constitute a major 
cause of cancer development.
Mutation of certain genes can cause cellular transformation as has 
been shown with the Harvev-ras-1 oncogene in the T24 human bladder 
carcinoma cell line (Tabin et al, 1982). Point mutations within this gene 
sequence leading to a single amino acid substitution in the gene product can 
cause activation of the encoded protein resulting in cellular transformation.
It has also been shown that amplification of several gene families including 
myc, mvb and erb-B have been found in several tumour cell lines and in 
tumour tissue isolated from cancer patients (Alitalo et aL 1985). Other 
genetic changes include chromosome translocation, where it occurs in 
Burkitt’s lymphoma and transduction events by retroviral vectors (Alitalo,
1987). The transduction event occurs when a slow transforming virus
4recombines with cellular proto-oncogenes resulting in an activated 
transduced oncogene. At least twenty different transforming oncogenes are 
a result of this type of genetic rearrangment, including v-src. v-ros. v- 
Kirsten-ras, v-Harvey-ras and v-erb-A.
B.Oncogenes and growth regulatory pathways.
An oncogene is defined as a sequence of DNA that will cause 
cellular transformation in vitro and will be tumoregenic in vivo. An activated 
oncogene may be a result of retroviral transduction, as already described 
above, ie a v-onc, or by other genetic mechanisms which include DNA 
hypermethylation resulting in a mutated cellular oncogene, c-onc (See 
Marshall, 1985). Oncogenes fall into distinct groups according to the 
location of the protein product in the cell. Table 1 shows some oncogene 
families and their protein products:
5IaM fi-1
Oncogene
sis
m
erb-B
ros
fms
ras
mil
mvc
fos
mvb
iun
Heldin et al (1987)
Protein Cellular location
p28 SIS Extracellular
B chain PDGF
pp60 SIS Inner surface plasma
membrane 
Truncated EGF Plasma membrane 
receptor
receptor? Plasma membrane
CSF-1 Plasma membrane
receptor
p21 ISS Plasma membrane
p71/p73 Cytoplasm
doublet
p58 c-myc Nucleus
p5 5  c-fos Nucleus
p7 5  c-myb Nucleus
p3 9 C-jun Nucleus
Function 
Growth factor
Tyrosine kinase 
Tyrosine kinase
Growth factor receptor 
and tyrosine kinase 
Growth factor receptor 
and tyrosine kinase
?
Serine/threonine
kinase
DNA binding
DNA binding
DNA binding
Mammalian 
transcription factor 
AP-1, binds 
p55 c-fQS
6The effect of activated oncogenes on cellular transformation is 
mediated by either growth factor interactions at the cell surface or by events 
associated with the nucleus. It is possible that the cytoplasmic oncogene 
products of mos and rof also have functions in cell transformation but the functions of the 
protein products of thes&oncogenes have not been identified.
The sis oncogene transduced by the Simian Sarcoma Virus (SS V), 
v-sis and the cellular counterpart, c-sis both encode the B chain of PDGF. It 
has been shown that antibodies to PDGF will reverse morphological 
transformation to the normal phenotype (Johnsson et aL 1985) and[ that 
suramin, which blocks PDGF binding to its receptor (Williams et al, 1984) 
will also abolish transformation (Betsholtz et al, 1986). The sis oncogene 
thus acts directly to increase the rate of cell proliferation by its direct action 
as a growth factor.
In contrast, the v-erb-B oncogene encodes a truncated form of the 
EGF receptor which lacks the EGF binding and autophosphorylation 
domains. The tyrosine kinase domain is intact and seems esscnVvA to cell 
transformation (Livneh et al, 1986). The aberrant EGF receptor synthesised 
as a result of v-erb B expression may be constitutively activated as a result 
of the lack of autophosphorylation and EGF binding sites. The oncogenic 
effects must therefore be mediated solely through the tyrosine kinase 
activity of the receptor.
It is notable that a large number of oncogene families exert their 
effects via tyrosine phosphorylation, however, the major substrates for 
these kinases remain to be identified.
The expression of nuclear oncogenes, c-myc and c-fos have been 
implicated in the control of DNA synthesis as they bind to DNA at specific 
sites (Heldin et al, 1987). These oncogenes are also co-expressed with 
oncogene products at the plasma membrane, for example, c-myc and the ras 
oncogene are co-expressed in transformed primary and secondary rat
7embryo cells ( Land et aL 1983; Schwab et al, 1985). This indicates that 
oncogene cooperativity is a necessary event for cell transformation in some 
systems. Also, the expression of the EJ c-Ha-ras-1 oncogene lacks 
complete transforming ability when injected into normal NIH3T3 fibroblasts 
with a limited life span but can transform fibroblasts immortalised by 
carcinogens (Newbold and Overell, 1983). This indicates that the 
expression of this oncogene is not sufficient to transform these cells and 
that in carcinogen transformed cells there may be other oncogenes expressed 
which co-transform the cells when the c-Ha-ras oncogene is expressed.
Growth factor signalling pathways can also induce oncogene 
expression. It has been demonstrated that PDGF, EGF and FGF can induce 
c-myc and c-fos expression in fibroblasts. In the case of c-fos. this is 
mediated through a serum-responsive element ( a DNA sequence) which 
binds a phosphoprotein, the serum-responsive factor (SRF) which then 
activates c-fos expression in response to serum (Treisman, 1986).The 
importance of coordinated oncogene expression between oncogene products 
at the cell surface and the nucleus in cell proliferation and transformation has 
been demonstrated in several experimental systems apart from the examples 
cited above. The existence of oncogene products as either growth factors or 
growth factor recptors indicates that the growth factor regulatory pathways 
are crucial in the development and maintenance of tumouregenesis both in 
vitro and in vivo and indicates the importance of tight regulation of these 
pathways in normal cell growth.
C.Regulation of growth factor pathways in transformation.
l.Mitogenic and growth inhibitory pathways
The central role of oncogene product involvement in growth factor 
pathways has already been described and in this section the regulation of 
these pathways and their effects on cancer cells will be discussed, ft has been 
shown that some cancer cells are growth factor autonomous, that is, these 
cells do not require exogenous serum factors for mitogenesis (See Spom et
8al, 1985). This could be explained by either increased production of a 
growth factor or increased production of growth factor receptors or of both 
these events taking place together. To be growth factor autonomous, a cell 
would have to secrete particular growth factors which would then bind to 
specific receptors on the cell surface. This endogenous production of 
growth factors which then bind to the producer cells is termed autocrine 
secretion.
At least three growth factors, TGFa, PDGF and bombesin are 
secreted in an autocrine manner by cancer cells. In rodent cells transformed 
with Kirsten-sarcoma virus (p21 Ki-ras) there is autocrine secretion of 
TGFa (Anzano et al ,1985) which then binds to EGF receptors on the same 
cell. Also, ras transformed cells and sis transformed cells express PDGF- 
like molecules in an autocrine manner. The autocrine PDGF secreted by 
SS V transformed cells is due to the expression of the sis oncogene and the 
protein it encodes. The fact that T24 human carcinoma cells and p21 Ki-fas 
transformed cells also secrete PDGF (Bowen-Pope et al, 1984) implies that 
there must be some oncogenic cooperativity to induce transformation via 
growth factor effects.
Bombesin is a tetradecapeptide isolated from frog skin and its 
mammalian analogue is the gastrin releasing peptide. Both these 
polypeptides bind to the bombesin receptor and it has been demonstrated 
that bombesin-like peptides can function as autocrine growth factors in 
human small cell lung cancer (SCLC) cells. A monoclonal antibody to the C 
terminus of amphibian bombesin will block the binding of bombesin to its 
receptor in SCLC cells and inhibit clonal growth of these cells in vitro and 
prevent tumouregenesis in vivo ( Cuttita et aL 1985).
Autocrine secretion can also be affected by a change in the number 
of high affinity receptors for a growth factor. Human cancers derived from 
the head and neck and the A431 cell line have very high levels of the EGF 
receptor (Spom gt aL 1985) and may explain part of the tumouregenic 
capacity of these cells. This may be one way in which cancer cells can have
9accelerated growth rates at a fixed concentration of growth factor(s) as 
compared to normal cells where the receptor number(s) is limiting.
Growth factor autonomy may be conferred also by post-receptor 
mechanisms along the growth factor axis. The ras family of proteins have 
been thought to act as coupling proteins analogous to the G proteins in the 
adenylate cyclase system. If  this is so, then the ias protein could 
peimanantly couple growth factor receptors to their effector systems without 
the need for exogenous growth factors or could permanently activate the 
effector systems without receptor occupation. So far, the mechanisms of 
growth factor pathways on transformation have been discussed in terms of 
positive growth factors that induce mitogenesis.There are autocrine systems 
that inhibit growth and these include TGFp.
TGFp has many effects depending on the cell type, but in some cell 
types it is an anti-proliferative factor. TGFp has been shown to inhibit the 
proliferation of epithelial cells and functions in an inhibitory autocrine 
manner in the MCF-7 breast cancer cell line (Spom et al 1987). It has been 
demonstrated that TGFp inhibits the growth of NIH3T3 cells (Liboi et aL
1988) and this is associated with sustained c-£qs expression. It is also 
known that fibroblast growth regulator (FGR) is an endogenous fibroblast 
product and will inhibit 3T3 cells growth in an autocrine manner (Wang et 
al, 1986).
The possibilitiy exists therefore, that oncogene expression in cancer 
cells can cause growth factor autonomy not only by increasing growth 
factors or their receptors by autocrine secretion, but may also suppress the 
responsiveness of the cell to inhibitory factors that would otherwise regulate 
cell growth. The mechanisms by which this latter process occurs may 
involve the down-regulation of the receptors for these inhibitory ligands, 
decreased synthesis or increased degradation of the inhibitors at the 
transcriptional and translational levels. There may also be a defect in the 
post-receptor coupling mechanisms in these growth inhibitory pathways.
10
2. The role of suppressor genes in transformation
Some oncogenes exert their effects on cell proliferation by 
modifying growth factor pathways to an extent that uncontrolled 
proliferation results. Studies on somatic cell hybrids between normal and 
transformed cells have demonstrated the existence of a family of genes that 
can suppress the neoplastic phenotype. Cell hybrids between tumouregenic 
HeLa cells and human diploid fibroblasts express the non-malignant 
phenotype, and from these studies, chromosomes 11 and 14 have been 
implicated in tumour suppression (Saxon ££ gl, 1986).
It has also been shown that hybrids between ras-transformed 
murine, human and hamster fibroblasts with their non-transformed 
counterparts result in non-tumouregenic cells although there is no change in 
the levels of p2 1 in the hybrid cells as compared to the parental tumour 
cells. The possibility exists, then, that normal cells have suppressor genes 
that regulate the activity of the rag oncogene in vitro (Heldin £t al ,1987).
The retinoblastoma gene (Rb gene) has been implicated in the 
suppression of cell proliferation as inherited deletion of the gene has led to 
specific tumours, retinoblastomas and osteosarcomas. The suppressive 
function of the Rb gene product can be removed by binding to transforming 
DNA virus encoded proteins (Whyte et al, 1988). The ability of the 
adenovirus or S V40 virus to transform cells may depend partly on the 
binding of the Rb gene product which abolishes its function.
The role of suppressor genes in transformation has been clearly 
established although the mechanisms of function are unclear. It may be that 
suppressor genes inhibit transformation by a direct effect on specific DNA 
regions, either to activate or inhibit transcription. It is not known if these 
events (if they occur) affect growth factor pathways in the cell, but 
hypothetically, controlled cell proliferation is probably restored to 
transformed cells by modifying responses to activating and inhibitory 
growth factors.
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2.The Cell Cvcle in relation to cell proliferation.
The cell cycle describes the distinct phases which occur during cell 
proliferation. These phases of the cell cycle are G i, S, G2  and M phase.
The Go phase is occupied by dormant cells. S phase is the phase in which 
DNA synthesis takes place and M phase is where cell mitotic division 
occurs. The phases Go-Gl and G2  are phases of the cell cycle that are not 
clearly defined in terms of associated events except that it is known that 
there are important control points in the cell cycle within these phases.
It is known however, that cells in vitro wm become quiescent in the 
absence of growth factors when they have reached confluence at the Go-Gl 
phase. If serum growth factors are replaced in the medium of these cells, 
they will enter S phase i.e. cell proliferation occurs. Growth factor 
stimulation of cells in the G()-Gi phase is probably the most important 
signal for the initiation of cell growth although other agents, for example 
cell permeability modulators, cyclic nucleotide elevating agents, microtubule 
• displacing agents and tumour promoters can stimulate DNA synthesis in 
fibroblasts (Rozengurt, 1985).
Cell cycle progression has been shown to be a pH dependent 
process and that an increase in intracellular pH is necessary for DNA 
synthesis to occur. Musgrove et al (1987) have demonstrated in human melanoma PMC 22 
;eiis that pH values of approximately 7.5 are associated with the S, G2  and M phases of the cell 
cycle but a lower pH of 7.2 is associated with G i. When cells are 
quiescent, they arrest in the Go-Gl phase and this occurs at an extracellular 
pH of between 6.8-6.3 and it seems that a specific extracellular pH- 
dependent restriction point exists in the G i phase. Therefore, there is an 
intracellular pH variation associated with exponentially growing cells.
It is not known however, if the high intracellular pH value 
associated with cell progression through the cell cycle is a regulatory signal 
or if it is coincidental with the process of cell proliferation. Recently, Perona 
and Serrano (1988) have demonstrated that the expression of the gene for 
yeast plasma membrane H+/ATPase in fibroblast cells causes a sustained
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increase in intracellular pH. This had a proliferative and tumouregenic effect 
on the cells and is the first demonstration that sustained intracellular 
alkalinity direcdy influences cell proliferation. This experimental technique 
by-passes the requirement for growth factor stimulation of the cells and 
therefore, a clear demonstration of the direct effects of increased intracellular 
pH can be achieved.
The events that induce cells from the Go-Gl phase into S phase are 
growth factor associated and involve the increase in cytosolic Ca2+ and the 
activation of protein kinase C. These effects of growth factors will be 
discussed in the following section.
3.The role of second m essengers in cell p ro liferation
A.The inositol phospholipid signalling pathway
Acetylcholine stimulated inositol phospholipid metabolism in 
pancreatic acinar cells was first shown by Hokin and Hokin in 1953. Since 
then, it has been demonstrated that inositol phospholipid metabolism is the 
signalling pathway activated by various mitogenic and non-mitogenic 
stimuli in different cell types (Berridge and Irvine, 1984). The transduction 
of extracellular signals at the plasma membrane occurs via this signalling 
pathway by the generation of two second messengers, inositol 1,4,5 
trisphosphate (Ins 1,4,5 P3 ) and sn-1,2 diacylglycerol 
(DAG).
Phosphatidylinositol is phosphorylated at the 4 position on the 
inositol ring to yield phosphatidylinositol 4 phosphate, a distinct kinase then 
phosphorylates this molecule on position 5 on the inositol ring to give 
phosphatidylinositol 4,5 bisphosphate (Ptdlns 4,5 P2 ) which acts as a 
substrate for the receptor mechanism. The inositol phospholipids have been 
proposed to exist in hormone sensitive and insensitive pools in the 
membrane (Monaco £t al, 1983)with only a small percentage of the total 
inositolphospholipid existing in a hormone sensitive state.
However, such a notion of pool segregation is perhaps not widely accepted 
now.
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1. Formation of Ins 1.4.5 P3 as a second messenger
T h e  phosphodiesterase stimulated cleavage of Ptdlns 4,5 P2  resulting in the
production of Ins 1,4,5 P3  in iris smooth muscle and hepatocytes indicated 
that Ptdlns 4,5 P2  was the substrate for enzymatic production of Ins 1,4,5 
P3  and DAG. The phosphodiesterase involved has been called 
phosphoinositidase, a phospholipase C (Benidge, 1987a).
The Ins 1,4,5 P3  produced can be removed in two ways. It can 
either be dephosphorylated to form Ins 1,4 P2  (Berridge, 1987a) or can be 
phosphorylated by Ins 1,4,5 P3  kinase to Ins 1,3,4,5 P4  (Irvine et al,
1986). The amount of Ins 1,4,5 P3  in a cell on agonist stimulation thus 
depends upon both the rates of phosphorylation and dephosphorylation
The role of Ins 1,4,5 P3  as a calcium mobiliser was proposed from 
initial observations that Ins 1,4,5 P3  production either coincided with or 
lagged a few seconds behind calcium dependent physiological processes in 
liver and GH3  cells (Berridge and Irvine, 1984). This confirmed that the 
generation of Ins 1,4,5 P 3  was rapid enough to qualify it both as a second 
messenger and also as a calcium mobiliser.
Using permeabilised pancreatic acinar cells, Streb et al (1983) 
demonstrated that exogenously added Ins 1,4,5 P3  caused a release of Ca^+ 
from a vesicular store thought to be the smooth endoplasmic reticulum 
(SER). This has since been shown to occur in many other cell systems 
(Berridge, 1987). The specific binding of Insl,4,5 P3  to the SER causes a 
passive efflux of Ca^+ from the SER into the cytoplasm.Ins 1,4,5 P3  has 
been shown to bind to a specific receptor on the SER (Spat et al, 1986) and 
it is clear that the vicinal 4 and 5 phosphate groups on the inositol ring are 
essential for receptor binding.In rat liver microsomal fractions, the release 
of Ca2+ from the SER in the presence or absence of Ins 1,4,5 P3  is 
increased in the presence of GTP (Dawson et al, 1986). However, Gill et al 
(1986) have shown that GTP directly activates Ca^+ release from the SER 
of permeabilised NIE-115 cells. This mechanism of Ca^+ release appears to
14
be distinct from the Ins 1,4,5 P3  Ca2+ release mechanism and may 
constitute an as yet undefined system for stimulated Ca2+ release.
The increase in intracellular Ca2+ (Ca2 +j) has been associated with 
secretory, mitogenic and metabolic processes and thus it is essential for the 
levels of Ca2+j to be maintained at or above threshold levels for these processes 
; to occur. It has been proposed that Ins 1,4,5 P3  also controls the re-filling of 
the SER from the extracellular space. The emptying of the SER Ca2+ pool 
itself is a signal for Ca2+ influx and will depend on the levels of Ins 1,4,5 
P3  in the cell (Putney, 1986).
The role of Ca2+ in cell proliferation has been determined from 
observations that rapid changes in Ca2+j is a feature of many mitogenic 
peptides. PDGF will stimulate an intracellular Ca2+ increase in Swiss 3T3 
cells and this may constitute an early event in cellular mitogenesis. It has 
been shown that an Ins 1,4,5 P3 induced Ca2+ efflux from intracellular 
stores occurs in permeabilised T cells and Ehrlich Ascites Tumour cells 
(Berridge, 1987b).
TheCa2+j increase seems crucial to the activation of the c-myc and 
c-fos genes (Coughlin et aL 1985) and may be the first signal for the onset 
of mitogenesis. Also, the onset of fertilisation in Xenopus oocytes is 
accompanied by a large increase in Ca2+j and this can be mimicked by 
microinjection of Ins 1,4,5 P3  (Busagt al, 1985).
2. The DAG/Protein kinase C pathway
When PtdIns4,5P2 has been enzymatically cleaved it yields both Ins 
1,4,5 P3  and an additional second messenger, DAG, which also has several 
effects. Firstly, DAG can be acted upon by DAG lipase to generate 
arachidonic acid and monoglyceride. Arachidonic acid can feed into the 
prostaglandin and leukotriene pathways and this can have effects on DNA 
synthesis through autocrine secretion which can, following receptor 
stimulation, result in Ca2+j and cAMP increases (Macphee ej al, 1984;
Rozengurt et al, 1983).
I J
DAG which is generated in the membrane can activate protein kinase 
C (PK C) which is a serine and threonine specific kinase and 
phosphatidylserine dependent enzyme (Takai £l al, 1979). The enzyme is 
also Ca2 + dependent and this demonstrates the interaction of the two arms 
of the phosphoinositide signalling pathway ie. the dual effects of Ca^+ and 
DAG on PK C. The activation of PK C is accompanied by a translocation of 
the enzyme from the cytosol to the membrane.
PK C has been shown to be the cellular receptor for tumour 
promoting phorbol esters (Castagna £t al, 1982) and these agents can 
mimick the action of PK C. The action of tumour promoters to induce 
tumouregenesis may thus J*. to modulate DNA synthesis by activating PK
C. The protein substrates for PK G include the EGF re c to r  (Hunter ££ al, 
1984), vinculin, lipocortin and an 80kD substrate in the cytoplasm 
(Berridge, 1987a). These events may influence growth factor pathways and 
lead to mitogenesis. PK C has also been shown to activate the Na+/H+ 
exchanger resulting in increased cytoplasmic pH. This increased 
cytoplasmic pH is a permissive event for cell proliferation and it has been 
shown that growth factor stimulation of cells such as Swiss 3T3 and A431 
results in increased intracellular pH. This increase in intracellular pH is also 
associated with cell proliferation in the PMC-22 cell line (Musgrove et al, 
1987). It has - - recently been demonstrated that multiple forms of PK C
exist (Nishizuka, 1988) and it is proposed that their activation might be 
differentially regulated by different growth factors. The multiple forms of 
PK C may have a role in : ^ ... other second messenger pathways
depending on the specific growth factor stimulus.
3. Interaction between Insl.4.5 P3/Ca2+ and DAG/PK C pathways and 
their role in transformation
The cooperative effect of both the arms of the phosphoinositide 
signalling system has been shown by the use of Ca^+ ionophores and 
phorbol esters to activate cellular processes normally activated by an agonist 
(Berridge, 1987b). The effect of PK C on the Na+/H+ antiporter has
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already been mentioned above. The Na+/H+ antiporter is a transmembrane 
protein and is amiloride sensitive. The activation of this antiporter system 
causes an intracellular alkalisation leading to an increased intracellular pH 
(pHj). Increased pHj has been associated with growth factor stimulation 
of nearly all cell types including such diverse cells as fibroblasts and 
lymphocytes in rodents and in humans. Growth factor stimulation of 
fibroblasts leads to an increased pH} which precedes DNA synthesis and it 
is now believed that this increase in pHj is necessary for DNA synthesis and 
therefore, mitosis. The mechanism of action of growth factors on the 
Na+/H+ antiporter is unclear but it is possible that growth factor mediated 
increased PK C activity results in a conformational change at the allosteric 
site of the Na+/H+ antiporter. This may cause an apparent increase in the 
affinity for cytoplasmic H+ ions, which leads to increased alkalinity of the 
cytoplasm (L'Allemain et a!> 1984; Moolenar et al, 1983).
The role of the Na+/H+ antiporter in uncontrolled cell proliferation 
has been demonstrated in Chinese hamster embryo fibroblasts (CHEF). 
Transformed CHEF cells exhibit a constantly elevated pHi as compared to 
the non-transformed CHEF cells. This is due to sustained activation of the 
Na+/H+ antiporter and therefore, a direct role for this antiporter system in 
the development of tumouregenic cells has been postulated (Ober and 
Pardee, 1987).
It has been shown that PK C can modulate the activity of the 
Na+/H+ antiporter. The increase in pHj on growth factor stimulation occurs 
on a time scale of minutes and it is possible that this increases in pHj is 
dependent upon the generation of second messengers in response to growth 
factors. Thus, it is possible that the phosphorylation of the Na+/H+ 
antiporter by PK C is a necessary event before increased pHj can occur.
The interaction between Ca^+ and PK C can be demonstrated by 
their effects on the Na+/H+ antiporter. It has been shown that the Na+/H + 
antiporter is not affected directly by Ca^+ or Ca^+/calmodulin changes 
(Mitsuhashi and Ives, 1988; Ives and Daniel, 1987; Ober and Pardee,
17
1987). However, growth factor stimulation of Swiss 3T3 cells causes an 
initial Ca^+ induced acidification of the cytoplasm (Ives and Daniel, 1987) 
which is then followed by an increase in pHj due to the Na+/H+ antiporter, 
It has been also shown that reduced intracellular Ca?+ will reduce growth 
factor induced activation of the Na+/H+ antiporter in vascular smooth 
muscle cells (Mitsuhashi and Ives, 1988). These data together suggest that 
firstly, an increase in intracellular Ca^+ on growth factor stimulation is a 
necessary event which precedes increased pHj. This may be a reflection of 
the fact that PK C is a Ca^+ dependent enzyme and it is only in the 
presence of sufficient Ca?+ will PK C activate the Na+/H+ antiporter via a 
phosphorylation reaction.
Secondly, the initial Ca^+ induced acidification of the cytoplasm 
may be an important modulator of Na+/H+ antiporter activity. The possible 
phosphorylation of the antiporter by PK C may then sensitise it to excess 
H+ ions in the cytoplasm caused by the Cs?+ induced acidification. These 
processes may together lead to increased activity of the Na+/H+ antiporter 
resulting in increased PHj.Thus, although Ca?+ does not play a direct role 
in controlling Na+/H+ activity, an increase in Ca^+j is necessary for PK C 
induced activation of the antiporter.
It has been demonstrated that the growth factor induction of c-fos 
( Grinstein et al, 1988) and c-mvc ( Kaibuchi al, 1986a) expression can 
be achieved using a phorbol ester or Ca^+ ionophore.This also suggsests 
the cooperativity between the two second messenger systems in the 
coordination of growth control processes.
The numerous reports that phorbol ester pre-treatment can inhibit 
growth factor induced inositol phosphate production (Berridge, 1987b) 
have suggested that the two pathways can also be antagonistic in effect. PK 
C has been thought to inhibit Ptdlns 4,5 P2  hydrolysis possibly by 
phosphorylation of the G protein and to activate Ca^+ pumps which reduce 
Ca^+i in two distinct negative feedback loops. PK C has also been shown
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to phosphorylate platelet Ins 1,4,5 P3  5' phosphomonoesterase, increasing 
the enzyme activity and reducing the levels of Ins 1,4,5 P3  in the cell 
(Connolly &!, 1986). This would have the effect of reducing the levels of 
the Ca2 + mobilising second messenger.
The effect of PK C in inhibiting stimulated inositolphospholipid 
metabolism may also be at the receptor level since phorbol esters inhibit 
bombesin induced inositol phosphate generation but not PDGF induced 
inositol phosphate generation in Swiss 3T3 cells (Sturani et al, 1987). This 
result suggests that PK C may phosphorylate the bombesin receptor but not 
the PDGF receptor, or that the two agonists activate distinct G proteins or 
phospholipase Cfs in the same cell.
Cell proliferation may be partly a consequence of the activation of 
the phosphoinositide signalling pathway which may be one of the key 
events in normal cell growth. In neoplastic cell growth,the expression of 
oncogenes that may be part of growth factor transducing mechanisms may 
result in excessive production of the two second messengers. This is 
consistent with several findings by different workers. Firstly, it has been 
shown in several ra$ expressing cell lines (Fleishman et al, 1986, Chiarugi 
et al, 1986 and Wakelam et aL 1986) that there is increased inositol 
phosphate metabolism. Microinjection of Ha-ras into Xenopus oocytes 
results in increased DAG levels (Lacal £t al, 1987a) and ras, src and fms 
transformed cells show increased levels of DAG (Wolfman et al, 1987). 
Other transformed cells have the capacity to grow in low Ca^+ medium 
compared to normal cells suggesting that they have high Ca^+j levels 
(Berridge, 1987b). Finally, Housey et al (1988) have shown that 
overproduction of the p i  form of PK C in Rat 6  cells leads to neoplastic 
growth in culture.
It may be then, that the aberrant growth and transformation caused 
by oncogene expression could be due in part to modulation of the 
phosphoinositide signalling system by the protein products of certain 
oncogenes. The sustained activation of the pathway may be sufficient to
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induce DNA synthesis and uncontrolled growth. It is interesting that work 
by Wolfman et al (1987), whilst showing elevated levels of DG in ras, src 
and fms transformed fibroblasts also demonstrated that PK C is 
downregulated in the transformed cells. It is not clear what the mechanism 
of this downregulation might be, although Young et aL £1987), have 
suggested that phorbol ester induced downregulation of PK C in rat glioma 
cells is due to increased degradation of PK C and therefore, increased DAG 
production in this cell line may promote PK C degradation.
The downregulation of PK C in transformed cells seems to 
antagonise the effects of growth pathway activation and is an interesting 
puzzle to further complicate the unresolved issue of how oncogenes exert 
their effects on the phosphoinositide signalling pathway.
B. Modulation of second messengers bv G proteins
Guanine nucleotide-binding proteins (G proteins) were first 
discovered to couple adenylate cyclase activity to hormone receptors (See 
Gilman, 1984). The adenylate cyclase enzyme, which converts ATP to 
cAMP is a major component in the cAMP signal transduction pathway. 
cAMP has many effects in the cell,among them the stimulation of cAMP- 
dependent protein kinases, cAMP-dependent phosphodiesterases and to 
regulate cell growth.
The two major classes of G proteins known to interact with the 
adenylate cyclase system are Gs and Gi. These G proteins are composed of 
an alpha, beta and gamma subunit heterotrimer. Activation of the G protein 
by GTP binding in exchange for GDP causes the dissociation of the 
complex to the alpha subunit and the beta/gamma dimer. The alpha subunit 
posseses sites for GTP/GDP binding and for NAD-dependent ADP- 
ribosylation by bacterial toxins (Gilman, 1984).
Other characterised G proteins include Gt a i and Gta 2 or transducin 
which activate cGMP phosphodiesterase in retinal rods and cones 
respectively. The heterogeneity between the different G proteins is due to
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differences in the alpha subunit sequence and there are now known 
differences between subtypes of each G protein subclass (Casey and 
Gilman, 1988).
Whereas the regulatory G proteins in the adenylate cyclase and light 
transducing systems have been well characterised, there has only been 
circumstantial evidence for the existence of G protein modulation of the 
phosphoinositide signalling pathway. Gomperts (1983) demonstrated that 
guanine nucleotide analogues could promote histamine secretion in mast 
, cells on addition of Ca^+. Also,.permeabilised platelets show stimulated 
DAG production in the presence of GTPyS, a non-hydrolysable analogue 
of GTP (Haslam and Davidson, 1984). It has since been demonstrated that 
guanine nucleotide analogues regulate the phosphoinositide activity in the 
absence and presence of receptor binding ligands in a variety of cell types 
(Cockcroft, 1987).
The current concept is that phosphoinositide activity is regulated by 
a stimulatory G protein (called Gp) although the identity and the structure of 
this protein remains unidentified.PtdIns 4 ,5 P2  hydrolysis and the 
generation of Ca^+ and DAG has been shown to be modified by bacterial 
toxins in some cell types. The phosphoinositide signalling pathway is 
inhibited by pertussis toxin in mast cells, macrophages,neutrophils and 
lymphocytes (Cockcroft, 1987). It is also inhibited in certain fibroblasts but 
only with certain stimulatory growth factors and not others (Hoshijima et al, 
1988, Taylor, et al, 1988 and Paris and Pouyssegur, 1986).
However, polyphosphoinositide hydrolysis is not pertussis toxin 
sensitive in GH3  cells (Martin et al, 1986) and this has also been shown in 
fpancreas, liver, heart and adipocyte cells (Cockcroft, 1987).There has been 
a recent report of novel GTP-binding proteins in neutrophils which are not 
pertussis toxin sensitive (Bokoch et al, 1988). A novel cholera toxin 
sensitive G protein in pituitary clonal cells which regulate phosphoinositide 
signalling has been proposed by Low and Hughes (1987) since pre­
treatment of these cells with cholera toxin inhibits the phosphoinositide
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response to agonists. However, whilst similar effects of cholera toxin have 
been observed in L6 skeletal myoblasts, the effects have been demonstrated 
to be cyclic AMP mediated and to be a consequence of reduced agonist 
binding (Gardner et al, submitted for publication). It is clear, therefore, that 
the sensitivity of the phosphoinositide system to pertussis toxin is not an 
indicator of the identity of Gp in the same way as toxin sensitivity can be 
used as an index of Gi function. The hypotheses that Gi can function as Gp, 
or is Gp was recently outlined (Ui, 1986) although it would be surprising if 
the overlap of two such distinct second messenger systems would exist at 
the G protein level. The heterogeneity in what appears to be Gp in terms of 
pertussis and cholera toxin sensitivity is apparently confusing but with the 
advantages of cloning and monoclonal antibody techniques the identity of 
Gp may be resolved.
The existence of inhibitory G proteins in the phosphoinositide 
signalling pathway was suggested in a report by Joumot e£ al (1987) who 
showed that dopamine inhibition of angiotensin and thyrotropin-releasing 
hormone in anterior pituitary cells could be abolished by pertussis toxin 
treatment Also, Baudry et al (1986) have shown that N-methylaspartic acid 
and other acidic amino acids inhibit stimulated phosphoinositide metabolism 
in hippocampus slices.
Therefore, experimental evidence suggests that the activity of the 
phosphoinositide signalling system is controlled by G proteins and this is 
probably the mechanism by which 'fine-tuning' of the signalling system 
occurs.
4. The ras oncogene
Research into the ras oncogene family has been on-going for twenty 
years since the genes were first identified as the transforming principle of 
Harvey (Ha) and Kirsten (Ki) strains of rat sarcoma virus, (Barbacid, 1987). The 
transforming Senes have been identified as mutated cellular genes and have been detected 
in human tumours. Since the identification of ras genes in human tumours,
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the occurance of ras genes has been estimated at between 5-40% of all 
human tumours with the majority of these being mutated genes. 
Approximately 1% have been detected as being amplified normal cellular 
genes (proto-oncogenes) (Barbacid,1987). There is also evidence of 
hypermethylation of ras genes in human tumours (Feinberg and Vogelstein, 
1983). The ras gene family comprises Ha-ras-1. Ha-ras-2. Ki-ras-1. Ki- 
ras-2 and N-ras. Ras genes have been identified in mammals, birds, insects, 
molluscs, plants fungi and yeasts and the existence of ras-related genes 
including the ral gene (Chardin al, 1986) have now been described.The 
genes code for very closely related proteins of 21kD molecular weight. The 
proteins are 189 amino acids long (188 in the case of Ki-ras-2) and are 
identical to each other for the first 85 amino acid residues between Ha-ras-1. 
Ki-ras-2 and N-ras.The next 80 amino acids are 85% homologous between 
different ras genes and the rest of the molecule contains a hypervariable 
sequence except for the last four amino acids where there is a site for 
palmitic acid acylation of the molecule, essential for membrane attachment. 
The acylation site is present in all members of the ras protein family and it 
has been proposed recently that an active acylation-deacylation cycle exists 
and that may play a role in the signal-transduction function of the molecule 
(Magee eta!, 1987).
The p21ISS protein is bound on the inner leaflet of the plasma 
membrane and displays intrinsic GTPase activity at a rate similar to other G 
proteins (Gibbs et al, 1985). There is also some sequence homology to the 
alpha subunits of G proteins, including transducin (Bourne and Sullivan, 
1986). The phosphorylation of p 2 1 b y  EGF has been demonstrated but 
has only been shown for the Ha-ras oncogene protein (Kamata and 
Feramisco, 1984). The physiological significance of this growth factor 
induced phosphorylation is unknown.
Mutations in the ras gene leading to gene activation and cell 
transformation are associated with a reduction in GTPase activity. Ras gene 
mutations at codons 12,59 or 61 result in transforming ras proteins and the
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GTPase activity in these mutants is severely impaired (Gibbs et al, 1985). 
Lacal et al (1986), in a series of elegant deletion experiments using p21 Ha* 
BIS, showed that regions 5-23 and 152-165 were absolutely required for 
GTP binding and cell transformation. They also proposed that these regions 
were essential for the normal function of the ras proto-oncogene which has 
been found in all tissues with high levels in rapidly proliferating tissue, 
embryonic tissue and terminally differentiated tissue (Barbacid, 1987).
A cytoplasmic protein, GTPase activating protein (GAP) has been 
shown to stimulate normal p2 1 Bfs GTPase activity but not oncogenic 
mutant p21BI§ (Trahey and McCormick, 1987). The GAP protein is thought 
to act at region 30 -40 of the ras protein although this interaction of GAP at 
this 'effector region1 is attenuated in mutant p2 1 Bi§ (Cales s i al, 1988). The 
oncogenicity of mutant p2 1 Bl£ may be due to the conformational change 
induced at the mutation site which prevents GAP binding, thus leading to 
persistent GTP binding to the ras protein.
The role of p21I&§ in cell proliferation, transformation and 
differentiation has not been resolved yet although there has been intense 
research in this field over the last five years. Oncogenic p2 1 ^ §  has been 
shown to induce morphological differentiation of PC 12 pheochromacytoma 
cells (Bar-Sagi and Feramisco, 1985) and the use of anti-ras antibody 
reverses this differentiation. This clearly implicates p21E§£ in the 
differentiation process normally induced by nerve growth factor (Hagag et 
aL 1986).
It is known that the ras protein plays an important role in regulating 
cell entry into the S-phase of mitosis (Mulcahey et al, 1985) and that mutant 
p2 1  Ha-ras expression results in intracellular alkalinisation and initiation of 
S-phase (Doppler 31, 1987). Other functions ascribed to p21 BIS are the 
control of cell endocytosis and exocytosis (Bar-Sagi et al, 1987) and the ras 
induced phosphorylation of mitochondrial proteins (Backer et al, 1986). Also, 
expression of the ras protein is necessary for the c-mvc induced 
transformation of NIH3T3 fibroblasts (Smith et al, 1986).
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The main function ascribed to the ras protein is the involvement of 
p21H£ in growth factor pathways. The mutated versions of the ras proto­
oncogene may cause transformation by activating certain growth factor 
pathways and by suppressing inhibitory controls. It is known that 
transformation or differentiation in experimental systems can be induced 
with mutant p2 l 23LS but it requires larger amounts of normal p21£2S to 
achieve the same effects. The mutated ras proteins may transform cells by 
providing a necessary 'limiting factor' for the constitutive activation of 
growth factor pathways.
The RAS yeast proteins, RAS 1 and RAS2 are closely related to 
mammalian ras proteins and have been shown to regulate adenylate cyclase 
activity (See Results chapter 6). In a recent report, it has been suggested that 
RAS proteins may be involved in glucose-induced inositolphospholipid 
turnover in S. Cerevisiae (TCaibuchi et aL 1986b}.
It is conceivable, then given the biochemical properties of p21f^, its 
cellular location and its involvement in mitogenesis, transformation and 
differentiation that p21I£§ may function as a major growth regulatory factor 
utilising second messenger systems.
The Aims of this Project
The occurance of the ras oncogene in human tumours has already 
been described although the role of p21I££ is still not clear in spite of the 
research in this direction. The importance of ras gene amplification in 
tumours led to the possibility of investigating the role of normal cellular 
p2iniS in transformation.The role of p21HlS in regulating second 
messengers as part of a signal transduction mechanism has never been 
resolved and it was from this starting point that this project was conceived.
This project was undertaken to study the effects of p21 N-ras 
overexpression on the proliferation and transformation of the NIH3T3 cell 
line. A number of reports have shown the involvement of the ras oncogene
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with the inositolphospholipid signalling pathway (See Chapter 3) and this 
was studied during this project. Also, it was necessary to define the effects 
(if any) of p21 N-ras on the cAMP signalling pathway. There has been 
much speculation in this area but there have been no conclusions drawn 
(See Chapter 6). The system used to study the effects of p21 N-ras jn cep 
proliferation and transformation was the T15 cell line, an inducible N-ras 
expressing clone of the NIH3T3 cell line (See Chapter 3 for details).
The purpose, therefore, of the project was to try to provide 
additional clues to the function of the ras oncogene and even perhaps 
answer the question W hat does ras do?'
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Chapter 2: Materials and Methods
l.C ell Culture Methods
a. Cell Culture
T15, NIH3T3 and N 866 cells were cultured in Dulbecco's Modification 
of Eagle's Medium supplemented with 100 units/ml of penicillin/streptomycin, 
2mM glutamine, 0.375%(w/v) sodium hydrogen carbonate ( referred to as 
DMEM) and 10% (v/v) donor newborn calf serum. T15- cells were grown in the 
absence of dexamethasone while T15+ cells were grown in medium containing 
2|iM dexamethasone which causes the induction of p21 N-ras expression in 
these cells. Sis 771 cells were grown in DMEM/5% (v/v) calf serum. The cells 
were grown at 37°C in a 5% C02/95% air, 95% humidity atmosphere.
b. Cell passage
Confluent cells (typically 10^ cells per 25 cm^ flask) were passaged 
using a trypsin solution containing 0.1% trypsin (w/v), 0.025% EDTA (w/v) 
and 10 mM glucose in phosphate buffered saline. The trypsinisation process was 
inhibited when the cells were 'rounded up' by the addition of 2 ml of 10% 
serum/DMEM and the cells washed off the bottom of the flasks. An additional 2 
ml of 10% serum/DMEM was added to the flask to ensure that most of the cells 
were removed. The cells were collected after trypsinisation, centrifuged at 800 g 
in a MSE Centaur for 5 minutes to pellet the cells, resuspended in DMEM/10% 
calf serum and plated as required.
c.Maintenance of cell lines. ^
Confluent cells were passaged as above and the cells resuspended in
biofreeze vials at a density of lO^cells per ml in freezing medium which 
consisted off 8% DMSO (v/v),20% calf serum (v/v) and 72% DMEM (v/v). The 
vials were packed in cotton wool and then frozen overnight at-80°C and then 
transferred to liquid nitrogen for storage.
To plate out frozen cells, each frozen vial was thawed and resuspended in
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1 ml of normal medium and the cells plated out in a final volume of 4 ml medium 
in a 25 cm^ flask.
d. Preparation of inositol free calf serum
Preparation of inositol-free calf serum was necessary as this calf serum 
was used in experiments to label cell with tritiated inositol.
1. Preparation of dialysis tubing: The dialysis tubing was boiled in 20mM EDTA 
for 20 minutes and washed in distilled water. The tubing was either used 
immediately or stored in 20% (v/v) ethanol at 4°C.
2. Dialysis of calf serum: Calf serum was aliquoted into the dialylsis tubing in 
either 50 or 100 ml lots and dialysed against 4 changes of 10 times its volume of 
dialysis medium at 4°C. The dialysis medium consisted of a 1:19 (v/v) dilution 
of a 20x strength Earle's Salt solution (See Materials section) in distilled, 
deionised water adjusted to pH 7.4 with 1 M sodium hydroxide.The dialysed 
calf serum was filter sterilised, aliquoted into tubes and stored at -20°C.
e. Preparation of steroid-free calf serum
The following buffer was made as required for the preparation of steroid- 
free calf serum: 20% (v/v) 0.1 M HEPES, pH 7.4, 0.0075% (v/v) 0.2 M 
EDTA, pH 7.4 and 10% (v/v) glycerol in water. 100 ml of this buffer was mixed 
with 500 mg charcoal and 5 mg dextran for 30 minutes at room temperature.This 
mixture was sufficient to treat 50 ml of calf serum. The charcoal suspension was 
aliquoted into 2 x 50 ml lots and centrtifuged in a MSE Centaur 2 at 800 g for 10 
minutes to pellet the charcoal. 50 ml of serum was added to one of the charcoal 
aliquots, mixed and incubated at 56°C for 15 minutes. The tube was centrifuged 
as before, the serum was removed and added to the second charcoal aliquot. The 
charcaol and serum was mixed and incubated at 56°C for 15 minutes as before 
and the tube centrifuged to pellet the charcoal as previously described. The 
serum was removed, filter sterilised and stored at -20°C.
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2. Tritiated thymidine incorporation
These experiments were performed to provide a measure of cell 
proliferation. To ensure that cells were synchronised, it was necessary to 
make them quiescent prior to the [^H] thymidine incorporation experiments. 
NIH3T3 and T15 cells were plated out in 6 cm diameter petri dishes at a 
density of 10^ cells per ml in 10% calf serum/ 90% DMEM with 
dexamethasone as necessary. The next day, the medium was changed to 1% 
calf serum/99% DMEM and the cells left for 5 to 7 days to reach quiescence.
At this stage, the cells were labelled with lfiCi m H  [^H] thymidine 
per dish in 10% calf serum/90% DMEM for the appropriate times. At these 
times, the cells were washed twice with 5 ml of Hanks Buffered Saline. 5 ml 
of 5% (w/v) trichloroacetic acid were added to each plate and the plate 
scraped and the contents removed to a 50 ml centrifuge tube. This was 
repeated 3 more times and the contents of the plate pooled each time, making 
a total of 20 ml in all. The tubes were spun in an MSE Centaur 2 at 2000 g 
for 5 minutes to pellet the acid-insoluble material which contained the [^H] 
thymidine incorporated into DNA. The supernatant was removed and 5 ml of 
ethanol were added to the pellet and the pellet resuspended. The tubes were 
centrifuged as before for 10 minutes, the supernatant removed and the pellet 
solubilised in 1 ml of 0.3 M sodium hydroxide. 0.5 ml of this was added to 
0.1 ml of 1.5 M hydrochloric acid in a scintillation vial and the radioactivity 
in the sample determined by scintillation counting in 6 ml of scintillation 
fluid.
3.Separation o f inositol phospholipids
l .Sample preparation
Two confluent 25 cm^ flasks of T15 and NIH3T3 cells were used for each 
time point. The cells were labelled for 16 hours prior to the experiment with lOjiCi 
m l'l ° f  [^H] inositol in inositol- and serum-free DMEM. After the labelling period, 
the cells were washed extensively with Hanks buffered saline, scraped and 
collected by centrifugation at 800 g for 5 minutes. The collected cells were 
resuspended in a final volume of 1.5 ml of Hank's saline with 1% BSA (w/v) and 
lOmM glucose.The cells were aliquoted in 0.5 ml volumes into plastic scintillation 
vials (triplicate determinations were made).The cells were killed with 500|il (20% 
v/v) ice-cold trichloroacetic acid and samples were kept on ice at all times after this 
stage.
1 .The samples were mixed and spun at 2000 g in an MSE Centaur 2 for 5 
minutes.The supernatant was discarded and the pellet washed with 1 ml of ice-cold 
5 % (w/v) trichloroacetic acid/lmM EDTA. The samples were spun again as above.
2.The supernatant was discarded and the pellet washed witli 1 ml ice-cold 
water.The samples were spun as above.
3.The supernatant was discarded and 1 ml of chloroform : m ethanol: hydrochloric 
acid (100:100:1 ,v/v) was added.The samples were mixed and left at room 
temperature for 20 minutes. The samples were then spun and the supernatant 
removed to clean tubes.
4. 0.33 ml chloroform : m ethanol: hydrochloric acid (200:100:1, v/v) was added 
to the remaining pellet from step 3. The tubes were mixed and spun and the 
supernatant was added to the supernatant from the previous wash and combined.
5. 0.5 ml chloroform and 0.37 ml 0.1M hydrochloric acid were added to the 
combined supernatants. The samples were mixed, allowed to phase split and the 
upper phase discarded.
6 . 0.7 mis of Folch's Synthetic Upper Phase was added to each of the samples and 
the tubes mixed and spun.
7. The aqueous upper layer was discarded and the samples could be stored frozen at
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this stage under nitrogen .
Folch Synthetic Phases:
The following were mixed in the ratios below (v/v): 
chloroform: m ethanol: 0.1M hydrochloric acid, 10 : 5 : 3.
These were mixed and left to stand in order to separate into two phases which were 
stored separately at room temperature.
2.Separation of the polyphosphoinositides
a.Hvdrolvsis of polyphosphoinositides to glvcerophosphoinositol monophosphate 
(GPIP) and glvcerophosphoinositol bisphosphate (GPIPo)
The samples from step 7 above were dried down in a Hetovac centrifuge 
and the following were added: 0.5 ml chloroform, lOOpl methanol, lOOjil 1 M 
sodium hydroxide in methanol. The samples were mixed and left for 15 minutes to 
allow deacylation to proceed. The following were then added: 0.5 ml chloroform,
0.3 ml methanol, 0.3 ml water and the samples were mixed and centrifuged in a 
Hettich microfuge at 16 000 g for 5 minutes.
0.5 ml of the upper phase were transfered to clean tubes and the samples 
neutralised by the addition of 290|il of 0.1 M Boric acid. 150pl o f 3 M ammonium 
formate and 125|il of 0.1 M sodium tetraborate were added to each sample and 
mixed. Then, 1.5 ml of water were added and the samples mixed again. This 
procedure reduced the ionic strength of the samples to permit binding of the 
samples to the ion exchange chromatographic resin (See below). The samples could 
be stored frozen at this stage of the assay.
b.Elution of GPIP and GPIP2  from Dowex formate columns
The samples were applied to 1ml Dowex-1-formate columns and washed 
with 2 x 17 ml of 0.18M ammonium formate/5mM sodium tetraborate. Following 
this, GPIP was eluted with 15 ml of 0.35 M ammonium formate/0.1 M formic acid 
and GPIP2  was eluted with 20 ml of 1M ammonium formate/0.1 M formic acid.
The amount of radioactivity in each sample was determined upon a known 
volume of each fraction by liquid scintillation counting.
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4. Determination of inositol phosphate production in T15 and 
NIH3T3 cells
Sample preparation
T15 and NIH3T3 cells were grown in 25 cm^ flasks and labelled 
with 2|iCi of [^H] inositol in 10% calf serum/ 90% DMEM (v/v ratios) in a 
total of 3 ml per flask for a period of 48 hours or in 10% inositol free calf 
serum and 90% inositol free DMEM for 16 hours. The different labelling 
protocols employed did not affect the magnitude of the inositol phosphate 
response to agonists of the cells but the latter increased the amount of 
radioactivity in the samples.
After the labelling period, the cells were washed twice with Hanks 
Buffered Saline containing 1% BSA and lOmM glucose (HBG). The cells 
were scraped and collected by centrifugation in an MSE Centaur 2 centrifuge 
at 800 g for 5 minutes. The pellet was washed with HBG and spun as 
before.The cell pellet was resuspended in fresh HBG to a final volume 
containing approximately 5 xlO^ cells ml" ! and aliquoted into plastic 
scintillation vials containing the appropriate ligand or water, in the case of 
control samples, and 1 OmM lithium chloride solution in a final volume of 250 |il.
The samples were incubated in a shaking waterbath at 37°C for the appropriate time 
period and reactions terminated by the addition of 0.94 ml chloroform: 
methanol (1:2, v/v). The tubes were left to stand for 10 minutes after mixing. 
Extraction of inositol phosphates and inositol phospholipids
0.31 ml of water and 0.31 ml of chloroform were added to each 
sample and mixed. The tubes were centrifuged at 2000 g in a MSE Centaur 2 
for 5 minutes to separate the aqueous and organic phases.
Inositol phosphate extraction
The aqueous layer contains the inositol phosphates which were batch 
eluted from Dowex formate. 0.8 ml of this layer was transferred to clean 
tubes and 2.2 ml water were added. 0.25 ml of Dowex formate was added to
/s
each tube, vortexed and left until the Dowex had settled. The supernatant
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was removed and 3 ml of 60 mM ammonium formate/5 mM sodium 
tetraborate were added to the samples and the supernatant aspirated off when 
the Dowex had settled This step was repeated once more and then the resin 
was washed with 3 ml of water three times.
Inositol phosphates were eluted from the resin with 0.6 ml o f 1M 
ammonium formate/0.1M formic acid. The tubes were vortexed and the 
Dowex left to settle. 0.5 ml of the supernatant were removed to a scintillation 
vial. 0.6 ml of 1M ammonium formate/0.1 formic acid were added to the 
Dowex and after mixing, 0.6 ml of the supernatant were added to the 
scintillation vial. This procedure was repeated once more, making a total of 
1.7 ml in the scintillation vials from each sample. 12 ml of Ecoscint 
scintillation fluid was added to each vial and the radioactivity in each sample 
determined by scintillation counting.
Inositol phospholipid extraction
The lower phase contains the inositol phospholipids. 0.25 ml o f this 
phase were dried down in scintillation vials and the radioactivity in each 
sample detemined by scintillation counting in 3 ml of Ecoscint
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5, Separation of inositol phosphates
T15+, T15- and NIH3T3 cells were plated in 24 well plates and 
grown to a density of 1 0 ^ cells per well in DMEM/10% calf serum. 16 hours 
prior to experimentation,the medium was changed to inositol-free DMEM 
containing 10}iCi m H  of [^H] inositol to label the inositol phospholipid 
pool. Following this incubation period,the cells were washed twice in 
Hanks buffered saline and then incubated at 37° C for 5 minutes in Hanks 
buffered saline containing l%(w/v) BSA,10 mM glucose (HBG) andlO 
mM lithium chloride. Cells were stimulated with 2.5 Jim bombesin in HBG 
containig 10 mM lithium chloride in a final volume of 25 jil for various 
times and incubations quenched with 50|il (10%,v/v) ice-cold perchloric 
acid.The wells were scraped with the addition of 50}il water, transfered to 
eppendorf tubes and the samples centrifuged at 16 000 g in a Hettich 
microfuge at 4°C. The supernatants were removed to eppendorf tubes and 
neutralised with 1.5 M potassium hydroxide /60 mM HEPES in the 
presence of universal indicator.The samples were centrifuged as before to 
pellet the precipated salt and the supernatants were added to 1 ml of 5 mM 
sodium tetraborate/0.5mM EDTA if the samples were run on Dowex 
columns,or if the samples were analysed by HPLC no sodium 
tetraborate/EDTA was added.
Separation of inositol phosphates from control and agonist 
stimulated cell extracts were carried out by two methods:
1.Separation on Dowex-formatelx 8-200 resin columns
2.HPLC using a Whatman Partisil 10 SAX column.
1.Separation of inositol phosphates using Dowex-formate resin 
Samples were applied to 1 ml Dowex-formate columns and the following 
[^H] labelled compounds eluted as follows:.
1. Inositol was eluted with 12 ml of water
2.Inositol and glycerophosphoinositol were eluted with 12 ml of 60 mM 
ammonium formate/5 mM sodium tetraborate.
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3.Inositol monophosphates were eluted with 18 ml of 0.2 M ammonium 
formate/0.1 M formic acid.
4.Inositol bisphosphates were eluted with 18 ml of 0.4 M ammonium 
formate/0.1 M formic acid.
5.Inositol trisphosphates were eluted with 15 ml of 0.8 M ammonium 
formate/0 .1  M formic acid.
The amount of radioactivity in each sample was determined by liquid 
scintillation counting aliquots of the collected samples.
2.Separation of inositol phosphates using HPLC
The column used was a Whatman Partisil 10 SAX and the gradient 
used was 0 - 1.7M ammonium formate adjusted to pH 3.7 with 
orthophosphoric acid (Irvine et al, 1985). The gradient was increased in a 
linear fashion from 0 to 43% ammonium formate solution over 19 minutes 
and held at this level for 2.3 minutes. The gradient was then increased to 
69% ammonium formate over 7 minutes, held at this level for 6 .8  minutes 
and then increased to 100% ammonium formate solution over 12.5 minutes. 
All column eluants were filtered through 0.45 micron Whatman filters 
before use. The 250p.l sample was applied to the column at time = 0 and
0.25 ml fractions were collected. The flow rate was lml/min. The 
radioactivity in each sample was determined by liquid scintillation counting.
[3h ] labelled inositol phosphate standards were run on the column 
to ensure that resolution of the inositol phosphates could be achieved using 
this column and to define the mobility of the individual inositol phosphates. 
The elution of [^H] labelled inositol phosphates from this column is shown 
in figure 2.1. Recoveries of the inositol phosphates were routinely between 
60-85%.
Figure 2.1: Separation of £ H1 inositol phosphate standards bv 
H PLC .
The figure shows the separation of inositol phosphate standards by 
HPLC using an ammonium formate gradient as previously described. The 
data was obtained from the resolution of [^H] inositol phosphate standards 
eluted from a Partisil 10 SAX column using the gradient described and 
peaks of inositol 1 monophosphate, inositol 1,4 bisphosphate and inositol 
1,4,5 trisphosphate are indicated. The dotted line indicates the elution 
gradient used.
fraction 
no.
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6.Inositol 1.4,5 trisphosphate kinase assay
1 .Preparation of enzyme extracts
Confluent 75 crrfi flasks of T15+,T15-and NIH3T3 cells were 
washed and scraped in ice-cold PBS. The cells were collected by 
centrifugation at 800 g for 5 minutes. The cells were resuspended in fresh 
PBS and spun again.The cells were resuspended in a final volume of 1 ml 
(or less if a concentrated preparation was necessary) in 0.25 M 
sucrose/50 mM Tris/HCl buffer at pH 7.2.The cell pellet was 
homogenised using a teflon on glass homogeniser for 2 0  strokes on ice 
and then sonicated in a sonicating waterbath for 1 minute. The 
homogenate was spun at 100,000 g for 90 minutes at 4°C in a Beckman 
TL-100 Ultracentrifuge. The supernatant was retained and either assayed 
immediately or stored in 100 fil aliquots at -20°C.
2. Assay for Inositol 1. 3. 4 .5 tetrakisphosphate formation
The high speed supernatant was incubated with the appropriate 
incubation buffer (see below), 1- 2|iCi of [^H]-inositol 1,4,5 
trisphosphate (Specific activity =1 or 44 Ci m m oH ) and various 
concentrations of inositol 1,4,5 trisphosphate in a final volume of 150fil 
at 30°C for 5 minutes. The reactions were terminated by the addition of 
50pl of perchloric acid (10%, v/v) and neutralised with 1.5 M potassium 
hydroxide/60 mM HEPES containing universal indicator. Samples were 
then centrifuged to remove precipitated salt as previously described.The 
samples were then either applied to a Partisil SAX HPLC column (as 
already described under 'Separation of inositol phosphates'), or, 
following the addition of 1 ml of 5mM sodium tetraborate/0.5 mM EDTA 
pH 7.2, were applied to 1 ml Dowex formate columns .The inositol 
phosphates were eluted from the columns as already described. In these 
assays, the amount of inositol monophosphate and inositol bisphosphate 
generated was minimal, and was the result of dephosphphorylation of the
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[^H] inositol 1,4,5 trisphosphate. Inositol tetrakisphosphate was eluted 
from columns with 15 ml 1.2 M ammonium formate/0.1 M formic acid. 
(See figure 2.2 for resolution of Ins 1,4,5 P3  and Ins 1,3,4,5 P4  
standards by Dowex anion exchange chromatography.) The amount of 
radioactivity in each sample was determined from an aliquot of the 1.2 M 
ammonium formate fraction by liquid scintillation counting.
Incubation buffer 1 (based on Irvine et al. (1986)1 
0.25 M sucrose,20 mM magnesium chloride, 10 mM disodium ATP, 50 
mM Tris adjusted to pH 9 with 1M sodium hydroxide. At this pH the 
activity of the IP3  phosphatase is inhibited whilst the Ins 1,4,5 P3  kinase 
remains active (See Results chapter 5) thus allowing the conversion of the 
Ins 1,4,5 trisphosphate substrate to Ins 1,3,4,5 tetrakisphosphate.
When this buffer was used at pH 7 ,2,3-diphosphoglycerate was added to 
the incubations at a final concentration of 2 mM to inhibit the activity of 
the IP3  5'-monophosphatase (See results chapter 5).
Incubation buffer 2 (based on Harden et al. (1987)1 
The buffer in these experiments contained 10 mM ATP, 12 mM free 
Mg2+ and 120 nM free Ca^+(based on the calcium measurements of 
Alison Lloyd) The buffer was: 0.02 M EDTA, 0.01 M disodium ATP, 
0.376 mM calcium chloride, 22.34 mM magnesium sulphate, 115 mM 
potassium chloride, 5 mM potassium dihydrogen phosphate andlO mM 
HEPES. The buffer was used either at pH 9 or if used at pH 7,2,3- 
diphosphoglyceriate was added to the incubations as described above.
Figure 2.2: Resolution of r3.Hl inositol 1.4,5 trisphosphate 
and inositol 1.3.4.5 tetrakisphosphate standards by Dowex 
anion exchange chromatography.
Figure 2.2a indicates the elution of a tritiated inositol 1,4,5 
trisphosphate standard from Dowex formate columns using 16 ml of 0.8 
M ammonium formate/0.1 M formic acid followed by 16 ml 1.2 M 
ammonium formate/0.1 M formic acid applied in 2 ml aliquots. Figure 
2 .2 b shows a similar experiment to determine the elution profile of 
tritiated inositol 1,3,4,5 tetrakisphosphate standard performed under the 
same conditions as experiment 2a. The figures indicate that there is clear 
resolution of inositol 1,4,5 trisphosphate and inositol 1,3,4,5 
tetrakisphosphate using this separation procedure.
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7. Whole cell cyclic AMP determinations
a.Sample preparation
T15, N 8 6 6 , NIH3T3 and sis 771 cells were grown as already 
described and plated in 24 well plates. T15- were cultured routinely until 
two days prior to experimentation, when the medium was changed to 1 0  % 
(v/v) steroid-free calf serum/90 % DMEM. This method was adopted to 
minimise the frequency of spontaneous transformation of T15- cells due to 
steroids in the growth medium.
The cells were used at a density of 10^ per well as determined using 
a haemocytometer.The cells were labelled with 2|iCi of [^H] adenine in 
serum-free DMEM for 90 minutes when maximum adenine incorporation 
into the acid soluble fraction was obtained (Figure 2.3). After the labelling 
period, the cells were washed extensively with PBS at 37°C and then 
stimulated with the appropriate ligand in a final volume of 100-500|il of 
DMEM at 37°C for 10 minutes in the presence of ImM 
isobutylmethylxanthine (IBMX). The reactions were terminated with 0.5 ml 
of 10% (w/v) trichloroacetic acid. The cylic AMP content of each well was 
determined immediately or the plates were stored at -20°C.
b.Preparation of Dowex and alumina columns
The method used to quantitate the amount of cyclic AMP in the 
samples was essentially that of Salomon et al (1974) and involves the 
separation of cyclic AMP from other nucleotides by Dowex and then 
alumina chromatography. Dowex-H+ 50x4-400 was washed in twice its 
packed volume with 1M hydrocholic acid and then with the same volume of 
water four times.The Dowex was mixed with water to a slurry (1:1, v/v 
ratio) and then 3 ml of this added to each column and the water left to drain 
out.The columns were then ready for use. After use the Dowex was washed 
with 2 ml oflM  hydrochloric acid and left in this state. Before the next 
samples were applied, the columns were washed with 8  ml of water.
The alumina columns were prepared by weighing 1.2g of neutral
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alumina per column and washing with 8 ml of 0.1M imidazole before use. 
After use, the columns were washed with 2 ml of 1M imidazole and left in 
this state. The columns were washed with 8 ml of 0.1 M imidazole before 
they were used again.
c.Separation of cyclic AMP on Dowex-H+ columns.
Before samples were run on Dowex columns, the elution volumes 
required for the separation of cyclic AMP were determined. This was done 
by applying a mixture of [^H] cyclic AMP and [32p] ATP to the column 
and determining the elution profile.
Freeze-dried [^H] cyclic AMP was reconstituted in either 10% 
trichloroacetic acid (w/v) or water and diluted so that lOOjjl o f the solution 
contained approximately 10000 dpm. [3^P] ATP was diluted so thatlOOfil 
of the solution contained approximately 2000 dpm. lOOjil of each of the 
cyclic AMP and ATP solutions were added to 0.5 ml of 10% trichloroacetic 
acid and the mixture loaded onto a Dowex column. The ATP and cyclic 
AMP were eluted from the column with up to 3 ml of 0.1 M hydrochloric 
acid followed by up to 10 ml of water in 0.5 ml fractions. All the fractions 
were collected, 3ml of Ecoscint was added to each and the radioactivity 
determined by liquid scintillation counting using a dual-label programme.
The elution volumes required to elute off the cylic AMP from the 
Dowex columns were then determined from a graph as shown in figure 2.4. 
Typical recovery from the Dowex columns was 80-90%.
The elution volume required to elute the cyclic AMP from alumina 
columns was determined as for the Dowex columns except only [^H] cyclic 
AMP was used and the eluting buffer was 0.1M imidazole. Typical 
recovery from the alumina columns was 90%.
4.Determination of cyclic AMP content of the cell extracts
The supernatant from each well was added to approximately 2500 
dpm of [^ C ] cyclic AMP, the internal standard which allows for an 
estimation of % recovery of the nucleotide from the columns. The
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percentage recovery of cyclic AMP from the Dowex and alumina columns 
was routinely 60-90%. When the recoveries of cyclic AMP fell below 50 
%, the columns were discarded and fresh columns prepared.The 
supernatants were applied to prepared Dowex columns and ATP eluted with 
2 ml of 0.1M hydrochloric acid. 8  ml of water was then added to the Dowex 
columns and this eluate allowed to run directly onto the alumina.The cyclic 
AMP fraction was eluted and collected with 10 ml of 0.1 M imidazole.The 
radioactivity in this fraction was determined by counting 4 ml of this 
The amount of cyclic AMP per sample was calculated from the amount of 
radioactivity in the sample by converting total dpm obtained (by taking into account 
the % recovery of cyclic AMP per sample) to pmol cyclic AMP, based on the 
specific activity of [3h] adenine used. Figure 2.3 indicates that [3H] adenine was 
maximal at a labelling period of 90 minutes.This experiment has since been repeated 
and the results obtained are similar to the experimental data shown. Also, 
experiments to determine the specific activity of [3H] labelled intracellular ATP in a ll- 
the cell types used in the experiments shown in Chapter 6  were performed (results 
not shown). The results indicate that there is no change in the specific activity of 
[3h] ATP between the different cell types after the 90 minute labelling period and 
that the specific activity of the ATP remained constant during the experimental period. 
Figure 2.3; Incorporation of tritiated adenine in T15+_cells__as 
a function of time.
The figure shows the incorporation of tritiated adenine into the 
trichloroacetic acid soluble fraction of T15+ cells. The experiment was 
performed using T15+ cells grown in 24 well plates to a density of 10^ cells 
per well as previously described. The cells were labelled with [3h ] adenine 
(2jiCi per ml) in serum-free DMEM at 37°C and incubations were 
terminated at appropriate time points. The cells were washed twice with 
PBS at 37°C and 0.5 ml 10% (w/v) trichloroacetic acid was added to each 
well. The wells were scraped and the contents of each well were transferred 
to Eppendorf tubes and the samples centrifuged for 10 minutes at 16 000 g 
in a Hettich microfuge at 4°C. The supernatants were transferred to 
scintillation vials and the radioactivity in each sample determined by the 
addition of 3 ml of Ecoscint followed by scintillation counting.
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Figure 2.4: Elution profiles of cyclic AMP and ATP standards 
from Dowex colum ns.
The results in figure 2.4 are from an experiment to determine the 
elution profiles of cyclic AMP and ATP from Dowex H+ columns. A [^H] 
cyclic AMP standard and a [^ P ]  ATP standard were applied to the Dowex 
columns (as described in the text) and eluted from the Dowex resin with 6  x 
0.5 ml of 0.1M hydrochloric acid follwed by 11 x 0.5 ml water. The 
radioactivity in each sample was determined as previously described.
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_ 8.Protein Determination
The method is based on that of Lowry et al (1951). The stock 
solutions were:
A. 2%(w/v) sodium carbonate in 0.1 M sodium hydroxide
B. 1% (w/v) copper sulphate
C.2% (w/v) sodium potassium tartarate
Just before use the reagents are mixed in the following v/v ratio:
A:B:C, 100:1:1.
Protein standards were prepared using lm g m H  bovine serum 
albumin fraction 5 and a standard curve was constructed for a maximum 
of 30 p.g protein per sample. 10 jil of the unknown sample was assayed 
in duplicate. 1 ml of the A:B:C solution above was added to each sample, 
mixed and left to stand for 10 minutes. lOOjil of Folin-Ciocalteau reagent, 
diluted 1:4 with water was added to each sample. The samples were 
mixed and left for 30 minutes. The absorbance of the samples were 
determined spectophotometrically at 750 nM in a LKB Ultrospec 2. x
47
9. Determination of fH 5.I1 iodocvanopindolol binding in T15 
£ g.U§t
The binding of [125 I] iodocyanopindolol to T15 cells was used as an 
index of P adrenergic binding since iodocyanopindolol binds to particular 
lipids associated with P adrenergic receptors (Levitzki, 1988) and therefore is 
a specific agonist for P adrenergic receptors. The following protocol was 
used to determine [1251] iodocyanopindolol binding to T15 cells in order to 
demonstrate any changes that may occur in p adrenergic binding upon 
p21 N-ras overexpression in this cell line.
T15 cells were cultured as previously described in twenty-four well 
plates and 2pM dexamethasone added to the medium as required (See 
Chapter 4). T15- cells were maintained in DMEM/10%, v/v, steroid-free calf 
serum for 2-3 days prior to the experiment in order to minimise the possibility 
of spontaneous transformation of the cells. The cells were used at a density of 
105 cells per well. The cells were washed twice with HBS and incubated 
with the following incubation medium at a volume of 1 ml per well at 4° C: 
0.1% BSA, lOmM glucose, lOmM HEPES, 2 mM glutamine and cell culture 
grade amirto acid mix (1:99 (v/v) dilution of GIB CO physiological amino acid 
mixture) in HBS at pH 7.2. The incubation buffer contained 10"9 M [125 j] 
iodocyanopindolol ( approximate specific activity = 2000 Ci m m oH ) and 
10_4 M isoproterenol either in the presence or absence of 10~3 M pindolol to 
estimate non-specific binding. The cells were incubated for a period of 90 
minutes as maximal binding of [125 j] iodocyanopindolol was obtained 
during this period ( See figure 2.5). After the incubation period, the cells 
were washed with the following ice-cold buffer in 3 x 1 ml volumes : 0.1% 
BSA and lOmM HEPES in HBS, pH 7.2. The cells were solubilised with 
0.5 ml sodium hydroxide/0.1% (v/v) triton-X-100 and radioactivity bound 
was determined by counting the solubilised cell samples in a LKB 1275 
MINIGAMMA gamma counter.
Under these conditions, the non-specific binding determined in the
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presence of 10~3 M pindolol was estimated to be between 10-30% of the total 
binding. The amount of [125 i] iodocyanopindolol bound to T15 cells was 
calculated from the specific binding of [125 j] iodocyanopindolol in cpm 
which was then converted to fmol iodocyanopindolol bound using the known 
specific activity of the iodinated ligand.
Figure 2.5: iodocyanopindolol binding in T15+ cells as a
function of time.
The figure shows the results from an experiment to determine the 
optimum incubation time of T15 cells with iodinated iodocyanopindolol 
which would result in maximal binding of the ligand. The experiment was 
performed as described except that no isoproterenol or pindolol was present 
in the incubation medium i.e.only total iodocyanopindolol binding was 
estimated in this experiment. T15 cells were incubated with the incubation 
medium containing 1 .8 jil of [*25]] iodocyanopindolol per well and the 
incubations were terminated at the time points indicated in the figure. The data 
are the mean values of cpm [125j] iodocyanopindolol bound per 1 0 ^ cells 
and is + S.D. (n=3).
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10. Bacterial toxin catalysed ADP-ribosvlation of T15 cell membranes.
T15 cells were grown as previously described. Membrane fractions were 
prepared from confluent cultures following washing of the cell monolayers with 
Hanks Buffered Saline at 37°C.The washed cells were homogenised with a teflon on 
glass homogeniser in a 10 mM Tris/ O.lmM EDTA buffer, pH 7.5 at 40C. The 
homogenate was centrifuged in a Beckman L5-50B ultracentrifuge using a Ti 50 rotor 
at 40 OOOg for 10 minutes. The pellet was resuspended in 0.5 ml of ice-cold buffer 
and the protein concentration determined by the Lowiy method. The membrane 
fractions from the samples were diluted to the lowest estimated protein concentration 
obtained in order to apply identical amounts of protein to each lane on the gel.
20 p.1 of the membrane fraction from each sample containing 14.2 jig of 
protein was incubated with 25 jil ribosylation mix and 5 fil o f either pertussis or 
cholera toxin (which were previously activated by incubating the toxins at 37°C for 1 
hour with the addition of 50 mM dithiothreitol) in order to ribosylate the membrane 
samples. The final reaction volume of 50 jil was incubated at 370C for 1 hour. The 
ribosylation mix contained: 0.2 M thymidine, 1.5 M potassium phosphate, 0.04 M 
ATP, 1 M Arginine/HCl and 1 mM NAD in water at pH 7.5. The incubations were 
terminated with 25 jil of 2% (w/v) sodium deoxycholate, 2.925 ml water and 1 ml 
24% (w/v) trichloroacetic acid. The tubes were centrifuged in a Beckman TJ- 6  
centrifuge at 2000 g for 20 minutes. The supernatant was discarded and 200 fil of 
the following buffer was added to each sample followed by 20 jil of 1 M Tris base: 5 
M urea, 0.17 M SDS. 0.38 M dithiothreotol, 50 jil of 1M Tris/ HC1 per ml of buffer 
and a few crystals of bromophenol blue in water. The samples were then applied to a 
10 % SDS polyacrylamide gel and the proteins separated by gel electrophoresis. The 
gel was stained to determine the positions of the protein bands and then destained 
before autoradiography for 3 days at -80°; C. The appropriate bands on the gel as 
indicated by molecular weight markers were cut from the gel and the radioactivity 
associated with each band was determined by liquid scintillation counting.
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Materials
The following is a list of sources for the materials used during the course of 
this project:
Amersham International pic. Amersham. Buckinghamshire. England.
[3H] adenine (Specific activity = 30 Ci mmol-1)
[3H] cyclic AMP (Specific activity = 52 Ci mmol-1)
[3H] Inositol (Specific activity = 22.8 Ci mmol-1)
[3h] Inositol 1 monophosphate (Specific activity =1 Ci mmol-1)
[3H] Inositol 1,4 bisphosphate (Specific activity =1 Ci mmol-1)
[3H] Inositol 1,4,5 trisphosphate (Specific activity =1 or 44 Ci mmol-1) 
[3H] Inositol 1,3,4,5 tetrakisphosphate (Specific activity =1 Ci mmol -1) 
[3H]thymidine (Specific activity = 1 Ci mmol-1)
[l^C] cyclic AMP (Specific activity = 261 mCi mmol-1)
[32p] ATP (Specific activity = 2000 Ci mmol-1)
[125i] iodocyanopindolol (Specific activity = 2000 Ci mmol-1)
BDH Chemical Company. Poole. England.
Ammoniom formate, copper sulphate, EDTA, glycerol, HEPES, 
orthophosphoric acid, potassium hydrogen phosphate, potassium 
dihydrogen phosphate, perchloric acid, sodium hydroxide, sodium 
carbonate, trichloroacetic acid and universal indicator.
Biomedical Technologies Ltd. England.
Epidermal Growth Factor
Bioprocessing Ltd. Consett. England.
Platelet Derived Growth Factor
Boehringer (UK) Ltd. Lewes. England, 
ATP, dithiothreotol, NAD and Tris.
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Calbiochem. Cambridge. England.
Forskolin
Cambridge Research Biomedicals. Cambridge. England.
Bradykinin, bombesin, gastrin releasing peptide and ^Arginine- 
vasopressin.
Formachem (Research International) pic. Strathaven. Scotland.
Boric acid, D-Glucose and sodium hydrogen carbonate,
FSA Laboratarv Supplies. Loughborough. England.
Sodium lauryl sulphate (SDS).
GIBCO. Paisley. Scotland.
All cell culture medium including amino acids mixture (50x) and glutamine 
(lOOx).
Koch-Light Ltd. Suffolk. England.
Calcuim chloride, dimethyl sulphoxide (DMSO), magnesium sulphate, 
potassium chloride and sodium potassium tartarate.
Mav and Baker. Dagenham. England.
Formic acid, hydrochloric acid and sodium tetraborate.
National Diagnostics. Aylesbury. England.
Ecoscint.
Riedel-DeHaenAg Seelze-Hannover. Germany.
Magnesium chloride and sodium dihydrogen carbonate.
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Whatman Limited. Maidstone. England.
Partisil 10 SAX HPLC column and 0.45 micron millipore filters.
All other chemicals were obtained from the Sigma Chemical Company, 
Poole, England.
B uffer C om position
Earle's Salts (x201 
2.33 M sodium chloride,
107 mM potassium chloride,
33.2 mM magnesium sulphate,
23.33mM sodium dihydrogen phosphate 
110 mM glucose
The pH of the buffer was adjusted to between 1.2-1 A  with 1 M sodium 
hydroxide.
Hanks Buffered Saline 
1.26 mM calcium chloride 
0.5 mM magnesium chloride 
0.9 mM magnesium sulphate 
5.37 mM potassium chloride 
137 mM sodium chloride
4.2 mM sodium hydrogen carbonate 
0.35 mM sodium dihydrogen phosphate
The pH of the buffer should be between pH 1.2-1 A  when freshly made.
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Phosphate Buffered Saline (PBS)
146 mM sodium chloride
5.36 mM potassium chloride
9.6 mM disodium hydrogen phosphate
1.46 mM potassium dihydrogen phosphate
The pH of the buffer was adjusted to between pH 7.2-7.4.
All buffers were made using distilled water and were stored at 4°C.
Preparation of Dowex 1 x8-200 formate form.
Dowex 1 x 8-200 chloride form was obtained from the Sigma Chemical 
Company and treated as follows to obtain Dowex formate for use in anion 
exchange chromatography of inositol phosphates: A known packed volume 
of Dowex was washed with distilled water, left to settle and the unsettled 
Dowex discarded. This process was repeated twice. The Dowex was 
transferred to a scintered glass funnel and washed with approximately 2 0  x 
its volume of 2 M sodium hydroxide. The Dowex was then washed with 10 
x its volume of water followed by approxomately 5 x its volume of 1 M 
formic acid. Finally, the Dowex was washed with 50 x its volume of water 
until the pH of the Dowex slurry was constant at approximately pH 5.5.
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Chanter 3: Inositol phosphate production in p 21 N-EHS 
transformed cells,
Introduction
The function of p2122$ in cell proliferation and transformation is not 
known, although its role has already been discussed (see introduction). In 
1985, Chiarugi el al showed that in Ha-ras transformed Balb/c3T3 murine 
fibroblasts, muscarinic stimulation of inositol phosphate production was 
increased. We utilised the T15 cell line to investigate the effects of p21 N-ras 
transformation on the inositol phospholipid signalling pathway.
The T15 cell line is a clone of NIH3T3 cells transfected with a human 
foetal genomic N-ras proto-oncogene. The expression of the proto-oncogene is 
under the control of a glucocorticoid-inducible MMTV-LTR promoter (McKay 
et al, 1986). The T15 cell line is derived from a clone obtained during the 
transfection experiments which resulted in 0 % transformants in dexamethasone- 
free growth medium and 1 0 0 % transformants when grown in dexamethasone- 
containing growth medium. When the cells are grown in the presence of 
dexamethasone (T15+) they exhibit the transformed phenotype.When T15 cells 
are grown in the absence of dexamethasone (T15-) they resemble wild-type 
NIH3T3 cells in morphology and growth characteristics. The transformation of 
the T15 cells is due to the overexpression of p21 N-ras which results in an 
approximately 50 fold increase in p21 N-ras levels compared to non­
transformed NIH3T3 cells. This provides a useful experimental system for 
studying the effects of the ras gene product on second messenger systems.
The effects of p21 N-ras transformation on the phosphoinositide 
signalling system are shown in this chapter. This was investigated by 
measuring basal and agonist stimulated total inositol phosphate production in 
T15 cells. Total inositol phosphate measurements are a useful indication of the 
activation of the phosphoinositide signalling pathway and indicates if inositol 
mono-, bis- and tris-phosphates and their isomers are generated. The generation 
o f total inositol phosphates is proportional to receptor mediated Ptdlns 4,5 P2
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hydrolysis, although this may also be a consequence of Ptdlns 4 P j  hydrolysis on receptor activation.
To measure total inositol phosphate accumulation on agonist
stimulation, the lithium assay was employed. Lithium ions have been shown to
inhibit the phosphatases which degrade inositol monophosphates to inositol
(Majerus et al, 1988). If this step is blocked there will be an accumulation of
inositol phosphates. Since [^H] inositol labelled cells are used in these
experiments, the accumulation of [^H] inositol phosphates can be determined
by liquid scintillation counting.In the absence of lithium, there will be very low
levels of radioactivity detected in both control and stimulated inositol phosphate
fractions.
R esults
The photographs overleaf show confluent cultures of T15+ and T15- 
cells and indicate the morphological transformation associated with p21 N-ras 
overexpression in this cell line. These photogrpaphs were taken at 360 x 
magnification and provided by Caroline Evans.
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T15+ cells
-X
[^H] thymidine incorporation can be used as an index of cell 
proliferation although it is not an absolute quantification of proliferation as^for 
example, cell counting. Bearing in mind the limitations of this method, tritiated 
thymidine incorporation was used to determine if p2 1  N-rgs transformed 
NIH3T3 cells demonstrated differences in the rate of proliferation as compared 
to wild type NIH3T3 or T15- cells. Rapid proliferation is one of the 
characteristics of transformed cells (See Introduction) and can be indicative of 
the activation of growth factor pathways.
The experiments were performed on quiescent cells, that is, cells that 
have been growth arrested in the G i phase of the cell cycle ( See Methods 
section). It was not possible to maintain T15+ cells in the G0/G1 phase since transformed
cells do not contact inhibit and have lower serum growth factor requirements. This is 
due to the associated secretion of autocrine growth factors in transformed cells 
and therefore these cells can grow with very low levels of exogenous growth 
factors in the medium. However, the experiment utilised T15+ cells that had 
been treated in the same way as T15- and NIH3T3 cells i.e. serum deprivation.
The data in figure 3.1 shows that T15+ cells incorporate thymidine into DNA more rapidly 
than T15- or NIH3T3 cells and this is thus an indication that T15+ cells have an 
increased rate of proliferation. The rates of [^H] thymidine incorporation into 
T15- and NIH3T3 cells appear to be similar and indicates that the transfected 
uninduced N-ras proto-oncogene does not affect cell proliferation. The 
thymidine incorporation in T15- and NIH3T3 cells is negligible until after 24 
hours and the increase in incorporation after this time is probably due to the 
entry of cells into S phase. However, in T15+ cells there does not appear to be 
a lag phase in the rate of [^H] thymidine incorporation.This rapid incorporation 
of thymidine into T15+ cells without any lag phase is possibly due to the non- 
synchronous cell population.
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Figure 3.1; Tritiated thymidine incorporation in T15 and NIH3T3 
c e i ls .
The graph in figure 3.1 shows the [^H] thymidine incorporation into 
acid insoluble fraction of NIH3T3 and T15 cells determined as described in the 
Methods section. The results are cpm /  dish ± S.D., n=3 and represent one 
experiment which is typical of two separate experiments.
The cells were incubated with [3H] thymidine for the appropriate times as 
indicated in figure 3.1.
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It has been demonstrated that T15+ cells have a higher proliferative rate 
than T15- or NIH3T3 cells. This could be due to the sustained activation of the 
phosphoinositide signalling system, which could be associated with cell 
proliferation. To investigate this possibility, experiments were performed on 
T15+ and NIH3T3 cells to determine if p21 N-ras transformed cells exhibited a 
greater turnover of their inositol phospholipids than NIH3T3 cells.This would 
indicate that the transformed cell are turning over Ptdlns 4,5 P2  at a greater rate 
than non-transformed cells and this may be a transformation-related event.
It was necessary to determine the characteristics of [3h ] inositol 
labelling of lipids in T15+ and non-transformed cells to investigate the 
possibility of different turnover rates of inositol phospholipids in these cells. 
Initially, NIH3T3 and T15+ cells were labelled with tritiated inositol over a 
period of 48 hours. After this time, the amount of radioactivity associated with 
the lipid fraction from chloroform/methanol treated cells was determined (see 
Methods). The data obtained from these experiments showed that there was 2.7 
times the amount of total [3h ] inositol labelled lipids in the N-ras transformed 
cells compared to the non-transformed cells (Results not shown).
The results in figure 3.2a show that T15+ cells have significantly higher 
incorporation of tritium into GPIP and GPIP2  than non-transformed cells 
(figure 3. 2b). The increased labelling in the GPIP and GPEP2  fractions in 
T15+ cells is not due to cell number differences as the data is normalised for the 
amount of protein assayed. Therefore,these higher levels of [3H] GPIP and 
[3H] GPIP2  (also [3H] GPI, results not shown) in the T 15+ cells are probably 
associated with cell proliferation. The peak levels of [3H] GPIP and [3H] 
GPIP2  in NIH3T3 cells appears at 8  hours and is followed by a decrease in 
[3H] GPIP and [3H] GPIP2  levels.
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F ig u re  3,2; f3 H l inositol labelling of inositol lipids in NIH3T3 
and  T15+ cells
Figure 3.2 shows the results of an experiment to label inositol 
phospholipids and then separate them into PI, PIP and PIP2 . The separation 
method involves the deacylation of these lipids into glycerophosphoinositol 
(GPI), glycerophosphoinositol monophosphate (GPIP) and 
glycerophosphoinositol bisphosphate (GPIP2 ). The graph in figure 3.2a 
shows the results from experiments performed on T15+ cells and the results in 
figure 3.2b show the resultsjfrom a similar experiment using NIH3T3 cells.
Both experiments were performed under the same conditions. The data in both 
figures are from one experiment and are expressed as mean dpm/mg protein ± 
S.D., n=3. Only results for GPIP and GPIP2  are shown.
The results from an experiment using [32p] inorganic phosphate to label 
the inositol phospholipids in T15+ and NIH3T3 cells over a period of 2 hours 
indicated the same trends in the deacylated fractions of GPI, GPIP and GPIP2 . 
Therefore, these results also suggest that T15+ cells have a higher turnover of 
inositol phospholipids than NIH3T3 cells.
j These experiments were not performed on T15- cells as it was thought that 
T15- cells, being non-transformed clones of NIH3T3 cells would exhibit similar 
characteristics in terms of [3H] labelling of inositol phospholipids as the parental cell 
line. Also, during the period these experiments were performed, T15- cells were not 
available due to the associated problems of spontaneous transformation.
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The higher labelling^[3H]jassociated with inositol phospholipids in 
T15+ cells as compared to NIH3T3 cells could be due to increased basal 
turnover of inositol ph ; ospholipids on p21 N-ras transformation. Increased 
basal turnover has been reported in RS V transformed quail embryo cells 
(Diringer and Friss, 1977) and may be a consequence of oncogene activation or 
due to increased receptor stimulated Ptdlns 4,5 P2  hydrolysis.
If the production of inositol phosphates is measured in the absence of 
agonists, then a basal level of inositol phosphate production can be determined. 
Basal levels of inositol phosphates and inositol phospholipids were determined 
as in the Methods section using T15- cells as a control for T15+ cells.
Figure 3.3 shows the results from an experiment to determine the basal 
rates of inositol phospholipid turnover in T15+ and T15- cells. Washed cells 
were incubated for the times shown in the presence of lithium ions and in the 
absence of any agonists and after the incubations were quenched, total inositol 
phosphates and phospholipids were determined.
The results show that there is no change in the basal rate of inositol 
phospholipid turnover between T15+ and T15- cells. The basal rate is defined 
as cpm phosphate /  cpm lipids % /  time in minutes. For both T15+ and T15- 
cells,this value is 0.048 m in 'l. The figure shows that at time 0, the T15+ cells 
have a higher inositol phosphate/inositol phospholipid ratio than the T15- cells. 
This is probably due to the cell number difference between T15+ and T15- cells 
in the assay.
Figure 3.3: Basal rates of inositol phospholipid turnover in TI5  
g.&US-i
Figure 3.3 shows the results of an experiment to determine the basal rate 
of inositol phosphate production in T15+ and T15- cells performed as already 
described. Results are means ±  S.D., n=3 and values are expressed as cpm 
inositol phosphates/cpm inositol phospholipids (%) which are plotted against 
time in minutes.
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8
T15+
T15-7
6
5
4
3
2
8 04 0 6 0200
Tim e/m ins
67
Thus, having determined that there is no change in the basal rate of 
inositol phospholipid turnover in T15+ and T15- cells, agonist stimulated 
inositol phosphate production in these cells was investigated.The production of 
inositol phosphates in response to agonist stimulation has been well 
documented (See Berridge and Irvine, 1984). A range of peptide and 
polypeptide agonists were screened for their ability to stimulate inositol 
phosphate production in T15 cells. This was to determine if there were changes 
in stimulated inositol phosphate production in cells transformed by the 
expression of p21 N-ras jn figure 3.4, only the results from experiments using 
T15+ and T15- cells have been shown. Preliminary experiments with NIH3T3 
cells indicated that basal and stimulated inositol phosphate production in this cell 
line was identical to that in the T15- cells.
The data indicates that only bradykinin, calf serum, GRP and bombesin 
stimulate significant inositol phosphate production in T15 cells. Bombesin 
stimulated an approximately 2.5-fold increase in the level of inositol phosphates 
in T15+ cells whilst in T15- cells bombesin stimulated a 1.3-fold increase.
Also, the levels of inositol phosphates stimulated by calf serum, bradykinin and 
GRP in T15+ cells was approximately 1.6-, 1.5- and 2-fold respectively as 
compared to basal levels. In contrast, these agonists caused an increase in 
inositol phosphates of approximately 1.3 -fold for calf serum and bradykinin 
and 1.4-fold for GRP as compared to basal levels.The inositol phosphate 
response to agonists in T15- cells was always lower than, or the same as, T15+ 
cells. Therefore, stimulated inositol phosphate production in T15+ cells is 
amplified compared to T15- cells. Previous experiments indicated that this 
amplification was not a consequence of cell number differences between the two 
cell types i.e. the increase in total inositol phosphates seen in growth factor 
stimulated T15+ cells was not due to a greater number of T15+ cells in the 
assay.
Figure 3.4: Agonist stimulated total inositol phosphate production 
in T15 cells.
Figure 3.4 shows results from experiments to determine stimulated 
inositol phosphate production in response to different agonists in T15+ and 
T15- cells. The concentrations of the agonists were as follows:
Bombesin: 2.5p.M (n=10), Bradykinin: 3.2p.M (n=4), EGF: 16 nM (n=7),
A VP: 0.4 jiM (n=3), Calf serum: 10% (v/v) (n=3), GRP: 1.4|iM (n=2)
PDGF: 44 nM (n=4).
Results are expressed as stimulated value/basal value (%). These ratios are used 
for all experiments unless otherwise stated. Data are pooled from the number of 
experiments shown (n),three replicates within each and are means ± S.E.M. 
where n >3 and are ± S.D. where n < 3. ! * p < 0.015 
N.B. AVP used above and in the figure indicates 8 Arg-Vasopressin
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Dexamethasone, which was used to induce p21 N-ras expression in the 
T15 cell line, is a glucocorticoid and can have a variety of effects upon cells, 
depending on the cell type. It was considered possible that dexamethasone 
treatment of T15 cells could have resulted in non-specific effects which could be 
the cause of the amplified inositol phosphate response in T15+ cells.
Therefore, it was necessary to determine if dexamethasone treatment of 
NIH3T3 cells resulted in amplified bombesin stimulated inositol phosphate 
production as in T15+ cells. NIH3T3 cells were treated with dexamethasone 
(2jiM) for 72 hours and treated and untreated control cells were stimulated with 
3 different concentrations of bombesin to determine stimulated inositol 
phosphate levels.
The graph in figure 3.5 shows that dexamethasone had no effect on 
stimulated inositol phosphate production at three different concentrations of 
bombesin. There was also no effect on the basal level of inositol phosphates in 
NIH3T3 cells. These results demonstrate that the amplified bombesin stimulated 
inositiol phosphate production in T15+ cells is not due to dexamethasone itself, 
but is probably associated with the overexpression of p21 N-ras.
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Figure 3.5: Basal and bombesin stimulated inositol phosphate 
production in dexamethasone treated NIH3T3 cells.
The results in figure 3.5 show the results from experiments to determine 
if dexamethasone treatment of NIH3T3 cells resulted in increased bombesin 
stimulated inositol phosphate levels as compared to control cells. Inositol 
phosphate values are expressed as % increase of basal values and are means ± 
S.D. and are from one experiment representative of two.
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Figure 3.5
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In order to investigate if there were transformation-related changes at the 
receptor level which caused the increase in bombesin stimlated inositol 
phosphate production in T15+ cells, a detailed characterisation of the bombesin 
response was performed. [ ^ I ]  bombesin binding to T15 cells demonstrated 
that the number of bombesin receptors in T15+ and T15- cells are the same, at 
approximately 4500 receptors per cell. (Wakelam et al 1986) Therefore, a dose 
response curve for inositol phosphate production in response to increasing 
concentrations of bombesin was constructed for both T15+ and T15- cells. This 
would indicate if there were changes in ligand binding characteristics of the 
bombesin receptor in T15 cells following ras induced transformation which 
would account for the amplified inositol phosphate response.
The results show that the bombesin stimulated inositol phosphate 
response in T15+ cells was amplified compared to T15- cells at all 
concentrations of bombesin tested. However, no change in the Ka value for the 
agonist was detected between the cell types, Ka=lnM bombesin. This indicates 
that the amplified inositol phosphate response in T15+ cells was not due to 
changes in the binding characteristics of the bombesin receptor. Since the 
number of bombesin receptors in T15+ and T15- cells was the same,
(Wakelam ej al, 1986) the amplification of stimulated inositol phosphate 
production was probably due to a post-receptor effect of p2 lN-ras^
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Figure 3.6; Dose .response curve of bombesin stim ulated inositol 
phosphate production in T15 cells.
The graph shows the results from experiments to determine the Ka 
values for bombesin stimulated inositol phosphate production in T15 cells. The 
data are means ±  S.E.M. and are pooled from 3-5 separate experiments, where 
n=3 in each.
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Bombesin was first isolated from frog skin and although it elicits a 
mitogenic response in several cell types (See Introduction) and stimulated 
inositol phosphate production in T15 cells, it was necessary to examine the 
inositol phosphate response of these cells to a mammalian equivalent of this 
peptide in more detail. As the data in figure 3.4 demonstrated that GRP caused 
an approximately 1.9-fold increase in inositol phosphate production in T15+ 
cells, a dose-response curve of inositol phosphate production to this peptide 
was constructed to determine if the characteristics of this recptor changed on 
p 2 1  N-ras transformtion of T15 cells.
The data in figure 3.7 shows that GRP stimulated inositol phosphate 
production in both T15+ and T15- cells at all concentrations tested although the 
response in T15+ cells was amplified. The Ka value of GRP stimulated inositol 
phosphate production in both cell types was estimated to be 2nM. This is in the 
same order of magnitude as the Ka value for bombesin and it was probable that 
GRP bound to the bombesin receptor in this cell line.
Figure 3.7: Dose response curve of GRP stimulated inositol 
phosphate production in T15 cells.
The graph shows the dose response curve of inositol phosphate 
production in response to GRP in T15+ and T15- cells. The experiment was 
carried out using the concentrations of GRP indicated in the figure. The results 
are means ± S.D., n=3 and are representative of two separate experiments.
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The previous results demonstrated that the inositol phosphate response 
to bombesin was increased in T15+ cells as compared to T15- cells. However, 
it was unclear if this effect was due to a ras-induced or transformation-induced 
effect Therefore, it was important to demonstrate that dexamethasone-induced 
p21 N-ras expression could be correlated to stimulated inositol phosphate 
production in T15+ cells. The hypothesis that p21 N-ras was involved with 
stimulated inositol phosphate production could be tested in this inducible cell 
line and would indicate if there was a 'titratable' function of p21 N-ras ^  the 
phosphoinositide signalling system directly associated with cell proliferation 
and transformation but occuring before the onset of these processes.
A time course of dexamethasone treatment of T15- cells was performed 
to determine if increasing the length of time of dexamethasone exposure to T15- 
cells would lead to increased stimulated inositol phosphate production in 
response to bombesin.T15- cells were treated with 2jiM dexamethasone for the 
times indicated and basal and bombesin (2.5pM) stimulated inositol phosphate 
production determined. The figure shows that significant inositol phosphate 
production occured six hours after dexamethasone treatment in response to 
bombesin. However, there was a decrease in the stimulated levels of inositol 
phosphates at 1 2  hours following the addition of dexamethasone but the levels 
of stimulated inositol phosphate then increase after this time point. The maximal 
response at 48 hours after dexamethasone treatment is 160% of the basal value 
and is a significant amplification in response as compared to T15- cells. These 
results indicated that stimulated inositol phosphate production in T15+ cells 
occured prior to morphological transformation and was a direct consequence of 
p2lN-ras expression. These results are consistent with data obtained by C. 
Marshall (results not shown) which indicate that p2 1  N-ras can ^  detected in 
whole cell lysates 6  hours after the addition of dexamethasone. The generation 
of p21 N-ras can thus be correlated with bombesin stimulated inositol 
phosphate production in this cell line.
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Figure 3.8; Time course of dexamethasone induced amplification 
stim ulated inositol phosphate production T15 cells.
The results in figure 3.8 are from experiments to determine if 
progressive dexamethasone treatement of T15- cells over a period of 48 hours 
resulted in a p21 N-ras induced increase in bombesin stimulated inositol 
phosphate production.The results are means ± S.D., n=3 and are representative 
of two separate experiments. The stimulated inositol phosphate levels are 
expressed as % stimulated inositol phosphate levels of the basal.
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Reports in the literature are conflicting as to if Gp is a pertussis toxin 
insensitive protein or not (See Introduction). It was important to determine if the 
bombesin stimulated inositol phosphate production in T15 cells was bacterial 
toxin sensitive for two main reasons: firstly, to determine if Gp in T15 cells was 
sensitive to the bacterial toxins, cholera and pertussis toxins and secondly, if 
p2 1  N-ras COuld function as, or interact with, Gf in stimulated inositol 
phosphate production.
Therefore, the effects of cholera and pertussis toxin treatment on 
bombesin stimulated production in T15+ and T15- cells were determined. T15+ 
and T15- cells were pre-treated with 100 ng ml-* of cholera and pertussis toxin 
for 16 hours prior to the experiment. It is clear that using this procedure, the 
pertussis toxin and cholera toxin substrates in T15 cells are maximally 
ribosylated (See figure 3.10). Therefore, any effects of the toxins on inositol 
phosphate production will be due to specific effects of the toxins as a 
consequence of NAD ribosylation.
The data in figure 3.9 shows that pertussis toxin treatment had no effect 
on bombesin stimulated inositol phosphate production but cholera toxin pre­
treatment of the cells resulted in a decrease of appoximately 40% of stimulated
inositol phosphate production. This result indicates that bombesin stimulated
+
inositol phosphate production in T15 cells was pertussis toxin insensitive but 
was inhibited by cholera toxin.
F igure 3.9: Effects of bacteria l toxin tre a tm ent on inositol 
phosphate p roduction  in T15 cells.
The results in figure 3.9 are from experiments to determine the effects of 
bacterial toxin treatment of T15 cells on basal and stimulated inositol phosphate 
levels. The experiments were carried out on pertussis toxin and cholera toxin 
treated T15 cells and basal and bombesin stimulated inositol phosphate 
production was measured in these cells using untreated cells as controls. The 
results are means ± S.D., n = 3 and are pooled from two separate experiments. 
The abbreviations used in the figure are:
B = bombesin 
PTox = Pertussis Toxin 
CTox = Cholera Toxin
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As it was necessary to demonstrate that bacterial toxin treatment of T15 
cells resulted in maximal ADP-ribosylation of their substrates the experiment - 
described below was performed. T15- and T15+ cells grown as previously 
described to confluency were either left untreated (control cells) or treated with 
either cholera or pertussis toxin at a concentration of 1 0 0  ngml"^ for 16 hours 
prior to the experiment. There were therefore, 6  different cell samples and these 
samples were treated as described in the Methods section.
If the pre-incubation of T15 cells with bacterial toxins resulted in 
further ribosylation of pertussis/cholera toxin pre-treated membranes by 
activated pertussis/cholera toxin then the conclusion must be that incubation of 
T15 cells with these bacterial toxins for 16 hours at a concentration of 100 
ngm l'l is not sufficient to maximally ribosylate the relevant G proteins. 
However, the photograph of the gel from this experiment shown in figure 3.10 
clearly demonstrates that this is not the case. The lanes marked a-n are described 
in the figure legend.
The photograph indicates that treatment of control T15+ and T15- 
membranes with activated cholera and pertussis toxins resulted in significant 
[32p] incorporation into proteins of 45 kD and 40 kD respectively. The band at 
45 kD corresponds to Gsa  whilst the band at 40 kD corresponds to G ja. The 
results indicate that there was no further cholera toxin catalysed ADP- 
ribosylation of cholera toxin pre-treated T15+ and T15- membranes (Lanes d 
and k). In contrast, there was cholera toxin catalysed ADP-ribosylation of Gsa  
in control and pertussis toxin treated T15+ and T15- cells (Lanes b,i and lanes 
f,m). Also, pertussis toxin ribosylation of T15+ and T15- membranes only 
occured in cholera toxin pre-treated cells (Lanes e and 1) and in control cells 
(Lanes c and j) whereas there was no ADP-ribosylation of membranes from 
pertussis toxin pre-treated T15 cells (Lanes g and n). Therefore, pre-treatment 
of T15 cells with bacterial toxins for 16 hours at 100 ng ml"l was sufficient to 
maximally ribosylate G protein substrates. The autoradiograph also indicates 
that there are no other cholera and pertussis toxin sensitive substrates detectable
in either T15- or T15+cells.The bands at approx. 20 000 Mr indicate the j
| i
intramolecular ADP-autoribosylated cholera toxin A chain as a result of the low j 
amounts of sample membrane protein incubated with this bacterial toxin.
The amount of radioactivity associated with the 45 kD and 39 kD bands
in each lane indicated that T15+ membranes contained approximately 6  times the
amount of Gsa  and 3 times the amount of GiOt compared to T15- cells.
However, this result is from one experiment and was based on very low
associated levels of [^^-P] with each band and therefore cannot be accepted as a J
conclusive result. This data, although based on one experiment, is inconsistent with the data
obtained by Milligan ££ a ! , see Discussion chapter. The reasons for this are unclear 
but may reflect the different cell preparations used between the experiments and may
also reflect differences in cell cycle stages between these different batches of cells.
F igure  3.1Q : A D P-ribosvlation of T15- and  T15+ m em branes 
w ith bacteria l toxins
The photograph shows the results from an experiment to determine the 
effect of pertussis and cholera toxin catalysed ADP-ribosylation of membranes 
prepared from bacterial toxin pre-treated T15+ and T15- cells. The lanes are as 
follows: (Cholera toxin and pertussis toxin have been abbreviated to CTox and 
PTox respectively.)
Lane a: Molecular weight markers
Lane b: Control T15+ cell membranes ADP-ribosylated with CTox.
Lane c: Control T15+ cell membranes ADP-ribosylated with PTox.
Lane d: CTox pre-treated T15+ cell membranes ADP-ribosylated with CTox.  ...........
Lane e: CTox pre-treated T15+ cell membranes ADP-ribosylated with PTox.
Lane f: PTox pre-treated T15+ cell membranes ADP-ribosylated with CTox.
Lane g: PTox pre-treated T15+ cell membranes ADP-ribosylated with PTox.
Lane h: Molecular weight markers
Lane i: Control T15- membranes ADP-ribosylated with CTox.
Lane j: Control T15- membranes ADP-ribosylated with PTox.
Lane k: CTox pre-treated T15- membranes ADP-ribosylated with CTox.
Lane 1: CTox pre-treated T15- membranes ADP-ribosylated with PTox.
Lane n: PTox pre-treated T15- membranes ADP-ribosylated with CTox.
Lane m: PTox pre-treated T15- membranes ADP-ribosylated with PTox.
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F i g ure 3 .1Q
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D iscu ssio n
The results in this chapter show that p21 N-ras transformed cells exhibit 
the growth characteristics of and the transformed phenotype associated with 
tumouregenic cells. The photographs of the T15 cells indicate the morphological 
changes associated with p2 lN-ras transformation of NIH3T3 cells. T15+ cells 
do not stop proliferating on contact with neighbouring cells, that is, they lose 
contact inhibition. T15+ cells also have elongated processes and grow in 
distinct clumps. This is in contrast with T15- cells which exhibit contact 
inhibition and therefore grow in a monolayer. T15+ cells are less adhesive than 
T15- cells and all these observations are consistent with the characteristics of 
transformed cells and reflects their ability to become invasive as tumours 
following injection into a mouse.
T15+ cells proliferate more rapidly and have a greater turnover of 
inositol phospholipids than non-transformed cells (see figures 3.1 and 3.2).
This indicates that there may be a role for increased inositol phospholipid 
turnover in cell proliferation and transformation.In figure 3.1, the lack of a lag 
phase in [^H] thymidine incorporation in T15+ cells may be due to the non- 
synchronous, non i-quiescent cell population. These cells do not become 
quiscent when grown in 1% calf serum and DMEM unlike the non-transformed 
cells, which indicates the reduced growth factor dependence of transformed 
cells. NIH3T3 and T15- cells do not exhibit significant thymidine incorporation 
until after 18 hours of exposure to 10 % calf serum. This probably reflects the 
initiation of a new cycle of mitosis after 18 hours in these synchronous cell 
populations.
Figure 3.2a indicates that there is ;[^H] inositol incorporation into inositol 
phospholipids in T15+ cells as compared to T15- cells (figure 3.2b) and this 
suggests a role for Ptdlns 4,5 P2  hydrolysis in cell proliferation and 
transformation. The incorporation of [^H] inositol into PIP and PIP2  in 
NIH3T3 cells reaches a steady level after 12 hours (figure 3.2b) although the 
rate of incorporation of [^H] inositol continues to increase in T15+ cells (figure
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3.2a). This may be due to the inhibition of mechanisms that normally 
desensitise inositol phospholipid turnover in normal cells in the transformed 
cells.This increase in inositol phospholipid turnover in T15+ cells could be due 
to an increased basal inositol phosphate production on p21 N-ras 
transformation. From the data shown in figure 3.3, it is clear that the basal rate 
of inositol phospholipid turnover is the same in T15+ and NIH3T3 cells and 
suggests that there is increased receptor-mediated Ptdlns 4,5 P2  hydrolysis in 
p21 N-ras transformed cells. Therefore, the increase in inositol phospholipid 
turnover in T15+ cells as shown in figure 3.2a cannot be explained by increased 
basal production of inositol phosphates but must occur by a different 
mechanism.
The data in figure 3.4 demonstrates that in T15+ cells there is an 
amplification of stimulated inositol phosphate production in response to gastrin- 
releasing peptide and bombesin and to a lesser extent, calf serum and 
bradykinin. This amplification is not due to a change in bombesin or GRP 
receptor number in T15+ cells (Wakelam et aL 1986) nor is it due to a change 
in receptor binding characteristics as a consequence of ras transformation 
(figures 3.6 and 3.7).The amplification of bombesin induced inositol phosphate 
production in T15+ cells is not due to autocrine secretion of growth factors like 
TG Fa which have been shown to bind to the EGF receptor. This possibility has 
been ruled out by the fact that EGF does not stimulate significant inositol 
phosphate production in T15 cells (figure 3.4) and that EGF and bombesin 
stimulate inositol phosphate production to the same extent as bombesin alone 
(Wakelam £t a!, 1986). Therefore, EGF and by extension, TG Fa cannot induce 
inositol phosphate production in this cell line.
The data in figure 3.4 also shows that vasopressin has no effect on 
inositol phosphate production in T15 cells and this indicates that this cell line 
may not have Y \  receptors, that is, vasopressin receptors that are linked to the 
phosphoinositide signalling system. PDGF did not stimulate inositol phosphate 
production in T15 cells although this may have been due to the relatively impure 
PDGF preparation used in these experiments. It has been demonstrated since
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these experiments were performed that highly purified PDGF will stimulate 
inositol phosphate production in NIH3T3 and T15 cells although there is no 
amplification of the response in ra$ transformed cells (Black, F., Gardner, S. 
and Wakelam, M.J.O. unpublished data). Indeed, a desensitisation of PDGF 
stimulated inositol phosphate production in ras transformed cells has been 
reported in the literature (See Discussion chapter).
EGF, as already discussed, does not stimulate inositol phosphate 
production in T15 cells although it has been shown to be a potent mitogen in 
this cell line (Wakelam si al, 1986). The effects of EGF on mitogenesis are 
clearly established although the mechanism(s) by which this occurs is unclear.
Besterman et al (1986) have demonstrated that inositol phospholipid
hydrolysis is not associated with EGF induced mitogenesis of BALB/c3T3
fibroblasts. It has also been shown that EGF stimulated inositol phosphate
production occurs via a distinct mechanism as compared to bradykinin
stimulated inositol phosphate production in A431 cells (Tilly £t al, 1988). EGF
stimulates a small accumulation of Ins 1,4,5 P3  after a lag period in these cells
as compared to bradykinin although there is an associated EGF induced rise in
cytoplasmic free calcium.Thus, it is becoming increasingly clear that the mechanism of inosit<
phosphate generation by EGF is distinct from that caused by other mitogenic
peptides. The fact that EGF does not induce significant inositol phosphate
production in the T15 cells line but does act as a mitogen is not surprising
when the facts above have been considered. The mode of action of EGF may be
due, in part, to the tyrosine kinase activity of the EGF receptor.
The results in figure 3.4 demonstrate that the mammalian eqivalent of 
bombesin, GRP, can stimulate inositol phosphate production in T15 cells to the 
same extent as bombesin.The binding characteristics of the receptors for these 
peptides appear to be similar and the Ka values for bombesin and GRP are 
within the same order of magnitude (see figures 3.6 and 3.7). Since the Ka 
values are very similar, it is probable that bombesin and GRP bind to the same 
receptor on T15 cells. This is clinically relevant as it has been shown that small 
cell lung cancer (SCLC) cells secrete bombesin and bombesin like peptides in
J  1
an autocrine fashion and that the peptides bind to the same receptor (Cuttita et 
a!, 1985; Alexander et al, 1988). This autocrine secretion of bombesin and its 
related peptides is associated with the development of the tumouregenic state 
and indicates that bombesin and gastrin releasing peptide can have important 
growth factor roles in some cells.
The data in figure 3.8 shows that p21 N-ras induced amplification of 
inositol phosphate production can be detected approximately 6  hours after 
dexamethasone treatment of T15- cells. The production of inositol phosphates 
in response to bombesin decreases at 1 2  hours and it is possible that this effect 
is due to reduced synthesis of p2 1  N-ras mRNA at this time point. Owen and 
Ostrowski (1987) have shown that dexamethasone induced expression of 
steroid-inducible p21 Ha-ras in NIH3T3 cells is reduced after 12 hours of 
dexamethasone treatment as indicated by the levels of mRNA for p21 Ha-ras in 
their cell system. It is possible that these effects are peculiar to the expression of 
the ras proto-oncogene linked to a dexamethasone-inducible promoter. It has 
been shown that dexamethasone induction of p21 N-ras js responsible for cell 
proliferation and transformation (McKay, et al 1986). Increased stimulated 
inositol phosphate production can be correlated with an increasing concentration 
of dexamethasone, and therefore, an increasing amount of p21 N-ras 
(Wakelam, et al 1987) .These data suggest that the ras-induced amplification of 
inositol phosphate production is not associated with the transformed state, but is 
an early event in cell proliferation and transformation and is directly a 
consequence of p21 N-ras expression .
The inositol phosphate response to bombesin is not pertussis toxin
4-sensitive m T15 cells although cholera toxin reduces stimulated inositol 
phosphate levels by approximately 40%. Low and Hughes (1987) have 
proposed that a novel G protein exists which is cholera toxin sensitive and 
inhibits inositol phosphate production in anterior pituitary cells. However, 
Guillon et al (1988) have shown that cholera toxin reduces the number of 
vasopressin receptors in WRK-1 cells, thus reducing vasopressin stimulated 
inositol phosphate production. Gardner et a! (1989) have demonstrated that
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inhibition of stimulated inositol phosphate production in L6  cells induced by 
cholera toxin is mediated by cAMP and is an effect upon receptor number. We 
have shown that cholera toxin does not alter the number of bombesin receptors 
in T15 cells although raising intracellular cyclic AMP levels results in an 
inhibition of bombesin stimulated inositol phosphate production (Milligan et al, 
in preparation). Therefore, the inhibition of bombesin stimulated inositol 
phosphate production in T15 cells could be due to a novel cholera toxin 
activated G protein or may be due to to an effect of cAMP in these cells. 
However, the data in figure 3.10 has demonstrated that there are no novel 
cholera toxin sensitive G protein substrates in T15 cells. Also, it has been 
shown that increasing cyclic AMP concentrations in T15+ cells by either 
forskolin treatment or via a (3 adrenergic agonist in the presence of a 
phosphodiesterase inhibitor has no effect on bombesin stimulated inositol 
phosphate production (Milligan et al, in preparation).
Recently, it has been demonstrated that the bombesin receptor is coupled 
to a pertussis toxin insensitive G protein in various cell types including Swiss 
3T3 cells (Fischer and Schonbrun, 1988) and it is possible that this G protein 
acts as Gp in T15 cells. It is also possible that p21 N-ras can act as or can 
interact with Gp as an a  subunit in this cell line due to the pertussis toxin 
insensitivity of the bombesin stimulated inositol phosphate response in T15+ 
cells and may explain the post-receptor effects of p2 1  N-ras on stimulated 
inositol phosphate production. The pertussis toxin insensitivity of this response 
further implies that p2 1  N-ras does not amplify the effects of Gj in this cell line 
and that Gj is not involved in modulating stimulated inositol phosphte 
production.
Therefore, the results presented in this chapter indicate that the effects of 
p2 1  N-ras overexpression in the T15 cell line on cell proliferation and 
transformation may be mediated in part by the amplification of growth factor 
stimulated inositol phosphate production in T15+ cells.
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Chapter 4; Bombesin stimulated Ins 1.4,5 P3 production in T15 
sells*
Introduction
In Chapter 3, the effects of p21 N-ras upon stimulated inositol 
phosphate production have been discussed. Although total inositol phosphate 
production can be an indication of Ptdlns 4,5 P2  hydrolysis as a result of 
phosphoinositidase activation, it could also occur as a consequence of Ptdlns 
hydrolysis (Majerus et al. 1988). To obtain conclusive evidence as to which of 
these processes occured, the separation of inositol phosphates from stimulated 
T15 cells was performed.
Cell extracts were prepared from control and stimulated cells in the 
presence of lOmM lithium chloride and these extracts were applied to Dowex 
formate columns to separate the different inositol phosphates. This method of 
separation will resolve inositol mono-, bis-, tris- and tetrakisphosphates 
(Benidge_et al, 1982) but will not separate the various isomers of these 
compounds. Therefore, cell extracts from basal and stimulated T15 cells were 
also applied to a Partisil 10 SAX column and the inositol phosphates separated 
by HPLC.
These methods allowed the investigation of the mechanisms of 
bombesin induced hydrolysis of inositol phospholipids in T15 cells. From the 
data obtained in figure 3.4, Chapter 3, bombesin and GRP stimulated the 
largest production of inositol phosphates in T15 cells compared to the other 
peptides tested. Since bombesin has been demonstrated to bind to the same 
recptor as GRP, bombesin was used as an agonist for stimulated inositol 
phosphate production in these cells.
Bombesin has been shown to stimulate inositol phosphate production in 
fibroblasts (Heslop e | aL 1986) and to act as a mitogen for Swiss 3T3 
(Rozengurt and Sinnet-Smith, 1983) and NIH3T3 cells (Wakelam et al, 1986). 
Thus, the stimulation of inositol phosphate production by bombesin can be an 
initial signal for cell proliferation in T15 cells if Ins 1,4,5 P3  is generated as a
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second messenger.
All experiments shown in this chapter were performed using a maximal 
concentration of bombesin as determined from figure 3.6, Chapter 3, which 
was 2.5jiM. «-o— ^  Vo ^
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Figures 4.1a-lc show the separation of inositol phosphates in basal and 
stimulated T15- cells extracts by Dowex anion exchange chromatogra phy. The 
experiment was performed as a time-course of bombesin stimulated inositol 
phosphate production.
Figure 4.1a shows that there was significant production of inositol 
monophosphate (IP) at 20 seconds of bombesin stimulation. The level of IP 
decreased at 30 seconds but increased up to 120 seconds. The decrease in IP 
levels at 30 seconds may be due to experimental error.Figure 4. lb  shows that 
there is an increase in inositol bisphosphate (IP2 ) production on bombesin 
stimulation of T15- cells between 20 seconds and 30 seconds. At 60 seconds 
there was a decrease in IP2  production in this cell line on bombesin stimulation 
which remained at this level for up to 120 seconds. Although there is no 
significant production of inositol trisphosphate (IP3 ) as shown in figure 4.1c, 
there are probably low, undetectable levels produced on bombesin stimulation 
which lead to increases in IP and IP2  with time.Therefore, in T15- cells there 
was no detectable increase in IP3  production on bombesin stimulation although 
there were significant increases in IP and IP2 .
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Figure 4.1: Time-depen dent bombesin stimulated inositol
phosphate production in T15- ceils. Separation bv Powex anion 
exchange chrom atography.
The results in the figure are means ± S.D., n=3 and are from one 
experiment. Figure 4.1a shows inositol monophosphate accumulation in T 15- 
cells stimulated with bombesin over a period of 120 seconds.Figure 4.1b and 
4.1c show inositol bisphosphate and trisphosphate respectively in bombesin 
stimulated T15- cell extracts over the same time period. The experimental results 
are representative of 4 separate experiments.
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A similar experiment to that in figure 4.1 was performed using T15+ 
cells to investigate the characteristics of bombesin stimulated inositol phosphate 
production in this cell type. Cell extracts prepared from control and bombesin 
stimulated T15+ cells were applied to Dowex formate columns and the results 
of a time-course experiment are shown in figure 4.2a-2c. Figure 4.2a shows 
the production of IP in bombesin stimulated T15+ cells which was first 
significant after 10 seconds of bombesin stimulation. The production of IP 
increased in a linear fashion up to 120 seconds and the stimulation of IP 
production was approximately 3 fold compared to basal levels.
The production of IP2  in bombesin stimulated T15+ cells is shown in 
figure 4.2b and was significant at 10 seconds. The level of IP2  then remained 
steady after 60 seconds, suggesting that the IP2  was being dephosphoiylated to 
IP at the same rate that it was being produced.
Bombesin stimulated IP3  production in T15+ cells is shown in figure 
4.2c. Peak production occured at 10 seconds after which there was a decrease 
to a level above the basal at 120 seconds. The production of IP3  was rapid and 
transient on bombesin stimulation and is consistent with its role as a second 
messenger. The stimulation of IP3  production in this experiment was 240% of 
the basal at 1 0  seconds following bombesin stimulation.
The data shows that in T15+ cells there was significant production of 
IP3  in response to bombesin stimulation.The stimulation of IP3  varied from 
160-300% of the basal between experiments and was not associated with cell 
density i.e. the confluency of cells used in these experiments did not affect the 
stimulation of IP3  production, although Wakelam (1988) has demonstrated that 
confluent T15+ cells exhibit a smaller bombesin stimulated inositol phosphate 
response than non-confluent T15+ cells. This does not appear to be the case in 
terms of IP3  production based on the results of these experiments and may be 
due to the different labelling conditions employed.
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Figure 4.2: Time-dependent bombesin stimulated inositol 
phosphate production in T15+ cells.Separation bv Dowex anion 
exchange chromatography.
The results in figure 4.2 are means ± S.D., n=3 and are representative 
of six experiments. Figure 4.2a indicates inositol monophosphate production in 
bombesin stimulated T15+ cells for up to 120 seconds. Figures 4.2b and 4.2c 
indicate inositol bisphosphate and inositol trisphosphate production respectively 
in bombesin stimulated T15+ cell extracts over the same time period.
cp
m
/w
el
l 
cp
m
/w
el
l
99
R gure_4!2a
16000
14000
12000
10000
Cl
8000
6000
4000
1000 5 0 15 0
Tim e/s
Figure 4.2b
900
' 800 -
700 -
600 -
500 -
400 -
300
0 5 0 1 0 0 15 0
Tim e/s
Figure 4.2c
700
600 -
500 -
400 -
300 -
200
0 5 0 1 0 0 15 0
Time/s
100
The HPLC technique is used to separate inositol phosphates for several 
reasons. Firstly, it is more conveniant than Dowex anion exchange 
chromatography and a detailed elution profile of a given sample can be obtained 
more rapidly. Secondly, unlike Dowex chromatography, the use of HPLC can 
resolve the individual isomers of inositol phosphates . Lastly, the HPLC 
method can be used to isolate the higher inositol phosphates, for example, 
inositol pentakisphosphate.
Cell extracts prepared from basal and stimulated T15- cells were 
therefore analysed by HPLC to obtain additional information not provided by 
Dowex anion exchange chromatography. The elution profile of extracts from 
T15- cells stimulated for 5 seconds with bombesin is shown in figure 4.3.
The figure illustrates that following a 5 second stimulation with 
bombesin, there was no significant production of IP3  or any of its isomers, nor 
of IP2  in T15- cells. There is only detectable production of IP. This IP co-elutes 
with an Ins 1 P standard and therefore, using our HPLC technique, the IP 
generated in bombesin stimulated T15- cells is probably be Ins 1 P. From the 
elution profile, the single peak obtained indicates that no isomers of IP are 
formed.
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Figure 4.3: HPLC elution profile of bombesin stimulated T15- 
cell extract,
The results shown in figure 4.3 show the HPLC elution profile of a
T15- cell extract prepared from T15- cells stimulated with bombesin for 5
seconds as described in the Methods section. The data shown in the figure is
from one sample within one experiment but is typical of two. The results are
drawn to a large y-axis to allow direct comparison to figure 4.4.
The experiment was not carried out using cells that were labelled with an
increased amount of pH ] inositol because this approach would not be cost effective.
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Time-course experiments were performed on bombesin stimulated T15+ 
cells and the cell extracts were analysed by HPLC both to determine the 
characteristics of bombesin stimulated inositol phosphate production 
production over a time period of 1 2 0  seconds and to also identify the isomers of 
inositol phosphates generated. Figure 4.4 illustrates the elution profile obtained 
by HPLC of an extract of T15+ cells stimulated for 5 seconds with bombesin.
The production of Ins 1 P in T15+ cells was much greater than in T15- 
cells ( See figure 4.3) although this is not due to cell number differences 
between the two cell types. There was production of IP2  on bombesin 
stimulation of T15+ cells and this peak was shown to be Ins 1,4 P2  by its 
elution position being identical to a tritiated Ins 1,4 P2  standard.
There was significant production of IP3  on bombesin stimulation of 
T15+ cells as already demonstrated by Dowex anion exchange chromatography. 
However, the use of HPLC to separate the bombesin stimulated inositol 
phosphates demonstrated that this IP3  consisted solely of the Ins 1,4,5 P3 
isomer.
In T15+ cells, therefore, there are no other isomers of inositol 
phosphates produced in response to 5 second bombesin stimulation apart from 
Ins 1 P, Ins 1,4, P2  and Ins 1,4,5 P3 . The Ins IP and Ins 1,4 P2  must be 
formed as a consequence of Ins 1,4,5 P3  dephosphorylation.
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Figure 4.4; HPLC elution profile of a bombesin stimulated T15+ 
cell extract.
The results in figure 4.4 are from an experiment to determine the inositol 
phosphates present in an extract prepared from T15+ cells stimluated for 5 
seconds with bombesin. The experiment was carried out as already described 
and the data in the figure is from one sample within an experiment but is typical 
of three separate experiments.
In addition to the elution profile of a T!5+ cell sample stimulated for 5 seconds with 
bombesin, the elution profile of a control T!5+ sample has been included. The 
| control elution profile indicates that there are significant levels of Ins 1 P and Ins 1,4 
P2  in this control sample although it is likely that the Ins 1 P and Ins 1,4 P2  I
detected are a result of the accumulation of these inositol phosphates as a result of 
basal inositol phospholipid turnover in the presence of lithium chloride. |
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The production of Insl,4,5 P3  in bombesin stimulated T15+ cells was 
determined by a time-course experiment. Bombesin was used to stimulate T15+ 
cells for various times up to 1 2 0  seconds and cell extracts prepared from each 
sample. The samples were applied to the HPLC column and from the elution 
profiles, the total amount of Ins 1,4,5 P3  produced in each sample was 
calculated by the sum of the cpm values of all the fractions within the Ins 1,4,5 
P3  peak. These values were then expressed as % stimulation of the basal levels.
Figure 4.5 shows that the generation of Ins 1,4,5 P3  in bombesin 
stimulated T15+ cells was rapid and reached a peak at 10 seconds. The level of 
Ins 1,4,5 P3  then declined to a level above the basal by 60 seconds.
This data correlates with that obtained by Dowex chromatography (See 
figure 4.2c) and indicates that bombesin stimulates Insl,4,5 P3  production in 
T15+ cells as a result of phosphoinositidase hydrolysis of Ptdlns 4,5 P2 .
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Figure 4.5: Tim e-course of Insl.4 .5  P? production in T15+ cells.
The data in figure 4.5 is from an experiment to determine the time- 
course of Ins 1,4,5 P3  production in bombesin stimulated T15+ cells.The 
results are obtained from HPLC analysis of bombesin stimulated T15+ cell 
extracts performed over a time period of 120 seconds as described. The results 
are expressed as % stimulated/basal levels of Ins 1,4,5 P3  and are from one 
experiment but the data is typical of three separate experiments.
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The data obtained in the previous experiments showed that there was no 
significant production of IP3  at any time point in T15- cells ( See figure 4.1c), 
Also, HPLC data showed that there was no significant production of Ins 1,4,5 
P3  in T15-cells at 5 seconds, unlike T15+cells.
Figure 4.6 shows part of the HPLC elution profiles of control and 10 
second bombesin stimulated T15- and T15+ cells. The data shown only 
indicates the part of the gradient between fractions 140-170; Ins 1,4,5 P3  elutes 
between fractions 150-160.
Figure 4.6a clearly shows that the peak time of Ins 1,4,5 P3 generation 
in T15+ cells was at 10 seconds. There is no significant generation of Ins 1,4,5 
P3  in T15- cells (figure 4.6b). In this experiment, the T15- cells had an 
apparent higher basal rate than the T15+ cells and this could be due to the 
different HPLC columns used for the two experiments.
The control elution profiles in the Insl,4,5 P3  region of T15- and T15+ 
cells were similar to the 10 second elution profile of T15- cells (figures 4.6a 
and 4.6b). At no time tested was there a detectable increase in Ins 1,4,5 P3  
production in bombesin stimulated T15- cells.
Figure 4.6: HPLC elution profile of extracts prepared from 10 
second bombesin stimulated T15 cells.
Figure 4.6a shows the HPLC elution profile obtained from the analysis 
of T15+ cell extracts prepared from control T15+ cells and T15+ cells 
stimulated with bombesin for 10 seconds. The region of Ins 1,4,5 P3  elution 
from the Partisil SAX column is shown and the data is from one experiment 
which is typical of three.Figure 4.6b is the data from a similar experiment using 
T15- cells and shows the results from HPLC analysis of cell extracts prepared 
from T15- cells which were either unstimulated or stimulated with bombesin for 
10 seconds. The data is from one experiment representative of two separate 
experiments.
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The data shown in this chapter illustrates that consistent results can be 
obtained using two different techniques to separate inositol phosphates in T15 
cells. The results obtained from experiments using Dowex anion exchange 
chromatography to separate inositol phosphates in T15- cells (Figure 4.1) 
demonstrated that there was no significant production of IP3  on bombesin 
stimulation. Although this result was obtained from one experiment, other 
experiments also failed to demonstrate an increase in IP3  production in 
bombesin stimulated in T15- cells.
Since there was significant IP2  and IP produced on bombesin 
stimulation of T15- cells, it must be concluded that there is IP3  production on 
bombesin stimulation but in such small amounts as to be undetectable by the 
assay method. This would be a reasonable assumption as there is a small 
increase in total inositol phosphate production as compared to basal levels in 
bombesin stimulated T15- cells (See chapter 3) and this increase in total inositol 
phosphates, although consists mostly of IP is probably due to IP3  production 
and its sequential dephosphoiylation. However, the possibility that the IP and 
ff*2 generated in bombesin stimulated T15- cells as a consequence of Ptdlns or 
Ptdlns 4 P breakdown can be ruled out. This is due to the fact that there was no 
significant generation of IP and IP2  (figures 4. la  and 4. lb) in cell extracts 
prepared from bombesin stimulated T15- cells until 30 seconds following 
bombesin stimulation. If these inositol phosphates are generated as a 
consequence of Ptdlns and Ptdlns 4 P breakdown, then the production of IP 
and IP2  would occur much more rapidly.
Analysis by HPLC data of extracts prepared from bombesin stimulated 
T15- cells (See figure 4.3) also showed no detectable increase in Ins 1,4,5 P3 
production. This is consistent with the data obtained from Dowex 
chromatography. The Ins 1 P peak in the elution profile must arise from 
Ins 1,4,5 P3  as a consequence of its sequential dephosphorylation and therefore, 
although there is no detectable Ins 1,4,5 P3 , it must be produced as a
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consequence of bombesin stimulated Ptdlns 4, 5 ?2 hydrolysis.
In contrast, T15+ cells exhibited a rapid, transient increase in Ins 1,4,5 
P3  production in response to bombesin stimulation. This increase reaches a 
peak at 10 seconds and has been demonstrated both by HPLC and Dowex 
chromatography (Figures 4.5 and 4.2 respectively). The generation of IP3  as 
detected by Dowex chromatography in figure 4.2 when analysed by HPLC was 
shown to shown to consist solely of Ins 1,4,5 P3  (figure 4.4). It is clear from 
figure 4.4 and figure 5.1 in chapter 5 that no Ins 1,3,4 P 3  is generated in T15+ 
cells following stimulation with 2.5jiM bombesin. Therefore,the inositol 
phosphates generated in response to bombesin stimulation of T15+ cells are a 
consequence of Ins 1,4,5 P3  production and that the assay for total inositol 
phoshates in control and stimulated T15+ cells is an accurate estimate of Ptdlns
4.5 P2  hydrolysis. Thus,the production of inositol phosphates in T15+ cells is 
a consequence of receptor mediated Ptdlns 4,5 P2  hydrolysis and not Ptdlns 
hydrolysis as the generation of IP3  preceded any significant increase in IP as 
shown in figure 4.2 of this chapter.
The data in figure 4.4 shows that bombesin can stimulate rapid Ins
1.4.5 P3  production in T15+ cells which leads to an increase in Ins 1,4 P2  and 
Ins 1 P as a consequence of sequential dephosphorylation of Ins 1,4,5 P3 . The 
generation of the Ca^+ mobilising second messenger, Ins 1,4,5 P3 , has been 
shown to occur in response to bradykinin in N G 115-40IL cells (Jackson et al,
1987) and A431 cells (Tilly et al, 1987) and also in Swiss 3T3 cells stimulated 
with PDGF (Benidge et al, 1984). It is generally accepted that the production of 
Ins 1,4,5 P3  in these cells in response to growth factor agonists is a 
consequence of Ptdlns 4,5 P2  hydrolysis by the phosphoinositidase enzyme.
The percentage stimulation of Ins 1,4,5 P3determined'from Dowex chromatography* 
T15+cells is variable between 160-300% of the basal. The reasons for this are unclear, but this
variability is not associated with cell density, although it has been demonstrated 
that high density culturing leads to an inhibition of bombesin stimulated inositol 
phosphate production in T15+ cells (Wakelam, 1988). Recently, it has been 
demonstrated that in T15+ cells, there is an amplification of bombesin
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stimulated increase in intracellular Ca?+ levels compared to T15- cells.(Lloyd et 
al, submitted for publication). The amplified bombesin stimulated increase in 
intracellular Ca^+ levels in T15+ cells is due to the responses in individual cells 
and is not due to a larger number of T15+ cells in a population responding to 
the agonist compared to a much smaller number of T15- cells. This has been 
verified by the measurement of intracellular Ca^+ changes in single T15 cells 
stimulated with 2.5jiM bombesin indicated by changes in Fura-2 fluorescence. 
Using this technique, it has been estimated that the bombesin stimulated 
increase in intracellular Ca^+ is on average 155% over basal levels in T15+ 
cells while in T15- cells the bombesin stimulated increase in intracellular Ca^+ 
is 39% over basal levels. However,this response is variable between cells, for 
example, the increase in intracellular Ca^+ stimulated by bombesin in T15 cells 
varies from 87% to 160% and it has been postulated that there are different 
levels of p21 N-ras ^  each cell. Therefore, the variability in Insl,4,5 P3 
production may be a reflection of the amount of p21 N-ras ^  each ceu in a 
particular cell population.
The basal levels of Ins 1,4,5 P3  in T15- and T15+ cells from HPLC 
experiments were the same (approximately 350 cpm per well) and indicate that 
there is no change in the basal rate of Ins 1,4,5 P3  production between the cell 
types. This supports the results obtained in figure 3.3, chapter 3 where it was 
demonstrated that the rate of inositol phospholipid turnover in these cells was 
the same.
Experiments to determine the levels of bombesin stimulated inositol 
phosphates in NIH3T3 cells demonstrated that the response of these cells to 
bombesin was the same as T15- cells. There was no detectable Ins 1,4,5 P3  
production although there was Ins 1 P and Ins 1,4 P2  produced on bombesin 
stimulation. Therefore, NIH3T3 and T15- cells respond in the same way to 
agonists linked to the phosphoinositide signalling pathway.
However, NIH3T3 cells stimulated with PGF 2 a  produce high levels 
of Ins 1,4,5 P3  and Ins 1,3,4,5 P4  and its dephosphorylated derivatives, Ins
1,3,4 P3 , Ins 3,4 P2  and Ins 4 P which can be resolved by HPLC (Black,F.
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and Wakelam, M.J.O., manuscript in preparation). T15 cells exhibit an 
inhibition of PGF2a induced inositol phosphate production which may be a 
consequence of activated protein kinase C. Activation of protein kinase C may 
be due to p21 N-ras overexpression and could result in phosphorylation of 
PG F2a receptors.
The results clearly show that in T15+ cells there is amplified Ins 1,4,5 
P3  production in response to bombesin as compared to T15- cells. The only 
isomers of IP, IP2  and IP3  detectable are Insl P, Ins 1,4 P and Ins 1,4,5 P3 
which implies that there is no Ins 1,3,4, 5 P4  synthesised in these cells in 
response to bombesin stimulation, or that the levels of Ins 1 ,3 ,4 ,5 P4  are so low 
as to be undetectable. The production of Ins 1,4,5 P 3  must occur as a 
consequence of receptor-mediated Ptdlns 4,5 P2  hydrolysis by the 
phosphoinoisitidase enzyme.
The amplification of bombesin stimulated inositol phosphates in T15+ 
cells as a result of Ins 1,4,5 P3  production as compared to T15- cells has to be 
due to post-receptor modifications in T15+ cells for reasons already discussed 
in chapter 3. It has been shown that bombesin and PDGF induced Ptdlns 4,5 
P2  hydrolysis are early events in mitogenesis and that microinjection of an 
antibody to Ptdlns 4,5 P2  will abolish growth factor induced mitogenesis in 
NIH3T3 cells (Matuoka et al. 1988). Also, bombesin induces c-mvc and c-fos 
expression in quiescent Swiss 3T3 cells (Bravo e£ aL 1987) and this may be due 
to bombesin induced production of Ins 1,4,5 P3  with subsequent intracellular 
Ca^+ mobilisation. Thus, the production of Insl,4,5 P3  may be an initial signal 
for cell proliferation in T15+ cells and may be generated at high levels in 
response to different growth factors as a result o f ' p21 N-ras expression. In 
T15- cells this process may also occur, but at a very much lower rate so that 
uncontrolled proliferation does not occur.
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The data in this chapter shows that p2 1^ - 12$ may have a direct role in 
the amplification of bombesin stimulated Ins 1,4,5 P3  production in NIH3T3 
cells. The properties of p2 1 Tas as already described, make it reasonable to 
consider that p2 1  N-ra§ may act as a guanine nucleotide binding protein to 
stimulate the phosphoinositidase enzyme on receptor occupancy. It may be in 
this capacity that the overexpressed N-ras proto-oncogene can cause 
uncontrolled cell proliferation and transformation.
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Chanter 5; Characterisation of the NTH3T3 inositol 1,4,5 
trisphosphate kinase enzyme.
Introduction
In chapter 4, bombesin stimulated inositol phosphate production in 
T15 cells was discussed. During the course of these experiments, it was 
noted that there was no detectable bombesin stimulated inositol 1,3,4,5 
tetrakisphosphate (Ins 1,3,4,5 P4 ) production in T15 and NIH3T3 cells.
Ins 1,3,4,5 P4  is formed by the phosphorylation of Ins 1,4,5 P3 by inositol
1.4.5 trisphosphate 3-kinase ( Ins 1,4,5 P3  kinase) an enzyme whose 
presence has been demonsrated in, for example, brain slices and in Xenopus 
oocytes (Irvineeta!, 1986).
The absence of Ins 1,3,4,5 P4 generation in bombesin stimulated 
T15 and NIH3T3 cells could be due to several factors. It is possible that this 
fibroblast cell line does not synthesize the Ins 1,4,5 P3 kinase enzyme and 
therefore, the conversion of Ins 1,4,5 P3  to Ins 1,3,4,5 P4 cannot be 
catalysed. To investigate this possibility, experiments to determine Ins 1,4,5 
P3 kinase activity in T15 and N3H3T3 cytosol extracts were performed. In 
order to measure Ins 1,4,5 P3 kinase activity in these cell types, the 
conversion of [3H] Ins 1,4,5 P3 to [3H] Ins 1,3,4,5 P4 in the presence of a 
known amount of the cytosolic preparation was measured. The amount of 
Ins 1,3,4,5 P4 generated in these samples was quantified by separating and 
collecting the [3H] labelled Ins 1,3,4,5 P4 by either HPLC or Dowex anion 
exchange chromatography as utilised in chapter 4.
A second possibility that may explain the undetectable levels of Ins
1.3.4.5 P4 in T15 and NIH3T3 cells is that the level of Ins 1,4,5 P3 formed 
following bombesin stimulation in these cells are too low to allow Ins
1.3.4.5 P4  to be detected if it is formed. Thirdly, if the phosphorylation and 
dephosphorylation pathways of Ins 1,4,5 P3 exist in these cell types as 
already discussed (See Introduction), then it may be that the 
dephosphorylation of Ins 1,4,5 P3  to Ins 1,4 P2  occurs at a greater rate than
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the phosphorylation of Ins 1,4,5 P3 to Ins 1,3,4,5 P4 . These possibilities 
are discussed further in this chapter based upon the results from the 
experiments to determine Ins 1,4,5 P3 kinase activity in T15 and NIH3T3 
cells.
R esu lts
The results from the HPLC analysis of bombesin stimulated inositol 
phosphate production in T15 cells showed that there was no detectable Ins
1.3.4.5 P4  in this cell line and this has been discussed in Chapter 4. The 
results in figure 5.1 show the results from a 120 second bombesin 
stimulated T15+ cell extract prepared as described in Chapter 4 and analysed 
by HPLC to separate the different inositol phosphates.
Figure 5.1 clearly shows that at 120 second bombesin stimulation 
there is no detectable Ins 1,3,4,5 P4  in T15+ cells. There are no different 
isomers of inositol trisphosphate, inositol bisphosphate and inositol 
monphosphate generated following bombesin stimulation as already 
discussed in Chapter 4. The figure shows that only inositol 1 
monophosphate, inositol 1,4 bisphosphate and Ins 1,4,5 P3  are generated 
on bombesin stimulation of T15+ cells. Therefore, there are no isomers of 
inositol monophosphate, inositol bisphosphate and inositol trisphosphate 
that are products of Ins 1,3,4,5 P4  dephosphorylation for example Ins 1,3,4 
P3 , Ins 3,4 P2  or Ins 1,3 P2  and Ins 3 P. Therefore, it can be concluded that 
there is no Ins 1,3,4,5 P4  formation following bombesin stimulation of 
T15+ cells. Alternatively,the levels of Ins 1,3,4,5 P4  are so low as to be 
undetectable by this HPLC method. There was also no detectable Ins
1.3.4.5 P4  in bombesin stimulated T15- or NIH3T3 cells up to 120 
seconds. Therefore, this lack of Ins 1,3,4,5 P4  is thus unlikely to be a 
consequence of p21 transformation of NIH3T3 cells since it occurs in 
the wild-type and non-transformed T15 cells.
Figure 5.1: HPLC elution profile of an extract prepared from  
T15+ cells stimulated with bombesin for 120 seconds.
Figure 5.1 shows a HPLC elution profile of a T15+ cell extract 
prepared from T15+ cells stimulated with 2.5jiM bombesin for 120 seconds 
as described in the Methods section. The data is from one sample within a 
single experiment but is representative of three separate experiments. The 
peaks are labelled to indicate the relevant inositol phosphates.
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The absence of Ins 1,3,4,5 P4  in bombesin stimulated T15 and 
NIH3T3 cells could be due to the absence of the Ins 1,4,5 P3  kinase enzyme 
in this cell line. To examine this possibility, cytosolic cell extracts (high 
speed supernatants) were prepared from a homogenate of T15+ cells and 
, incubated at 30°C for 5 minutes in the presence o f 0.67 nmol of l3 H| Ins 1,4,5 P3  
(Specific activity = ICi mmol-!) in incubation buffer A at pH 7 and at pH 9. 
The experimental procedure is described in detail in the Methods section.
The incubations were terminated by the addition of perchloric acid and the 
neutralised supernatants analysed for Ins 1,3,4,5 P4  by HPLC as already 
described.
Figure 5.2a shows the HPLC elution profile of a T15+ cell extract 
incubated with [3H] Ins 1,4,5 P3  at pH 9. It clearly shows the resolution of 
a peak between fractions 205-220 which coelutes with a [3h] Ins 1,3,4,5 
P4  standard and is therefore probably Ins 1,3,4,5 P4 . The Ins 1,3,4,5 P4  
peak has a maximal value of 900 dpm. The peak obtained between fractions 
155-160 is Ins 1,4,5 P3  and the preceeding peak at fractions 144-154 is 
probably Ins 1,3,4 P3 . There are detectable isomers of inositol bisphosphate 
and inositol monophosphate which probably include Ins 1,4 P2 , Ins 3,4 P2  
or Ins 1,3 P2  and Ins 4 P and Ins 1 P respectively.
Therefore, it has been demonstrated that phosphorylation of Ins
1,4,5 P3  to Ins 1,3,4,5 P4  can be catalysed by a T15+ cell extract at pH 9. 
However, it has been demonstrated that the phosphomonoesterase that 
dephosphorylates Ins 1,4,5 P3 is inhibited at this pH (Downes et al, 1982). 
It is probable that this enzyme also dephosphorylates Ins 1,3,4,5 P4  to Ins
1,3,4 P3  (Majerus et al, 1988). In T15+ cells there is dephosphorylation of 
Ins 1,3,4,5 P4  to Ins 1,3,4 P3  at pH 9 and therefore, the phosphatase in 
these cells is not completely inhibited at pH 9.
Figure 5.2b shows the elution profile of a replicate experiment 
performed at pH 7. At this pH, the Ins 1,3,4,5 P4  peak has a maximal value 
of 750 dpm. There are small peaks of Ins 1,4,5 P3  and Ins 1,3,4 P3  but the
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maximal value of the of the Ins 1 monophosphate peak has increased to 
1000 dpm as compared to 350 dpm at pH 9. Therefore, at this pH, the Ins
1.4.5 P3  kinase is still active, but the dephosphorylation of Ins 1,4,5 P3  and 
Ins 1,3,4,5 P4  to inositol 1 monophosphate is probably more rapid than the 
phosphorylation reactions.
A value for the activity of the Ins 1,4,5 P3  kinase was obtained by 
calculating the total dpm for all fractions between and including 203-220. 
This gave a total dpm value for Ins 1,3,4,5 P4 produced and was converted 
into pmols Ins 1,3,4,5 P4  produced. The value obtained for the specific 
activity of the Ins 1,4,5 P3  kinase in this T15+ cytosolic preparation as 
determined by HPLC was 2.88 pmol Ins 1,3,4,5 P4  m in 'l mg_l protein at 
pH 9 and 2 pmol Ins 1,3,4,5 P4  m in 'l mg'* protein at pH 7. These values 
were consistent with those obtained from Dowex anion exchange 
chromotography of replicate samples which were 2.95 ± 0.01 at pH 9 and 
1.96 ± 0.3 at pH 7 (n=2, means ± S.D.).
To determine if NIH3T3 cells showed evidence of possesing Ins
1.4.5 P3  kinase activity, similar experiments as those shown in figure 5.2 
were performed using cytosolic preparations. The experiments shown in 
Figures 5.3a and 5.3b were performed under the same experimental 
conditions as those in figure 5.2. Figure 5.3a shows the HPLC elution 
profile of a sample of NIH3T3 cytosolic extract incubated with [3H] Ins
1.4.5 P3  as already described at pH 9. There is a significant peak of Ins
1.3.4.5 P4  which had a maximal value of 875 dpm. The figure also shows a 
large peak of Ins 1,4,5 P3  with no significant peaks of Ins 1,3,4 P3 , inositol 
bisphosphate isomers or inositol monophosphate isomers. It is clear that 
firstly, there is evidence of Ins 1,4,5 P3  kinase activity in NIH3T3 cells and 
secondly, that the dephosphorylation of Ins 1,4,5 P3  and Ins 1,3,4,5 P4  is 
completely inhibited at this pH unlike in T15+ cells.
Figure 5.3b shows the HPLC elution profile of a sample of NIH3T3 
cytosolic extract incubated with [3h] Ins 1,4,5 P3  as above but at pH 7. At 
this pH, the maximal value of the Ins 1,3,4,5 P4  peak was 550 dpm as
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compared to 875 dpm in figure 5.3a. There was dephosphorylation of Ins
1.3.4.5 P4  and Ins 1,4,5 P3  at this pH as significant peaks of Ins 1,3,4 P3 
and Ins 1,4 P2  and Ins 3,4 P2  or Ins 1,3 P2  are clearly present in figure 
5.3b, associated with reduced levels of Ins 1,4,5 P3  and Ins 1,3,4,5 P4  as 
compared to the data from the experiment performed at pH 9 (figure 5.3a).
The specific activity of the Ins 1,4,5 P3  kinase assayed in this 
sample of NIH3T3 cytosolic extract was calculated to be 4.3 pmol Ins
1.3.4.5 P4  min-lmg-1 protein at pH 9 and 3.04 pmol Ins 1,3,4,5 P4  m h r 
lmg-1 protein at pH 7 from the HPLC data. These values were confirmed 
from data obtained by Dowex anion exchange chromatography of the 
samples and were 5.6 ± 0.4 pmol Ins 1,3,4,5 P4  min-lmg-1 protein at pH 9 
and 4.7± 0.6 pmol Ins 1,3,4,5 P4  min-1 mg-1 protein at pH 7 (n=2, ±
S.D.)
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Figure 5,2; Analysis of T15+ cytosolic extracts for Ins 1,4,5 
Pgi kinase activity bv HPLC,
Both figures 5.2a and 5.2b show the elution profile from HPLC 
analysis of T15+ cytosolic preparations incubated with lp.1 of [^H] Ins 1,4,5 
P3  (approximately 12500 dpm). Figure 5.2a shows the data from one 
sample within a triplicate set of samples incubated at pH 9. Figure 5.2b 
shows the data from the same experiment performed at pH 7 and represents 
the data from one sample. The duplicate samples within each triplicate set 
were applied to Dowex anion exchange columns and the Ins 1,3,4,5 P4  
quantified as already described. Recovery of standard [3H] Ins 1,3,4,5 P4  
from HPLC was 62% and was 95% from Dowex anion exchange 
chromatography.
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Figure 5.3; Analysis of NTH3T3 cell extracts for Ins 1,4,5 
kinase activity bv HPLC. _
Figures 5.3a and 5.3b show the HPLC elution profiles of a NIH3T3 
cytosolic preparation incubated with [3H] Ins 1,4,5 P3  as in figure 5.2 at pH 
9 and pH 7 respectively. Triplicate determinations were made, one sample 
was analysed by HPLC and duplicate samples were analysed by Dowex 
anion exchange chromatography to determine if Ins 1,3,4,5 P4  was 
generated as a result of Ins 1,4,5 P3  kinase activity. The conditions of the 
experiment were as described in Figure 5.2.
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From the proceeding results, it was clear that T15+ and NIH3T3 
cells can synthesise Ins 1,3,4,5 P4  from Ins 1,4,5 P3  as a result of Ins
1.4.5 P3  kinase activity. It was therefore interesting to compare these results 
with a rat brain cytosolic preparation under the same conditions. Rat brain 
high speed supernatant ( a gift from Dr. S. Palmer) was incubated with [3H] 
Ins 1,4,5 P3  at pH 9 or pH 7 as in figures 5.2 and 3. The generation of Ins
1.3.4.5 P4  in these samples was quantified by either HPLC or Dowex anion 
exchange chromatography as previously described. Figure 5.4a shows the 
HPLC elution profile of a sample of rat brain cytosolic extract incubated with 
[3h] Ins 1,4,5 P3  under appropriate conditions at pH 9. There was a large 
peak of Ins 1,3,4,5 P4  with a maximal value of 1660 dpm. 
Dephosphorylation of Ins 1,3,4,5 P4  at this pH occured as there was a 
significant peak of Ins 1,3,4 P3  in this elution profile. There are no other 
peaks in this elution profile suggesting that no further dephosphorylation had 
taken place at pH 9.
Figure 5.4b shows that the maximal value of the Ins 1,3,4,5 P4  peak 
is reduced to 1050 dpm when incubations were performed at pH 7. There is 
evidence of further dephosphorylation of Ins 1,3,4,5 P4  and Ins 1,3,4 P3  to 
Ins 3,4 P2  or Ins 1,3 P2  and Ins 1,4 P2  and also to Ins 1 P and Ins 4 P. 
From this HPLC data, the specific activity of rat brain Ins 1,4,5 P3  kinase 
was calculated to be 7.6 pmol Ins 1,3,4,5 P4  min-1 mg-1 protein at pH 9 
and 4.3 pmol Ins 1,3,4,5 P4  min-lmg-1 protein at pH 7. Data obtained from 
Dowex anion exchange chromatography of the samples indicated that the 
specific activity of the rat brain Ins 1,4,5 P3  kinase was 8.17±0.26 pmol Ins
1.3.4.5 P4  min-1 mg-1 protein at pH 9 and 6.5±0.58 pmol Ins 1,3,4,5 P4  
min-1 mg-1 protein at pH 9. (n=2, ± SD)
1 3 0
Figure 5,4; Analysis of rat brain cytosolic extract for Ins 1,4,5 
P t  kinase activity bv HPLC.
Figures 5.4a and 5.4b show the HPLC elution profiles of rat brain 
cytosolic extract incubated with [3H] Ins 1,4,5 P3  as already described (See 
legend Figure 5.2) at pH 9 and pH 7. The experiment was performed on 
triplicate samples where one sample was analysed by HPLC and duplicate 
samples applied to Dowex anion exchange columns to determine if Ins
1,3,4,5 P4  was generated. The conditions of the experiment were as 
described for figure 5.2.
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The appropriate assay conditions for Ins 1,4,5 P3  kinase in the 
NIH3T3 fibroblast cell line were determined in order to assay this enzyme 
routinely and to attempt to obtain consistent data between different cytosolic 
preparations. Therefore, Ins 1,4,5 P3  kinase activity was assayed in T15+ 
and NIH3T3 cytosolic preparations at pH 9 and pH 7 in two different 
buffers. Buffer A is that of Irvine et al (1986) and buffer B is based on 
Harden el al (1987) and has a higher ionic strength than buffer A. At pH 7, it 
is necessary to add 2,3 diphosphoglyceric acid (2,3 DPG) to the incubations 
so as to prevent dephosphorylation of Ins 1,4,5 P3  and possibly Ins 1,3,4,5 
P4  by the inhibition of the 5’ monophosphatase activity. 2,3 DPG was 
found not to inhibit the Ins 1,4,5 P3  kinase in a T15+ cytosolic extract at a 
concentration of 2mM at either pH 9 or pH 7 in buffer A i.e. the specific 
activity of Ins 1,4,5 P3 kinase in T15+ cells was unchanged in the presence 
of 2,3 DPG when assayed at the two pH values described.
The results in Table 2 show that the specific activity of both T15+ 
and NIH3T3 enzymes was inhibited at all substrate concentrations tested 
when incubated in buffer B at pH 7 in the presence of 2,3 DPG. The degree 
of inhibition between the T15+ and NIH3T3 enzymes differed. The T15+ 
enzyme retained some activity at pH 7 in buffer B, whilst the NIH3T3 
enzyme was completely inhibited under these conditions except at 0.067}iM 
Ins 1,4,5 P3 . In an experiment to determine if pH, different buffers and the 
presence of 2,3 DPG would affect Ins 1,4,5 P3  kinase activity in cytosolic 
preparations from T15+ and NIH3T3 cells, it was noted that the specific 
activity of T15+ Ins 1,4,5 P3  kinase was greater at pH 9 in buffer A than at 
pH 7 in the same buffer. Therefore, the inhibition of Ins 1,4,5 P3  kinase 
specific activity in buffer B at pH 7 was not due only to the pH of the buffer, 
but to the composition of the buffer itself. The results in Table 2 also show 
that at pH 9 in buffer A, the specific activity of the T15+ enzyme was lower
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than the NIH3T3 enzyme when assayed as a high speed supernatant.
On the basis of these experimental results, it was decided that most 
experiments to assay Ins 1,4,5 P3  kinase activity in the NIH3T3 fibroblast 
cell line would be performed at pH 7 to mimick the physiological state 
despite the lower specific activity at this pH. Assays would be carried out in 
buffer A although this buffer is not a 'physiological' buffer unlike buffer B. 
The exceptions to these experimental conditions are the experiments 
described in Figure 5.8.
Table 2: Specific activity of Ins 1,4,5 kinase in T15+ and 
NIH3T3 evtosoiic extracts under different assay conditions.
Table 2 shows the specific activity of Ins 1,4,5 P3  kinase in T15+ 
and NIH3T3 cytosolic preparations in pmol Ins 1,3,4,5 P4  min-1 mg-1 
protein ± S.D. (n=3). The data is pooled from two experiments where 
incubations were performed in triplicate and under the conditions indicated 
where [S] indicates Ins 1,4,5 P3 concentration (jiM ). N.D.=not 
determined.
pHJL. .buffer B + 2,3 P PG. pH 9.buffer A
LSI T 15+ N IH 3T 3 T 1 5 t N IH 3T 3
0.067 0.13±0.003 0.6210.06 5.910.05 10.110.33
0.33 1.84±0.009 0 32.410.82 4812.1
0.67 7.3±0.03 0 57.110.84 10217
1.67 12.9±0.45 0 88.011.82 260125
3.33 84.511.61 0 248141 449156
4.99 N.D. N.D. 31418 7521238
6.67 11.910.87 0 484154 155161
9.99 N.D. N.D. 75518 138111
13.33 N.D. N.D. 537188 12911239
IHaving defined the most appropriate conditions to assay the 
NIH3T3 fibroblast Ins 1,4,5 P3  kinase enzyme, the substrate requirements 
of the enzyme were investigated. This was undertaken to determine the 
appropriate substrate concentration at which to assay the enzyme and also to 
determine the kinetics of the enzyme reaction. This investigation into the 
characteristics of the Ins 1,4,5 P3  kinase in a cytosolic preparation was 
carried out mainly on the wild-type NIH3T3 cell line. Although there are 
some differences between the characteristics of the Ins 1,4,5 P3  kinase 
enzyme of T15+ and NIH3T3 cells, as seen from Table 2, it was decided to 
characterise the NIH3T3 enzyme initially, before any effects of 
transformation by p21 N-ras were examined.
Initial experiments to determine the Michaelis-Menten constant (Km) 
for the NIH3T3 Ins 1,4,5 P3  kinase were performed using [3H] Ins 1,4,5 
P3  at a specific activity of 1 Ci mmol- !. This had one main disadvantage 
i.e. at high substrate concentrations it was not possible to detect Ins 1,3,4,5 
P4  formation above blank levels because of the low specific activity of the 
3H Ins 1,4,5 P3 . For example, at 20pM Ins 1,4,5 P3 , there was no 
detectable Ins 1,3,4,5 P4  formation in samples incubated at 30°C for up to 1 
hour. Therefore, in the experiments shown here, lfil of [3H] Ins 1,4,5 P 3  
at 44 Ci mmol'^ was used per assay. In these experiments, samples of 
NIH3T3 high speed supernatants were incubated with [3H] Ins 1,4,5 P3 as 
already described with increasing amounts of unlabelled Ins 1,4,5 P3  to give 
the required final concentration and the samples incubated at 30°C for 5 
minutes in buffer A at pH 7 in the presence of 2,3 DPG. The incubations 
were terminated and the neutralised supernatants were assayed for Ins
1,3,4,5 P4  formation by Dowex anion exchange chromatography.
The results in Figure 5.5a show the velocity of the reaction for 
Ins 1,4,5 P3  kinase in a NIH3T3 cytosolic preparation. The V max 
calculated from this data was 23 nmol Ins 1,3,4,5 P4  min-1 mg-l protein.
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The half maximal substrate concentration determined from this plot is 
approximately 8.7 pM  Ins 1,4,5 P3 . From this plot, the NIH3T3 Ins 1,4,5 
P3  kinase appears to display Michaelis-Menten kinetics.Figure 5.5b is the 
Lineweaver-Burke plot of the data in figure 5.5a. From this graph, the value 
of -1/Km was estimated to be -0.079 which gave a Km value of 12.7pM. 
These results indicated that the NIH3T3 Ins 1,4,5 P3  kinase enzyme as 
assayed in a cytosolic extract prepared from the cells has a higher Km value 
than the enzyme from other mammalian tissues (See Discussion at the end of 
this chapter) and therefore, seems to have a low substrate affinity.
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Figure 5.5; Substrate requirement of Ins 1,4,5 P? kinase 
specific activity from NIH3T3 high speed supernatants.
Figures 5.5a and 5.5b show the kinetics of the NIH3T3 Ins 1,4,5 P3 
kinase enzyme as determined by assaying enzyme activity of a high speed 
supernatant prepared from NIH3T3 cells in buffer A at pH7 in the presence 
of 2mM 2,3 DPG between 0.003 and 20|iM Ins 1,4,5 P3  with ljil of [3H]
Ins 1,4,5 P3  ( 44 Ci m m oH ) per assay. The results are from one 
experiment performed on triplicate samples and Figure 5.5a is a plot of 
velocity (v) of the enzyme reaction in nmol Ins 1,3,4,5 P4  min-1 mg-1 
protein versus substrate conce 'ntration in fiM (s). The data is representative 
of three separate experiments performed in triplicate and is ±  S.D. (n=3).
Figure 5.5b is the same data plotted as 1/v versus 1/s. The errors in this 
figure have been omitted for clarity.
|The last two points on the Lineweaver-Burke plot have not been included on the
! ' 1 
straight line obtained as they are derived from the first two points on the V versus S
plot (figure 5.5a). Both these points indicate a negligible specific activity of the Ins
I 1,4,5 P3  kinase and are therefore likely to be largely erroneous when converted to
j
the inverse values.
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The Ins 1,4,5 P3  concentration dependence of NIH3T3 Ins 1,4,5 P3 
kinase have been demonstrated in the previous figure. Further experiments 
were performed to investigate the ATP requirement of the enzyme. All 
experiments previous to these were performed using 10 mM ATP (Irvine £t 
al, 1986). A cytosolic preparation from NIH3T3 cells was incubated with 
ljil of [3H] Ins 1,4,5 P3  (Specific activity = 44 Ci mmol-1) and a final 
concentration of IOjiM Ins 1,4,5 P3  in ATP-free buffer A at pH 7 in the 
presence of 2,3, DPG with increasing concentrations of ATP at 30°C for 5 
minutes. The incubations were terminated as described and neutralised 
supernatants were analysed for Ins 1,3,4,5 P4  content by Dowex anion 
exchange chromatography.
Figure 5.6 shows the results of an experiment to determine the 
optimum ATP concentration for NIH3T3 Ins 1,4,5 P3  kinase activity. The 
results show that the specific activity for the enzyme increased up to 15 mM 
ATP and then decreased at 20 mM. From this experiment, theKmvalue for 
ATP was approximately 4 mM. This result suggests that an assay 
concentration of lOmM ATP is acceptable to measure Ins 1,4,5 P3  kinase 
activity from NIH3T3 high speed supernatants routinely. Although this 
result is from one experiment, two separate experiments performed on 
different cytosolic preparations from NIH3T3 cells indicated Km values of 
approximately 2 mM ATP and 4 mM ATP respectively which are consistent 
with the result obtained from the experiment shown.
Figure 5.6: ATP concentration dependence of Ins 1,4,5 
kinase activity from NIH3T3 cells.
Figure 5.6 represents the data obtained from an experiment to 
determine the concentration of ATP required for half-maximal Ins 1,4,5 P3  
kinase activity (Ka). The experiment was performed as described upon 
triplicate samples at concentrations of ATP between a range of 0- 20 mM and 
at lOpM Ins 1,4,5 P3 . The results are expressed as pmol Ins 1,3,4,5 P4  
min-1 mg~ 1 protein versus ATP concentration (mM) and are means ±S.D. 
(n=3 ) and are from one experiment representative of three separate 
experiments.
Sp
ec
if
ic
 
ac
tiv
ity
 
In
s 
1,
4,
5 
P3
 
ki
na
se
14 1
Figure 5.6
1000
800
600 -
400
200
20 3 01 0
[ATP] (mM)
142
The results in Figure 5.5 demonstrate that the NIH3T3 enzyme has a 
high Km value for Ins 1,4,5 P3 . One of the reasons considered for this was 
that there may be that an endogenous inhibitor of the enzyme existing in the 
cytosol. One way of testing this hypotheses was to assay Ins 1,4,5 P3 
kinase activity in diluted cytosolic preparations and compare this to a non­
diluted preparation. Therefore, a 'concentrated' cytosolic fraction from 
NIH3T3 cells was prepared by homogenising a cell pellet collected from 5 x 
75 cm2 flasks (approximately 3  x 1 0 ^ cells in total) in 1 ml of 
homogenisation buffer (See Methods Section). The homogenate was 
centrifuged to obtain a high speed supernatant which was diluted 
sequentially up to 100 fold in homogenisation buffer. The supernatants were 
assayed for Ins 1,4,5 P3  kinase activity at lOfiM Ins 1,4,5 P3  in buffer B at 
pH 7 in the presence of 2mM 2,3 DPG. Buffer B was used because the 
enzyme activity is inhibited in this buffer as already shown and thus if an 
inhibitor was present in the cytosolic preparations, the effects of dilution 
may enhance the enzyme activity in buffer B compared to buffer A, where 
no inhibition of NIH3T3 Ins 1,4,5 P3  kinase activity was found (Refer to 
Table 2 ).
Figure 5.7 shows the results of a dilution experiment performed as 
described above. The graph shows the specific activity of NIH3T3 Ins 1,4,5 
P3  kinase expressed as nmol Ins 1,3,4,5 P4  min- lm g- l protein plotted 
against fold dilution of the supernatants. There was an approximately 100 
fold increase in specific activity of the enzyme when diluted 1 0 0  fold 
(approximately 0.5}ig protein per assay). A significant increase in specific 
activity was first seen at a 25 fold dilution of the supernatant (approximately 
12.5p.g protein per assay) as compared to the undiluted preparation.
These results indicated that an increased specific activity of the 
Ins 1,4,5 P3  kinase enzyme in NIH3T3 cells was associated with increased 
dilution of the supernatants. Therefore, there may be an endogenous 
inhibitor of the enzyme which is reduced in concentration upon dilution.
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Figure 5.7: Specific activity of Ins 1.4.5 kinase in diluted 
NIH3T3 high speed supernatants,
Figure 5.7 shows the results of an experiment designed to determine 
if dilution of a high speed supernatant prepared from NIH3T3 cells had any 
effect on the specific activity of Ins 1,4,5 P3  kinase. Diluted high speed 
supernatants were assayed for Ins 1,4,5 P3  kinase activity at IOjiM Ins
1,4,5 P3  in buffer B at pH 7 in the presence of 2mM 2,3 DPG. The results 
are expressed in nmol Ins 1,3,4,5 P4  min-lmg-1 protein and are means 
±S.D. (n=3). Similar experiments performed at 3nM and 13nM Ins 1,4,5 P3 
gave results that showed exactly the same trend as in figure 5.7 but with 
lower specific activities. The protein concentration of the concentrated 
NIH3T3 high speed supernatant was determined to be 2.5 p.g per jjl. The 
amount of protein assayed per sample is indicated below:
Concentrated sample: 50 }ig 
2 fold dilution : 25 jag 
4 fold dilution : 12.5 jig 
10 fold dilution : 5 pig 
25 fold dilution : 2.5 p.g 
50 fold dilution : 1.25 p.g 
100 fold dilution : 0.5 pig
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It has already been demonstrated that the specific activities of T15+ 
and NIH 3T3 Ins 1,4,5 P3  kinase in high speed supernatants is reduced in 
buffer B compared to buffer A. Also, the results in figure 5.7 have 
demonstrated that there is a large increase in the specific activity of NIH3T3 
Ins 1,4,5 P3  kinase following dilution of the high speed supernatant 
prepared from these cells. To determine if this effect was due in part to the 
composition of the assay buffer, the experiment as described in figure 5.7 
was repeated under 2  different assay conditions.
A concentrated high speed supernatant from NIH3T3 cells was 
diluted up to a 100 fold in homogenisation buffer and assayed for Ins 1,4,5 
P3  kinase activity as already described i.e. at 10|iM Ins 1,4,5 P3  at pH 7 in 
the presence of 2,3, DPG. However, the experiment was performed in 
buffers A and B under the above conditions. Figure 5.8 shows the results of 
the experiment described above. The diluted high speed supernatant assayed 
in buffer B showed up to a 200 fold increase in Ins 1,4,5 P3  kinase specific 
activity as compared to the undiluted supernatant. In contrast, when Ins
1,4,5 P3  kinase activity was assayed in buffer A, there was only a 70 fold 
increase in specific activity at a 100 fold dilution. When the enzyme was 
assayed in buffer B, there is no significant increase in specific activity until a 
10 fold dilution, but in buffer A, a significant increase in specific activity 
occured after a 4 fold dilution.
The data shown in this figure indicates that the increase in specific 
activity of NIH3T3 Ins 1,4,5 P3  kinase that occurs on sequential dilution of 
the high speed supernatant is greater when assayed in buffer B than in buffer 
A. This suggests that the composition of the assay buffer used had a role in 
the modultion of Ins 1,4,5 P3  kinase activity by possibly affecting an 
endogenous inhibitor of the enzyme present in the cytosol.
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Figure 5.8; Specific activity of Ins 1,4,5 kinase from  
diluted NIH3T3 high speed supernatants assayed in either 
buffer A or B.
Figure 5.8 shows the results of an experiment to determine Ins
1,4,5 P3  kinase activity in diluted samples of NIH3T3 high speed 
supernatant when assayed in either buffer A or buffer B at pH 7 in the 
presence of 2,3, DPG and with lp l of pH ] Ins 1,4,5 P 3  (Specific activity = 
44 Ci mmol_l)  The amount of Ins 1,3,4,5 P4  from these samples was 
quantified by Dowex anion exchange chromatography. The results are 
expressed as nmol Ins 1,3,4 5 P4  min-1 mg-1 protein and are means ± S.D. 
(n=3) and are from one experiment. The amount of protein assayed per 
sample is indicated below:
Concentrated sample : 4.5 jig 
2 fold dilution : 2.25 qg 
4 fold dilution : 1.1 jig 
10 fold dilution : 0.45 |ig 
25 fold dilution : 0.18 |ig 
50 fold dilution : 0.09 pig 
100 fold dilution : 0.045 }ig
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It is clear from the data shown in Figures 5.7 and 5.8 that dilution of 
NIH3T3 high speed supernatants resulted in higher Ins 1,4,5 P3  kinase 
specific activities. This increased specific activity could be due to either an 
increased velocity of the enzyme reaction i.e. increased V max or a reduced 
Km value following dilution. To examine these possibilities, the Ins 1,4,5 
P3  kinase activity in selected diluted high speed supernatants were assayed 
against a range of substrate concentrations as utilised in Figure 5.5.
Figures 5.9a-5.9b show the results of experiments to determine if 
there was a change in either the V max or Km of NIH3T3 Ins 1,4,5 P3  
kinase in high speed supernatants diluted 10-, 50- and 100 fold as compared 
to a non-diluted supernatant. The figure shows the plot of v versus S for a 
non-diluted supernatant and of a 1 0  fold dilution of the same supernatant 
(figure 5.9a). The Vmax for the non-diluted sample was approximately 0.4 
nmol Ins 1,3,4,5 P4  min-1 mg-1 protein although the substrate range was 
0.003-15|iM Ins 1,4,5 P3  as compared to 0.003-20p.M Ins 1,4,5 P3  for all 
the diluted samples. The V max for the 10 fold diluted sample was 4 nmol 
Ins 1,3,4,5 P4  min-lmg-1 protein.
Figure 5.9b shows the results of similar experiments carried out on 
50 fold and 100 fold diluted high speed supernatants. They clearly show that 
the Ins 1,4,5 P 3  kinase specific activity was greatly increased compared to 
the 10 fold diluted and non-diluted samples of high speed supernatant. From 
these graphs, the Vmax value for the 50 fold diluted sample was estimated to 
be 14.5 nmol Ins 1,3,4,5 P4  min-lmg-1 protein and was approximately 400 
nmol Ins 1, 3,4,5 P4  min-1 mg-l protein for the 100 fold diluted sample. 
Thus, these results show that the activity of Ins 1,4,5 P3  kinase increased 
with increasing dilution of NIH3T3 high speed supernatants at all 
concentrations of substrate tested.
To obtain an estimate of the Km values of the Ins 1,4,5 P3  kinase in 
non-diluted and diluted high speed supernatants, Lineweaver-Burke plots 
were drawn from the data shown in Figure 5.9a and 5.9b. Figure 5.9c
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shows the Lineweaver-Burke plot of the data from the non-diluted high 
speed supernatant. From the intercept on the x-axis, the Km value has been 
estimated to be 15.9|iM. Figure 5.9d shows the Lineweaver-Burke plot of 
the data obtained for the 10 fold diluted high speed supernatant and a Km 
value of 15.9|iM has been estimated from this graph. Figures 5.9e and 5.9f 
show Lineweaver-Burke plots for the 50 fold and 100 fold diluted enzymes 
and km values of 15.9 |iM  and 15 }iM have been estimated have been 
estimated from these graphs.
Thus, these experiments demonstrate that on dilution of NIH3T3 
high speed supernatants, the Km for Ins 1,4,5 P3  of the Ins 1,4,5 P3  kinase 
enzyme remains unchanged but the Vmax increases.
Having established the possibility of an endogenous,soluble inhibitor 
of Ins 1,4,5 P3  kinase in NIH3T3 fibroblasts, the following experiment was 
performed to determine if this inhibitor was specific for NIH3T3 Ins 1,4,5 
P3  kinase. A concentrated NIH3T3 cytosolic extract was prepared as 
previously described and this was mixed in a 1 :1  (v/v) ratio with a high 
speed supernatant prepared from bovine adrenal glands by S. Palmer and F. 
Black. 20jil o f this mixture was assayed in a final volume of 150jil for Ins
1,4,5 P3  kinase activity at pH 7 in buffer A at 10|iM Ins 1,4,5 P3  as already 
described. Control incubations of adrenal high speed supernatant only, 
NIH3T3 extract only, adrenal extract diluted with sucrose/tris buffer (1:1,v/v 
ratio; See Methods for buffer composition) and NIH3T3 extract diluted with 
sucrose/tris buffer (1:1,v/v ratio) were also assayed for Ins 1,4,5 P3  kinase 
activity under the same conditions.
The results in table 3 are from the experiment described above and 
show that dilution of adrenal high speed supernatant resulted in a decrease in 
the amount of Ins 1,3,4,5 P4  produced as compared to the undiluted adrenal 
extract. However, dilution of the NIH3T3 high speed supernatant resulted in 
the same amount of Ins 1,3,4,5 P4  produced as the undiluted cytosolic 
extract and suggested that the possible inhibition of Ins 1,4,5 P3  kinase that 
occured in the NIH3T3 cell line did not occur in bovine adrenal gland. The
1 5 0
mixture of the adrenal and NIH3T3 high speed supernatants resulted in a 
smaller amount of Ins 1,3,4,5 P4  formed compared to either diluted 
NIH3T3 or adrenal supernatants. Since the amount of Ins 1,3,4,5 P4  
formed in the NIH3T3/adrenal mixture was lower than either the diluted 
adrenal or NIH3T3 extracts which act as controls in this experiment, it is 
possible that there was inhibition of bovine adrenal gland Ins 1,4,5 P3  
kinase activity by the NIH3T3 cytosolic extract. This suggests that the 
possible inhibitor in NIH3T3 cells of Ins 1,4,5 P3  kinase is not specific for 
the fibroblast enzyme.
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Figure 5.9a and 5.9b: v versus TS1 plot of Ins 1.4.5 kinase 
specific activities in undiluted and diluted NIH3T3 high speed 
gppernatantSx
These figures show the results of a v (nmol Ins 1,3,4,5 P4  min-1 
mg-1 protein) versus S plot for undiluted, 10-, 50- and 100 fold diluted 
NIH3T3 high speed supernatants assayed at pH 7 in the presence of 2,3, 
DPG in buffer B. The results are means ±  S.D. (n= 3) and are from one 
experiment, although the experiment using a 50 fold diluted high speed 
supernatant was performed twice, with the same estimated Km value being 
derived each time.
F igures 5 .9c-5 .9f: Lineweaver-Burke plots of data obtained  
from figures 5,9a and 5.9b.
These figures are Lineweaver-Burke plots for the data shown in 
Figures 5.9a and 5.9b. As the data has been derived from the results in 
figures 5.9a and 5.9b the standard errors have been omitted for clarity.
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However,the results shown in the table are only from one experiment 
and the results obtained from the assays of adrenal Ins 1,4,5 P3  kinase 
activity indicate a value much lower than expected and was much lower than 
that found for concentrated NIH3T3 cytosolic extract This could be due to 
the fact that the adrenal gland cytosolic extract was not a recent preparation 
and therefore, these experiments will have to be repeated using a more recent 
preparation of adrenal gland high speed supernatants. The experiments will 
also have to be performed over a range of dilutions of the adrenal extract 
with NIH3T3 extract using both buffers A and B to obtain more information 
on the nature of this possible non-specific inhibition of 
Ins 1,4,5 P3  kinase. The results in table 3 therefore, are not conclusive but 
are only suggestive of a possible inhibitor of Ins 1,4,5 P3  kinase that is not 
specific for the enzyme in this fibroblast cell line.
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Table 3; Effect of NIH3T3 cvtosolic extract on production of 
Ins 1,3,4,5 Pd in bovine adrenal gland high speed supernatant.
The results shown in table 3 are from an experiment to determine the 
effect of mixing NIH3T3 concentrated high speed supernatant with high 
speed supernatant from bovine adrenal glands on the production of Ins
1,3,4,5 P4 . The experiment was carried out as described in the text and in 
the Methods section and the results are pmol Ins 1,3,4,5 P4  produced/5 min 
and are means ±  S.D.(n=3). The protein concentrations of the high speed 
supernatants were as follows:
bovine adrenal gland = 2 5 .5 ^ | i l - l ; NIH3T3 = 2.5 nA Ji H
JPttifratiQns pmol Ins 1,3,4, 5 V/\
Adrenal 0.62 ± 0 . 1 2
NIH3T3 0.55 ± 0 .1
Adrenal/NIH3T3 0.31 ± 0 .1 2
Adrenal/buffer 0.48 ± 0.07
NIH3T3/buffer 0.48 ± 0 .1 2
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D iscu ssio n
The results presented in this chapter are from experiments performed 
to investigate the possible reasons for the absence of Ins 1,3,4,5 P4 in 
bombesin stimulated T15 and NIH3T3 cells. The first observation that led to 
these investigations was that there was no detectable Ins 1,3,4,5 P4 in 
bombesin stimulated T15+ cells. In figure 5.1, the HPLC elution profile of 
an extract prepared from T15+ cells stimulated for 120 seconds with 
bombesin is shown. From this data, it is clear that there was no Ins 1,3,4,5 
P4 produced. Further, no detectable dephosphorylated derivatives of Ins
1,3,4,5 P4 i.e. Ins 1,3,4 P3 , Ins 3,4 P2 or Ins 1,3 P2 or Ins 3 P were 
detected. The reasons for this were postulated as being either that these cells 
lacked the Ins 1,4,5 P3 kinase enzyme or that the levels of Ins 1,4,5 P3 
produced on bombesin stimulation were too low for Ins 1,3,4,5 P4 
formation to occur. The other possibility was that the phosphatase enzymes 
that dephosphorylate Ins 1,3,4,5 P4 and Ins 1,4,5 P3 were extremely active 
in these cells.
At no time point in bombesin stimulated T15 or NIH3T3 cells was 
there detectable Ins 1,3,4,5 P4 despite the peak of Ins 1,4,5 P3 reaching 
1000 dpm in T15+ cells in some cases. In A431 and NG 115-40IL cells, 
the levels of Ins 1,3,4,5 P4 reach approximately 50% and 25% respectively 
of the peak levels of Ins 1,4,5 P3 and detectable levels of Ins 1,3,4,5 P4 
following a 15 second mitogen stimulation in these, cell types (Jackson et al> 
1987 and Tilly et al, 1987). If the phosphorylation and dephosphorylation 
pathways of Ins 1,4,5 P3 in different cell types are similar, then from the 
facts above, there should be detectable Ins 1,3,4,5 P4 production in T15+ 
cells on bombesin stimulation.
Although the presence of Ins 1,3,4,5 P4 in mitogen stimulated cells 
is thought to occur in most cell types (See Introduction), there have been 
reports in the literature that demonstrate that Ins 1,3,4,5 P4 production does 
not occur in all tissues. Woodcock et al (1987) have reported that there is no
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Ins 1,3,4,5 P4 formation in epinephrine perfused rat hearts and that there is 
no detectable Ins 1,3,4 P3. These workers only detected stimulated increases 
of Ins 1,4,5 P3 and Ins 1,4 P2 and Ins 1 P. They have suggested that there 
is a lack of Ins 1,4,5 P3 kinase activity in rat heart.
Figures 5.2a and 5.2b illustrate that T15+ cells are not deficient in 
Ins 1,4,5 P3 kinase activity, although from figure 5.2a it is clear that the Ins
1.4.5 P3 5' monophosphatase enzyme is very active in this cell line and is 
not completely inhibited at pH 9. This contrasts with the enzyme assayed in 
extracts from rat liver cells (Storey si al, 1984). Figure 5.2b shows that 
further dephosphorylation of Ins 1,4,5 P3 and Ins 1,3,4,5 P4 occurs at pH 
7. This suggests that the phosphorylation/dephosphorylation pathways of 
Ins 1,4,5 P3 and Ins 1,3,4,5 P4 can occur in T15+ cells.
In NIH3T3 cells, the Ins 1,4,5 P3 5' monophosphatase is 
completely inhibited at pH 9 (figure 5.3a) but not at pH 7 (figure 5.3b). As 
in T15+ cells, the phosphorylation and dephosphorylation of Ins 1,4,5 P3 
occurs and Ins 1,3,4,5 P4 is dephosphorylated to its derivatives. From the 
calculated specific activities of Ins 1,4,5 P3 kinase in T15+ and NIH3T3 
cells it is clear that T15+ cells have a lower Ins 1,4,5 P3 kinase specific 
activity than NIH3T3 cells and this may be due in part to the increased Ins
1.4.5 P3 5' monophosphatase activity in T15+ cells. However, both cell 
lines exhibit a lower Ins 1,4,5 P3 kinase specific activity than the rat brain 
enzyme (Refer to figures 5.4a and 5.4b) and this low Ins 1,4,5 P3 kinase 
specific activity may partly explain the lack of Ins 1,3,4,5 P4 in bombesin 
stimulated T15 and NIH3T3 cells.
Table 2 shows that the NIH3T3 fibroblast Ins 1,4,5 P3 kinase 
enzyme is inactive at pH 7 as compared to pH 9 and is less active in an ionic 
buffer compared to a low ionic strength, non-'physiological' buffer. Data 
from a similar experiment to compare the specific activities of T15 Ins 1,4,5 
P3 kinase in buffers A and B at pH 7 or pH 9 also showed that the enzyme 
was inhibited at pH 7 as compared to pH 9 in buffer A. This was not an 
effect of inhibition of Ins 1,4,5 P3 kinase specific activity by 2,3 DPG at pH
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7 as the specific activities of the enzyme assayed in the presence or absence 
of 2,3 DPG at pH 7 or at pH 9 were the same.This could suggest that the Ins
1.4.5 P3 kinase enzyme has an optimum pH that is above pH 7 and is 
inhibited in a high ionic strength buffer. It has been shown that the optimum 
pH of the Ins 1,4,5 P3 kinase from other sources is greater than pH 7, for 
example, the pH optimum for the enzyme from pig aortic smooth muscle is 
7.7 (Yamaguchi et al, 1988) and is 8.5 for the enzyme from bovine brain 
(Ryu et al, 1987). The extent to which the T15+ and NIH3T3 Ins 1,4,5 P3 
kinase enzymes were inhibited differed to a marked degree. While it was 
possible to assay the T15 enzyme in buffer B at pH 7 in the presence of 2,3 
DPG, there was no detectable NIH3T3 Ins 1,4,5 P3 kinase activity under 
these conditions. For this reason, subsequent enzyme assays were 
performed in buffer A and at a pH that was closest to in vivo conditions
i.e.at pH 7, although the enzyme specific activities were lower at this pH 
than at pH 9.
Experiments to determine the Km for Ins 1,4,5 P3 of the Ins 1,4,5 
P3 kinase in NIH3T3 cells (figure 5.5) indicated that this enzyme has a 
higher Km value than the enzyme from rat brain cytosol (0.6|iM, Irvine £t 
al, 1986; 0.44jiM, Morris et a!, 1988), from retina (1.3|iM, Tarver and 
Anderson, 1988), from bovine brain (0.7pM, Ryu et al, 1988) and in pig 
aortic smooth muscle (0.4pM, Yamaguchi el al, 1988). The Km value of the 
NIH3T3 enzyme as derived from experiments utilising high speed 
supernatants prepared from NIH3T3 cells is between 12 and 15 fiM Ins
1.4.5 P3 and is at least 10 times higher than the Km for Ins 1,4,5 P3 kinase 
from other tissue and suggests that the NIH3T3 enzyme has a low affinity 
for Ins 1,4,5 P3. This is supported by the fact that while bombesin 
stimulated NIH3T3 cells do not generate significant amounts of Ins 1,4,5 P3 
or Ins 1,3,4,5 P4 , this is not true of PGF2a stimulated NIH3T3 cells. PGF 
2a stimulates a 20-30 fold increase in total inositol phosphates in NIH3T3 
cells and it appears that a large increase in Ins 1,4,5 P3 levels occurs before 
Ins 1,3,4,5 P4 formation can occur in this cell type. PGF2a stimulated
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NIH3T3 cells exhibit a 4 fold increase in Ins 1,4,5 P3  production with the 
peak of Ins 1,4,5 P3 generation occuring at 15 seconds after agonist 
stimulation and an associated increase in Ins 1,3,4,5 P4  and Ins 1,3,4 P3  is 
seen in these cells (Black, F. and Wakelam, M J.O ., manuscript in 
preparation). Although the curve drawn in figure 5.5a indicated Michaelis- 
Menten kinetics for the NIH3T3 Ins 1,4,5 P3  kinase, it is possible that this 
curve is sigmoidal. If this is true, it suggests another possible reason for the 
lack of Ins 1,3,4,5 P3  formation at low concentrations of Ins 1,4,5 P3  and 
the detection of Ins 1,3,4,5 P4  when there are large mitogen stimulated 
levels of Ins 1,4,5 P3  apart from the high Km value for Ins 1,4,5 P3 . A 
sigmoidal curve would also suggest that positive cooperativity was a 
regultory feature of this enzyme. However, until conclusive data is obtained 
which indicates a linear rate of enzyme reaction, the considerations above 
cannot be tested.
In figure 5.6, the ATP requirement of the NIH3T3 Ins 1,4,5 P3  
kinase is shown and from this data, a Km value for ATP of approximately 4 
mM was derived. This value is high compared to the Km for ATP for the 
retinal Ins 1,4,5 P3  kinase (1.4 mM, Tarver and Anderson, 1988),the 
enzyme from bovine brain (0.04 mM, Ryu et al, 1987) and the enzyme from 
rat brain (460 jiM, Morris et al, 1988). This suggests that the NIH3T3 
enzyme as as£yed in a high speed supernatant has a lower affinity for ATP
than the enzyme from other sources. As with the substrate affinity of the
We.
enzyme, this apparently low affinity for ATP could^a factor that influencing 
the phosphorylation of Ins 1,4,5 P3  to Ins 1,3,4,5 P4  in NIH3T3 cells. 
Further experiments are necessary to test the possibility that the amounts of 
ATP in the assay were not a limiting factor for Ins 1,4,5 P3  kinase activity 
as there was no ATP regenerating system present. However, on the basis of 
the experiments described, it is not possible to determine if these high Km 
values for both Ins 1,4,5 P3  and ATP derived for NIH3T3 Ins 1,4,5 P3  
kinase were due to enzyme characteristics or to endogenous factor(s) in the 
cytosol which modify the affinity of the enzyme for Ins 1,4,5 P3  and ATP.
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Experiments using purified preparations of NIH3T3 Ins 1,4,5 P3 kinase 
may provide a solution to these questions and may also suggest if NIH3T3 
fibroblasts regulate Ins 1,4,5 P3 kinase activity differently from other 
tissues, although the enzymes from different tissues seem to have different 
characteristics from each other (See examples cited above).
The apparent high Km value for Ins 1,4,5 P3 of the NIH3T3 Ins
1,4,5 P3 kinase as determined from figure 5.5 indicated that the enzyme did 
not have a high affinity for its substrate. Dilution of NIH3T3 high speed 
supernatants and the subsequent assay of the diluted high speed supernatants 
for Ins 1,4,5 P3 kinase activity as shown from the results in figure 5.7 have 
suggested that dilution of the high speed supernatant increases the specific 
activity of Ins 1,4,5 P3 kinase in the preparation. This raises the possibility 
of the existence of an endogenous inhibitor of the enzyme in NIH3T3 cells. 
Increasing specific activity was associated with decreasing amounts of 
protein and indicates that either the affinity of the enzyme for its substrate 
has increased or that the V max of the enzyme reaction had increased on 
dilution. As this effect is associated with reduced amounts of protein assayed 
for Ins 1,4,5 P3 kinase activity it may be possibly due to the removal of an 
inhibitory factor(s) upon dilution of the high speed supernatant.
A further modification of NIH3T3 Ins 1,4,5 P3 kinase specific 
activity occurs when the enzyme is assayed in either a physiological- type 
buffer ( buffer B ) or a non-physiological buffer ( buffer A ). When the 
dilution experiment was repeated in buffers A and B and the results 
compared (figure 5.8), it is clear that the increased specific activity 
associated with dilution of the high speed supernatant is more apparent using 
buffer B. In table 2, it has been shown that in this physiological type buffer 
there is no Ins 1,4,5 P3 kinase activity in NIH3T3 high speed supernatants. 
However, dilution of these supernatants and subsequent assay of the 
samples in buffer B greatly enhanced the Ins 1,4,5 P3 kinase specific 
activity. In buffer A, there was no inhibition of NIH3T3 Ins 1,4,5 P3 kinase 
activity compared to buffer B but dilution of the high speed supernatants
1 6 2
and assay of these diluted supernatants in buffer A did not increase the Ins
1.4.5 P3 kinase specific activity to the same extent as in buffer B. This 
suggests that the composition of the assay buffer can affect NIH3T3 Ins
1.4.5 P3 kinase activity and that if an endogenous inhibitor is present, then 
its activity is modified by buffer composition, perhaps by the action of Ca 
2+ ions on the inhibitor. If the inhibitor is not active in buffer A, then 
detectable Ins 1,4,5 P3 kinase activity will be observed when assayed in this 
system but only a small increase in Ins 1,4,5 P3 kinase activity will be 
detected on dilution of high speed supernatants since the enzyme is not 
completely inhibited, or because only a small proportion of the total inhibitor 
concentration will be in an active state. However, in the physiological, high 
ionic strength buffer which reflects the cellular environment, the inhibitor 
may be in an active conformation and therefore, no activity of the Ins 1,4,5 
P3 kinase will be detectable unless the high speed supernatant is diluted. On 
dilution of the supernatants, therefore, a very large increase in Ins 1,4,5 P3 
kinase specific activity will be detected.Thus, the differences in the specific 
activities of Ins 1,4,5 P3 kinase in undiluted and diluted NIH3T3 high speed 
supernatants when assayed in either buffers A or B may be a reflection of the 
activity of the possible inhibitor(s) in cytosolic extracts and the interaction of 
this inhibitor with the NTH3T3 Ins 1,4,5 P3 kinase.The increase in specific 
activity of Ins 1,4,5 P3 kinase in diluted high speed supernatants was shown 
to be due to an increase in V max of the enzyme reaction rather than a change 
in the Km of the reaction ( Figures 5.9a-5.9f). This result suggests that if 
such an endogenous inhibitor of NIH3T3 Ins 1,4,5 P3 kinase is present in 
the cells, then the inhibition is^competitive as deduced from Lineweaver- 
Burke plots of the data.
The results presented in Table 3 suggest that the inhibition of 
NIH3T3 Ins 1,4,5 P3 kinase may not be specific to this cell line as mixing a 
concentrated cytosolic extract of NIH3T3 cells with a cytosolic extract from 
bovine adrenal glands caused a reduction in the amount of Ins 1,3,4,5 P4 
produced as compared to either adrenal gland or NIH3T3 high speed
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supernatants assayed under the same experimental conditions. More 
importantly, the amount of Ins 1,3,4,5 P4  generated in a sample of adrenal 
gland high speed supernatant 'diluted' with NIH3T3 high speed supernatant 
was reduced compared to Ins 1,3,4,5 P4  generated in adrenal gland and 
NIH3T3 high speed supernatants which were diluted in the same ratios with 
a sucrose/Tris buffer. This suggests that the effect of addition of NIH3T3 
cytosolic extract to the adrenal gland high speed supernatant may be to 
inhibit the adrenal Ins 1,4,5 P3  kinase activity and therefore, shows that the 
'inhibitor' of Ins 1,4,5 P3  kinase activity in NIH3T3 cells can also affect Ins
1,4,5 P3 kinase activity from other tissue.
The results in table 3 also show that dilution of NIH3T3 high speed 
supernatant did not affect the amount of Ins 1,3,4,5 P4  generated compared 
to undiluted NIH3T3 high speed supernatant whilst dilution of adrenal high 
speed supernatant resulted in a decrease in the amount of Ins 1,3,4,5 P4  
generated compared to undiluted samples. This suggests differential 
regulation of Ins 1,4,5 P3  kinase activity in these two different cell types and 
also shows that the possible inhibition of Ins 1,4,5 P3  kinase activity in 
NIH3T3 cells does not occur in bovine adrenal gland.
The results presented in this chapter indicate that there may be an 
inhibitor of Ins 1,4,5 P3  kinase activity in the NIH3T3 cell line. The 
mechanism of this inhibition is at present unclear but may be competitive in 
nature. The lack of Ins 1,3,4,5 P4  production in the T15 cells may therefore 
be explained by the possible inhibition of Ins 1,4,5 P3  kinase activity in this 
cell line but from Table 1 and the data in figure 5.2, it is clear that T15+ cells 
exhibit a higher Ins 1,4,5 P3  5'monophosphoesterase activity than either 
NIH3T3 or brain cytosolic extract. The Ins 1,4,5 P3 
5'monophosphoesterase activity in T15+ cells is not inhibited at pH 9 
suggesting that this enzyme may be differently regulated in this transformed 
cell line or is present at a greater level.
The biological significance of these differences in the regulation of 
Ins 1,4,5 P3  and Ins 1,3,4,5 P4  dephosphorylation between T15+ and
1 b4
NIH3T3 cells is not clear at present but it is possible that peptide growth 
factor stimulated Ins 1,3,4,5 P4  production in T15 cells does not have a role 
in cell proliferation. Also, it is not known if one of the effects of p2 1  N-ras 
transformation on NIH3T3 cells is to increase the rate of Ins 1,4,5 P3  
degradation or if these effects are due to the onset of transformation as a 
consequence of p2 1  N-ras overexpression and are therefore not specific to 
the ras oncogene.Therefore, the investigation into the regulation of Ins 1,4,5 
P3  kinase activity in the NIH3T3 cell line should be carried out on the 
purified enzyme and studies on transformed cell lines following the study of 
the NIH3T3 enzyme would perhaps demonstrate the significance of these 
preliminary results described in this chapter. The role of the ras oncogenes 
and other oncogenes on this component of the phosphoinositide signalling 
pathway would thus possibly be more clearly defined.
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Chapter 6: The effects of p 2 lN -£M  overexpression on cyclic AMP 
production in the NTH3T3 cell line.
Introduction
The results in the preceeding chapters have shown that p21 N-ras 
affects bombesin stimulated inositol phosphate production which may correlate 
with cell proliferation. However, the other main cellular signalling system 
which uses cyclic AMP as a second messenger, may also be modified by p21 
The adenylate cyclase signalling system is regulated by two G proteins (Gs 
and GO and the production of cycle AMP is mediated by extracellular signals 
via stimulatory and inhibitory receptors coupled to the appropriate G proteins. 
The activity of these G proteins can be modified by ADP-ribosylation of their 
alpha subunits in the presence of bacterial toxins (Gilman, 1984). ADP- 
ribosylation catalysed by pertussis toxin will inactivate Gi while cholera toxin 
catalysed ADP-ribosylation will activate Gs. Therefore, the effect of both these 
toxins is to increase the activity of adenylate cyclase whilst acting on different 
substrates.
In the yeast, S. Cerevisiae. it has been shown that the RAS 2 gene 
product regulates adenylate cyclase activity (Broek et al, 1985). The yeast RAS 
proteins are closely related to the mammalian p2 1  —  proteins and therefore, it 
was possible that mammalian p2 1  —  was involved in the regulation of 
adenylate cyclase activity. The homology between p21 ^  and the a subunits of 
GTP binding proteins, for example transducin, also suggest the possibility that 
p2 i_ras_may function as a regulatory G protein for the mammalian adenylate 
cyclase signalling system. However, there is no evidence for this function of 
p2 1  —  in the literature although some of the reports show conflicting evidence 
(See Discussion at the end of this chapter).
As the previous chapters have demonstrated that p2 lN"ias 
overexpression is involved with increased agonist-stimulated Ins 1,4,5 P3  
production, the effects of p2 lN ‘E&s overexpression on cyclic AMP production 
was investigated in the T15 cell line.The effects of p21 N-ras 0verexpression on
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the adenylate cyclase system in NIH3T3 cells have not been reported in the 
literature. Therefore these experiments were performed to investigate the effects 
of p21 N-ras OVerexpression in NIH3T3 cells on the cyclic AMP signal 
transduction pathway which may be associated with cell proliferation. These 
experiments were performed on T15- cells, T15- cells treated with 
dexamethasone for 24 hours prior to the experiment (T15+/24 hours) and T15- 
cells treated with dexamethasone for at least 2  passages resulting in complete 
morphological transformation (T15+ cells ). This allowed the progressive 
increase of p21 N-ras 0verexpression in T15 cells and the investigation of these 
effects on cylic AMP production. T15- cells were cultured routinely until 2 days 
prior to experimentation, when the medium was changed to 1 0  % (v/v) steroid- 
free serum/90 % DMEM. This was to minimise the frequency of spontaneous 
transformation of T15- cells due to the presence of steroids in the growth 
medium. Culturing of NIH3T3 cells in the steroid-free medium described above 
did not affect either basal or agonist stimulated intracellular cyclic AMP levels 
compared to cells grown in routinely used 10 % calf serum/90 % DMEM. 
Therefore, it can be assumed that steroid-free culture of T15- cells would not 
affect either basal or agonist stimulated intracellular cyclic AMP levels.
Initial attempts to characterise the effects of p2 1  N-ras on adenylate 
cyclase using membrane preparations from T15 and NIH3T3 cells proved 
unsuccessful and therefore, cyclic AMP levels in whole cells were measured. 
The reasons for the lack of detectable adenylate cyclase activity in membrane 
preparations in T15 cells are not clear but it is possible that the procedure for the 
preparation of membranes from these cells resulted in the removal of necessary 
cytosolic factors which stimulate the activity of adenylate cyclase. It is also 
possible that the methods utilised for the preparation of crude membrane 
fractions from T15 and NIH3T3 cells affected the adenylate cyclase enzyme and 
the associated components in the membrane. As these problems could not be 
resolved, an indirect measure of adenylate cyclase activity was determined by 
estimating intracellular cyclic AMP content in unbroken cells in the presence of 
the cyclic AMP phosphodiesterase inhibitor, IBMX.
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R esu lts
Experiments using T15 cells were performed to determine cyclic AMP 
levels in control and agonist stimulated cells. T15- cells were grown in 2jiM 
dexamethasone for 24 hours prior to the experiment generating T15+/24 hours 
cells. These cells express significant amounts of p21 N-ras protein and exhibit 
amplified bombesin stimulated inositol phosphate production (See Chapter 3). 
T15+/24 hour cells differ from T15+ cells in that the latter are cultured in 
dexamethasone for at least two passages. The experiments were performed on 
these three different T15 cell types to determine if long-term p21 N-ras 
overexpression affected cyclic AMP levels in NIH3T3 cells. These experiments 
demonstrate one of the advantages of this inducible cell line.
The experiments were carried out as described in the Methods section in 
the presence of ImM IBMX in order to inhibit cyclic AMP phosphodiesterases. 
In all cell types shown in this and following experiments, the basal levels of 
cycle AMP were measured in the presence of ImM IBMX. If IBMX was not 
included in the assays, the levels of cyclic AMP measured in all cell types were 
approximately 50% of the levels measured in its presence. All concentrations of 
agonists were 1 0 "^ M except for forskolin which was 10"^ M.
Figure 6.1 shows the levels of cyclic AMP in unstimulated and agonist 
stimulated T15 cells. The results indicate that in non-transformed cells, there 
was a large stimulation (approximately 7 fo ld ) of cyclic AMP production in 
response to isoproterenol, adrenaline and forskolin. The isoproterenol and 
adrenaline stimulated levels were reduced in T15+/24 hour cells by 
approximately 30% and 50% respectively. However, there was no inhibition of 
forskolin stimulated cyclic AMP levels in T15+/24 hour cells. In contrast, in 
T15+ cells there was a marked reduction in isoproterenol, adrenaline and 
forskolin stimulated cyclic AMP levels by approximately 80%, 90% and 75% 
respectively. Although the stimulated levels of cyclic AMP production were 
inhibited when p2 1  N-ras OVerexpression was induced, there was no change in 
the basal rate of cyclic AMP production in all three cell types, taking into
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account the standard errors of the data. Therefore, the data shown in this figure 
suggest that overexpression of p2 1  N-ras ^  ^ 5  cells resulted in the inhibition 
of agonist stimulated cyclic AMP levels but did not affect the basal rate of 
cyclic AMP production.
From figure 6.1, it is clear that adrenaline at a concentration of 10'^ M 
acts to stimulate an increase in cyclic AMP levels in T15 cells. However, 
adrenaline can act via p or (X2  receptors which are stimulatory and inhibitory 
respectively, for adenylate cyclase. To investigate if adrenaline could act via <X2  
receptors in this cell line, experiments were carried out where adrenaline was 
incubated with cells together with propranalol and forskolin as described in the 
Methods section. Propranalol, an antagonist for p receptors, will inhibit 
isoproterenol and adrenalin stimulation of cyclic AMP levels (See table 1). If 
propranalol is added with adrenaline and forslfclin, then adrenaline cannot act 
through b receptors but must act through 0C2  receptors. If adrenaline does act 
through (X2  receptors in this cell line, then a reduction in forskolin stimulated 
cyclic AMP levels in T15 cells would be observed.
The results shown in table 1 show that propranalol at 10“^  M effectively 
inhibited adrenaline stimulated cyclic AMP production in T15 cells, since 
propranalol and adrenaline together did not cause an increase in cyclic AMP 
over basal levels. When adrenaline, forskolin and propranalol are added 
together in T15 cells, there was no inhibition of cyclic AMP levels below the 
levels stimulated by forskolin alone z.e.under these conditions adrenaline does 
not act via (X2  receptors to inhibit forskolin stimulated cyclic AMP levels in 
T15- and T15+/24 hour cells. Therefore, these results demonstrate that 
adrenaline acts only through p adrenergic receptors in T15 cells and not through 
0C2  receptors, suggesting that the use of adrenaline as a p adrenergic agent in 
these experiments is valid.
169
Figure 6.1: Basal and stimulated cyclic AMP levels in T15-. 
T15+/24 hour and T15+ ceils.
The figure shows the basal and agonist stimulated levels of cyclic AMP 
in T15-, T15+/24 hour and T15+ cells expressed as pmol cyclic AMP/10 
min/10^ cells. The experiments were carried out as described in the Methods 
section and incubations performed in the presence of lm M  IB MX. 
Concentrations of agonists were as follows: Isoproterenol=10"^ M, 
Adrenaline=10“~* M and forskolin=10'^ M. These concentrations were used in 
all experiments in this chapter unless otherwise stated. The results shown in this 
figure are pooled data from 4-6 separate experiments where n=3 in each and are 
means ±  S.E.M.
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Table 1: Adrenaline acts as a B adrenergic agonist in T15 cells.
The table shows data from an experiment to determine if adrenaline acts 
through either P or (X2  receptors, or both, in T15 cells at a concentration of 10"5 
M. The experiment was performed as described in the Methods section on 
T15-, T15+/24 hour and T15+ cells using propranalol at a concentration of 10"^ 
M and other agonists at concentrations already described. The data is from one 
experiment representative of 2-4 separate experiments and are expressed as 
mean pmol cyclic AMP/10 min/10^ cells ± S.D., n=3 in each. N.D.= not 
determined.
C elilyp g
C Qn,ditiQn$ T 15- T15+/24 h o u r T 15 +
B asa l 0.33±0.02 0.3±0.02 0.33±0.02
A d ren alin e 3.23±0.28 1.98±0.38 0 .68±0.10
A drenaline  + 0.4010.10 0.35±0.02
P ro p ra n a lo l
0.1810.02
F o rsk o lin 1.8510.35 2.010.18 0.7510.03
F o rsk o lin + 1.7310.15 1.9310.15 N.D.
A dren a lin e+
P ro p ra n a lo l
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The data in the previous figures have shown that the overexpression of 
p2 1  N-ras^ induced by dexamethasone, resulted in an inhibition of agonist 
stimulated cyclic AMP levels. As this effect could be due to a non-specific effect 
of the steroid in this cell type, experiments were performed on NIH3T3 cells 
treated with dexamethasone to determine if such cells exhibited an inhibition of 
agonist stimulated cyclic AMP levels. Therefore, NIH3T3 cells were treated 
with 2jiM dexamethasone for 24 hours prior to the experiment and control and 
treated cells assayed for cyclic AMP content under basal and agonist stimulated 
conditions as previously described.
The data shown in figure 6.2 indicates that there were no differences in 
the basal and agonist stimulated cyclic AMP levels in control and 
dexamethasone treated NIH3T3 cells. The data also shows that although the 
basal level of cyclic AMP in NIH3T3 cells was similar to T15- cells, the agonist 
and forskolin stimulated cyclic AMP levels were lower than in T15- cells. This 
result is surprising, as the two cell types are non-transformed cells, T15- cells 
being derived from NIH3T3 cells. The reasons for this variation is unclear but 
may represent clonal differences between the cell lines.
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Figure 6.2: Basal and agonist stimulated cyclic AMP levels in 
control and dexamethasone treated NIH3T3 cells.
The figure shows the data from experiments to determine the cyclic 
AMP levels in NIH3T3 cells which were either treated or untreated with 2jiM 
dexamethasone for 24 hours prior to the experiment. The experiment was 
performed under the conditions of previous experiments (See figure 6.1). All 
concentrations of agonists were as already described and incubations were 
performed in the presence of ImM IB MX. The data is expressed as pmol cyclic 
AMP/10 min/10^ cells and is pooled from two separate experiments, n=3 in 
each case and the results are means ±  S.D.
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The T15 cell line is transfected with a dexamethasone inducible 
promoter which controls p21 N-ras OVerexpression. Transformation of the cells 
can thus be 'switched on' or 'switched o ff by the addition of the steroid to the 
growth medium of the cells. As the previous results have demonstrated that p21 
N-ras overexpression can affect cyclic AMP generation, the constitutive 
overexpression of p21 N-ras fa  NIH3T3 cells and its relevance to cyclic AMP 
production was examined.
The N 8 6 6  cell line was utilised to investigate if constitutive 
overproduction of p21 N-ras wouid affect cyclic AMP production in NIH3T3 
cells. N 8 6 6  cells are NIH3T3 cells transfected with the human foetal genomic 
p2 i N-ras proto-oncogene. The difference between this cell line and T15 cells is 
that the N 8 6 6  cell line constitutively overproduces p2 1  N-ras ? ^  thus 
permanantly 'switched on' and thus exhibit the transformed phenotype.This cell 
line was utilised to investigate cyclic AMP production under the same 
conditions as described in figure 6.1. All assays were performed in the presence 
of ImM IBMX and all concentrations of agonists used were as previously 
described.
The data in figure 6.3 shows that both basal and agonist stimulated 
levels of cyclic AMP were reduced in N 8 6 6  cells compared to T15 cells. There 
was an approximately 33% decrease in basal levels of cyclic AMP in N 8 6 6  
cells as compared to T15 cells. In N 8 6 6  cells there was no significant increase 
in cyclic AMP levels when the cells are incubated with isoproterenol or 
adrenaline. However, there was an approximately 1.6 fold increase in 
stimulation of cyclic AMP levels in response to forskolin stimulation. This 
increase, however, was small compared to the 6.7 fold increase detected in 
T15- cells and 2 fold increase detected in T15+ cells. Therefore, in N 8 6 6  cells 
there is negligible p adrenergic stimulation of cyclic AMP production. This 
indicates that cells that are constitutively transformed by p2 1  N-ras have much 
lower cyclic AMP levels than T15 cells and indicates that the inhibition of 
stimulated cyclic AMP levels seen in T15+/24 hour cells and T15+ cells is
associated with p2 1  N-ras overexpression and may affect cell proliferation.
The effects of p2 1  N-ras overexpression on basal and stimulated cyclic 
AMP production as shown in the preceeding figures and Table 1 could have 
been mediated by the inhibitory G protein for adenylate cyclase, Gi. To 
determine if this was the case, T15+ and N 8 6 6  cells were treated with pertussis 
toxin at a concentration of lOOng m H  for 16 hours. This procedure enabled 
maximal ribosylation of G ia  as shown in figure 3.10. Following pertussis 
toxin treatment, control and pertussis toxin treated cells were assayed for cyclic 
AMP content under basal and agonist stimulated conditions as already 
described. If Gj played a role in modulating cyclic AMP levels in these cells, 
then the ribosylation of Gja  and therefore, its inactivation, would result in an 
increase in cyclic AMP levels in the toxin treated cells as compared to control 
cells.
The results in figure 6.4 show that in both T15+ and N 8 6 6  cells 
pertussis toxin treatment did not affect either basal or agonist stimulated cyclic 
AMP levels. This indicates that G{ does not have a role in the inhibition of 
cyclic AMP production in cells that overexpress p21 N-ras ancj these effects 
are due solely to the overexpression of the p2 1  N-ras proto-oncogene.
The data in figure 6.4 indicates that there is no stimulation of adenylate 
cyclase by either p adrenergic agents or forskolin in T15+ cells which are either 
treated or untreated with pertussis toxin. This data is not in agreement with that 
shown in figure 6.3, where there is a small stimulation of adenylate cyclase in T! 5 4 - 
cells by the ligands above. One reason for this variability may be the different cell 
preparations used between the experiments. The T15-f cells used in the experiment 
of figure 6.4 may have been in an advanced state of transformation compared to the 
cells used in previous experiments and consequently respond to p adrenergic agents 
and forskolin in a similar manner to the N 8 6 6  cells.
I : (
Figure 6.3: Basal and agonist stimulated cyclic AMP levels in N 
866 cells.
The data in figure 6.3 shows the basal, isoproterenol, adrenaline and 
forskolin stimulated cyclic AMP levels in N 8 6 6  cells. For comparison, cyclic 
AMP levels in T15- and T15+ cells under the same conditions are indicated. All 
concentrations of IBMX and agonists used are as already described. The data is 
from between 4-6 experiments for T15- and T15+ cells, n=3 within each 
experiment and are means ± S.E.M. but the data from N 8 6 6  cells is from two 
experiments, n=3 in each and are means ± S.D. The data is expressed as pmol 
cyclic AMP/10 min/10^ cells.
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Figure 6.4: The effect of pertussis toxin treatment on basal and 
agonist stimulated cyclic AMP levels in T15+ and N 866 cells.
The figure shows the results from experiments to determine basal and 
agonist stimulated cyclic AMP levels in pertussis toxin treated T15+ and N 8 6 6  
cells. The cells were grown as described in the Methods section and cells were 
treated with 1 0 0  ngm H  pertussis toxin for 16 hours prior to the experiment to 
maximally ribosylate G ia . These cells and untreated, control cells were then 
assayed for cyclic AMP under basal and isoproterenol, adrenaline and forskolin 
stimulated conditions. All incubations were performed in the presence of ImM 
IBMX and all concentrations of agonists used were as in figure 6.1. The results 
are expressed in pmol cyclic AMP/1 Omin/10^ cells and are from one 
experiment, n=3 ( means ±  S.D.) for T15+ cells and are from two pooled 
experiments, n=3 in each ( mean ± S.D.) for N 8 6 6  cells.
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All the results in the previous figures indicate that the overexpression of 
the N-ras proto-oncogene can modify cyclic AMP production in the NIH3T3 
cell line. In order to determine if these effects were confined to cells expressing 
the N-ras proto-oncogene, the cyclic AMP levels in cells expressing the c-sis 
oncogene were determined. The cell line used was the sis 771 cell line. The 
cells were grown as described in the Methods section and basal and agonist 
stimulated cyclic AMP levels determined as in previous experiments.
The results in figure 6.5 show that there was no change in the basal 
level of cyclic AMP in sis 771 cells as compared to T15- cells. The 
isoproterenol stimulated cyclic AMP levels in sis 771 cells were lower than in 
T15- cells but the adrenaline stimulated cyclic AMP levels were the same in 
both cell types suggesting that there was no real difference between both cell 
types in terms of agonist stimulated cyclic AMP levels. However, forskolin 
stimulated cyclic AMP levels in sis 771 cells were approximately 30% lower 
than in T15- cells and may suggest that c-sis expression may modify forskolin 
stimulation of cyclic AMP levels. Therefore, this suggests that c-sis expression 
does not modify the basal nor the p adrenergic agonist stimulation of cyclic 
AMP levels but may alter the forskolin stimulated cyclic AMP response in 
NIH3T3 cells.
182
Figure 6.5: Basal and agonist stimulated cyclic AMP levels in sis 
771 cells.
The figure shows the basal and agonist stimulated levels of cyclic AMP 
in sis 771 cells. For comparison, corresponding values for T15- cells have been 
included. The data was obtained from cells grown as in the Methods section and 
experiments were carried out in the presence of ImM D3MX as already 
described. All concentrations of agonists were used as described in figure 6.1. 
The data is expressed as pmol cyclic AMP/10 min/10^ cells and is from 4-6 
separate experiments, n =3 in each and are expressed as means ± S.E.M.
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The p21 N-ras induced inhibition of agonist stimulated cyclic AMP 
levels in NIH3T3 cells has been shown to be specific for the effects of 
p2 iN-ras 0verexpression ( See figure 6.5) and does not appear to involve Gi 
function (See figure 6.4). Therefore, this inhibition of stimulated cyclic AMP 
production may be due to a change in the (3 adrenergic receptor affinity in T15 
cells upon p21 N-ras overexpression. In order to investigate this possibility, 
T15-, T15+/24 hours and T15+ cells were stimulated with a range of 
isoproterenol concentrations and stimulated cyclic AMP levels measured to 
obtain a dose response curve to isoproterenol in these cell types. Only 
isoproterenol was used and not adrenaline as it has been demonstrated that 
adrenaline only acts as a ligand for (3 receptors in this cell line (See Table 1) and 
therefore, the binding characteristics of adrenaline would be essentially similar 
to isoproterenol.
The data in figures 6 .6 a - 6 .6 c clearly shows that the dose-response 
curves for isoproterenol in T15- (figure 6 .6 a), T15+/24 hour (figure 6 .6 b) and 
T15+ (figure 6 .6 c) cells were similar in shape and differ only the in magnitude 
of the cyclic AMP response. In all three cell types, significant amounts of cyclic 
AMP are generated at 10-5 M and the peak value of cyclic AMP generation 
occurs at 10-4 M isoproterenol. The fold stimulation of cyclic AMP production 
at 10-4 M isoproterenol compared to basal levels is approximately 4.2 in T15- 
cells, approximately 2.6 in T15+/24 hour cells and approximately 1.75 in T15+ 
cells. Basal levels of cyclic AMP for the cells were: T15-: 0.24 ±  0.04,
T15+/24 hour : 0.22 ± 0.03 and T15+ : 0.22 ± 0.02. The units of measurement 
were: pmol cyclic AMP/10 min/105 cells.
The graphs also show that the Ka (concentration of isoproterenol 
required for half maximal stimulation of cyclic AMP levels) for all three cell 
types was the same at approximately 3.2 x 1 0 " 6  M isoproterenol.This suggests 
that the p receptor affiniity for isoproterenol is unchanged upon p2 lN-ras 
overexpression. Therefore, the inhibition of stimulated cyclic AMP production 
in T15+/24 hour, T15+ and N 8 6 6  cells is probably not due to a change in
185
receptor properties.
The results shown in figures 6 .6 a - 6 .6 c suggest that the p21 N-ras 
induced reduction of P adrenergic stimulated cyclic AMP levels was not due to a 
change in receptorefficacyfor P adrenergic ligands. The other mechanism by 
which this p21 N-ras induced inhibition could occur would be the alteration of 
the number of available binding sites for p adrenergic ligands upon p21 N-ras 
overexpression. To investigate this possibility initial attempts were made to 
determine the number of p adrenergic binding sites in T15-, T15+/24 hour and 
T15+ cells by using [125 I] iodocyanopindolol as a ligand for P adrenergic 
receptors (See Methods section). These attempts were unsuccessful as 
Scatchard analysis of the data obtained from these experiments was not possible 
as no displacement of the radiolabelled ligand occured at any concentration of 
unlabelled ligand except at 10“3 M isoproterenol or pindolol. The reasons for 
this are unclear but these experimental results may suggest that these cells 
readily bind and internalise iodocyanopindolol and that displacement of this 
internalised ligand does not occur unless very high concentrations of the 
competing ligand are introduced. Due to these problems, the cells were labelled 
with [125 j] iodocyanopindolol in the presence of 10"4 M isoproterenol to 
obtain an estimate of the amount of [1251] bound under conditions where 
maximal stimulation of cyclic AMP levels occured. Non-specific binding was 
estimated in the presence of 10"3 M pindolol (See Methods Section) and these 
values used to calculate the data shown in Table 2.
The results shown in Table 2 are from 2 experiments performed as 
detailed in the Methods section to determine the amount of [1251] 
iodocyanopindolol bound to T15-, T15+/24 hour and T15+ cells. The results 
shown indicate that there was a reduction in the amount of [125 1] 
iodocyanopindolol bound to p21 N-ras transformed T15 cells. From the data in 
experiment 1, there was an approximately 20% decrease and 89% decrease in 
[1251] iodocyanopindolol binding in T15+/24 hour cells and T15+ cells 
respectively, as compared to T15- cells. The data in experiment 2 indicates that 
an approximately 40% reduction in T15+/24 hour cells and an approximately
F igures 6,6a - 6.6c: Dose response curves for isoproterenol in 
T15-, T15+/24 hour and T15+ cells.
The data shown in figures 6 .6 a - 6 .6 c are from experiments to determine 
the Ka values for isoproterenol stimulated cyclic AMP production in T15-, 
T15+/24 hour and T15+ cells. The experiment was performed on the three cell 
types as already described in the presence of 1 mM IBMX and isoproterenol 
was used at concentrations of and between 10“9 M - 1 0 "3 M. The data shown is 
from one experiment, n= 3 in each and are expressed as means ± S.D. but is 
representative of three separate experiments and indicates pmol cyclic AMP 
generated per 10 minutes per 10^ cells. Figure 6 .6 a : T15- cells; Figure 6 .6 b : 
T15+/24 hour cells; Figure 6 .6 c : T15+ cells.
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95% reduction in T15+ cells occured in [125 i] iodocyanpoindolol binding as 
compared to T15- cells.
This suggests that p21 N-ras transformation results in a reduction in p 
adrenergic stimulated cyclic AMP levels by modifying binding of p adrenergic 
ligands to the cell surface receptors. It is possible that this can occur either by a 
downregulation of receptors on p21 N-ras transformtion or by a modification of 
the recptors which results in reduced ligand binding. However, this mechanism 
seems to be only a partial explanation for the reduction in agonist stimulated and 
basal cyclic AMP levels in NIH3T3 cells transformed with the p21 N-ras proto- 
oncogene.
Table 2: II iodocyanopindolol binding in T15-. T15+/24
hour and T15+ cells as an estimate of p adrenergic ligand binding 
in these cell types.
The data shown in the table are from experiments to determine the 
amount of [1251] iodocyanopindolol bound to T15-, T15+/24 hour and T15+ 
cells. The experiments were carried out as already described and the results are 
expressed as mean fmol [125 j] iodocyanopindolol bound/10^ cells ± S.D., 
n=3 in each experiment Non-specific binding was determined in the presence 
o f 10"3 M pindolol and was estimated to be approximately 10-30% of the total 
binding obtained.
Cell tvoe Experiment 1 Experiment 2
T 15- 4.46 ±0.07 6 .96± 0 .59
T15+/24 hour 3.63 + 0.11 2.93 ± 0.7
T 15+ 0.5 + 0.15 0.2910.01
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The results shown in this chapter are from experiments to determine 
cyclic AMP levels in unbroken T15, N 8 6 6 , NIH3T3 and sis 771 cells. This 
method was used as attempts to directly measure adenylate cyclase activity in 
T15 and NIH3T3 cells were unsuccesful. The reasons for this are unclear 
but as these could not be resolved, an indirect measure of adenylate cyclase 
activity was obtained by quantifying cyclic AMP levels in whole cells in the 
presence of IB MX.
In figure 6 .1, it is shown that the overexpression of p21 N-ras jn 
T15+/24 hour cells results in a reduction of agonist stimulated cyclic AMP 
levels compared to non-transformed cells. However, there was no change in 
the stimulation of cyclic AMP in response to forskolin.Prolonged expression 
of p21 N -ras 'm  T i5 + cells led to a further inhibition of p adrenergic agonist 
stimulated cyclic AMP levels but under these conditions, there was also a 
reduction in forskolin stimulated cyclic AMP levels. These results show that 
p21 N-ras overexpression may result in an inhibition of adenylate cyclase 
activity by either receptor- or post-receptor mediated mechanisms. The use 
of adrenaline as a P adrenergic agonist in T15 cells is valid as the results in 
Table 1 show that adrenaline acts only through P adrenergic recptors and not 
through 0C2  receptors in these cell types. It may be that T15 cells lack a 2  
receptors altogether,or that they are present in such small numbers that a 
significant alteration in cyclic AMP levels as a result of (X2  receptor binding 
by an appropriate ligand may not be detectable using this assay system.
Dexamethasone treatment of T15- cells resulted in reduced 
intracellular cyclic AMP levels as already shewn. This effect is due to the 
expression of p21 N-ras ancj js not due t0  the effects of dexamethasone 
itself. This is supported by the results shown in figure 6.2 which indicate 
that NIH3T3 cells either treated or untreated with 2jiM dexamethasone 
exhibit similar basal and agonist stimulated cyclic AMP levels. The data also 
indicates that the stimulated cyclic AMP levels in NIH3T3 cells are lower
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than in T15- cells. This is an unexpected result as the two cell types are 
essentially similar, both are non-transformed cells and the levels of basal and 
stimulated inositol phosphates in these cell types are the same. However, the 
fold stimulation of cyclic AMP levels differ by approximately 30% although 
the forskolin stimulated cyclic AMP levels were the same in both cell types. 
The data indicates that the differences between the NIH3T3 and T15- agonist 
stimulated cyclic AMP levels may be due to a difference in p adrenergic 
receptor numbers between the two cell types although this possibility 
remains to be investigated.
Having demonstrated that prolonged overexpression of p21 N-ras 
induced by dexamethasone results in a decrease in agonist stimulated cyclic 
AMP levels, the N 8 6 6  cell line was used to investigate the effects of 
constitutive p21 N-ras overexpression upon intracellular cyclic AMP 
levels.The transformed N 8 6 6  cells exhibit an increased reduction in agonist 
stimulated cyclic AMP levels and also show a reduced basal level of cyclic 
AMP compared to chronically transformed T15+ cells (figure 6.3). This 
suggests that the inhibition of cyclic AMP production as a consequence of 
p21 N-ras overexpression is not only linked to p21 N-ras concentration in 
the cell but also to the consequences of continual p2 1  N-ras overexpression, 
for example, continuous cell proliferation.
The experimental results obtained as discussed above are in 
agreement with published studies on the effect of p2 1  N-ras on adenylate 
cyclase signalling system. Tarpley et al_(1986) have shown that p21 Na-ras 
expression in NIH3T3 cells led to reduced hormone stimulated adenylate 
cyclase activity and stimulated intracellular cyclic AMP levels. Furthermore, 
Chiarugi et ai (1985) have demonstrated that transformation of Balb/3T3 
fibroblasts with the EJ/ T24/Ha-ras oncogene causes a reduction in basal, 
PGEi and forskolin stimulated cyclic AMP levels compared to control cells. 
Also, C127 mouse fibroblasts infected with a temperature sensitive mutant 
of Kirsten Sarcoma virus (TS 371) i.e. the Ki-ras oncogene, when assayed 
for adenylate cyclase activity, exhibited reduced adenylate cyclase activity
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compared to wild-type cells (Saltarelli et al, 1985). Therefore, it is clear that 
in some cell lines, the effect of p2 1  £&£_expression is to reduce adenylate 
cyclase activity with a resulting decrease in intracellular cyclic AMP levels.
Although the results discussed in this chapter have implicated the 
N-ras proto-oncogene in the modulation of cyclic AMP levels in mouse 
fibroblasts, there was the possibility that these effects were due to the 
expression of other oncogenes either together with, or as a result of, p2 1  N- 
—  overexpression. To investigate this possibility, the NIH3T3 cell line 
transfected with a p 5M1 c-sis cDNA containing plasmid (sis 771) was used 
and basal and agonist stimulated cyclic AMP levels were measured. The 
results in figure 6.5 show that there is no change in the basal and (3 
adrenergic stimulated cyclic AMP levels compared to T15- cells but there is 
an approximately 30% decrease in the forskolin stimulated cyclic AMP level 
in sis 771 cells. The fact that the basal and p adrenergic agonist stimulated 
cyclic AMP levels are similar in sis 771 and T15- cells suggests that the 
expression of the c-sis proto- oncogene does not modulate adenylate cyclase 
activity directly. Since the basal levels of cyclic AMP are similar in T15, 
NIH3T3 and sis 771 cells, the inhibition of forskolin stimulated cyclic AMP 
levels in sis 771 cells may be due to a modification of adenylate cyclase that 
either inhibits forskolin binding, or inhibits forskolin stimulation of cyclic 
AMP production. The fact that c-sis expression does not affect basal cyclic 
AMP levels suggests that this modulation is specific to the regulation of 
adenylate cyclase activity by agonists that bind directly to this enzyme.The 
results in figure 6.5 suggest that the p21 N-ras in d e ed  inhibition of p 
adrenergic stimulated cyclic AMP levels is not due to c-sis oncogene 
expression and is a specific effect of p21 N-ras expression. However, the 
inhibition of forskolin stimulated cyclic AMP levels in T15+ cells may be a 
consequence of c-sis co-expression with p21 N-ras,, has been shown that 
other oncogenes that may be co-expressed with the ras oncogene do not 
affect cyclic AMP levels, for example, Saltarelli gt al (1985) demonstrated 
that c-mvc transformed NIH3T3 cells do not have altered cyclic AMP levels
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as compared to control cells. Using src-transformed NIH3T3 cells, Tarpley 
et al (1986) demonstrated that stimulated cyclic AMP levels in these cells 
were comparable to wild-type NIH3T3 cells. These results suggest that even 
if oncogenes are co-expressed with p2 1  BIS, 0r expressed as a consequence 
of p2 1  expression (See Introduction chapter) they do not have a direct 
role in modulating cyclic AMP levels in mouse fibroblasts. However, it is 
possible that c-sis proto-oncogene expression in T15+ and N 8 6 6  cells may 
cause the decrease in forskolin stimulated cyclic AMP levels.
The effect of p21 expression on intracellular cyclic AMP levels is 
thought to occur via Gi in some cell types. Franks et al (1987) have 
suggested that p2 1  interacts with Gi to inactivate the inhibitory 
component of the adenylate cyclase enzyme in NRK cells. However, 
Beckner et al (1985) have demonstrated that MDCK cell membranes ADP- 
ribosylated with pertussis toxin exhibited an increase in agonist stimulated 
adenylate cyclase activity in wild-type cells but not in p2 1  Ha-ras 
transformed cells. Therefore, they have suggested that p21 E1S does not act 
as Gi although the cell lines transformed with p21 Ha-ras an(j p2 i Ki-ras 
exhibit reduced adenylate cyclase activity. The results shown in figure 6.4 
demonstrate that in T15+ and N 8 6 6  cells, pertussis toxin treatment does not 
increase the basal or stimulated cyclic AMP levels. Although this experiment 
was only performed on p21 N-ras transformed cells and not on control T15- 
or NIH3T3 cells, the results do suggest that p21 N-ras does not inhibit 
cyclic AMP production in this cell line by interacting with, or acting as, G[. 
The inhibition of cyclic AMP production seen must therefore occur at a 
receptor level or at a post-receptor level which does not involve the 
inhibitory Gi proteins.
To investigate the possibility of whether the inhibition of cyclic AMP 
production in p21 N-ras transformed T15 cells was a consequence of a 
change in receptor affinity for p adrenergic ligands on p2 1  N-ras expression, 
dose-response curves to isoproterenol in T15-, T15+/24 hour and T15+ cells 
were performed and cyclic AMP levels measured. The results shown in
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figure 6 .6  indicate that there is a significant increase in cyclic AMP levels in 
all three cell types only between 10“^  M and 10"3 M isoproterenol. Also, in 
all three cell types the maximal stimulated level of cyclic AMP occurs at 10"^ 
M isoproterenol, therefore giving a Ka value of approximately 3.2 x 1 0 '6  M 
for each cell type. Therefore, from this data it is clear that there is no change 
in the receptor affinity for isoproterenol on p21 N-ras expression. This is 
also probably true for adrenaline and therefore, a change in receptor affinity 
is not the cause of the inhibition of cyclic AMP production in p21 N-ras 
transformed cells.
The inhibition of [3 adrenergic stimulation of cyclic AMP levels in 
p21 N-ras overexpressing T15 cells could be due to a reduction in the 
number of p adrenergic receptor binding sites as a consequence of p21 N-ras 
expression. This possibility is strongly suggested by the data shown in 
Table 2 which indicates that T15+/24 hour and T15+ cells have reduced 
amounts of [1^5 j] iodocyanopindolol bound per 1 0 ^ cells as compared to 
T15- cells. The reduction in the amount of iodocyanopindolol bound to T15 
cells under conditions of maximal cyclic AMP stimulation i.e. in the 
presence of 10~4 M isoproterenol, is associated with increasing lengths of 
time over which p21 N-ras js expressed in these cells.T15+ cells exhibit an 
approximately 90% reduction in [1251] iodocyanopindolol binding 
compared to T15 cells while T15+/24 hour cells show a reduction of 
approximately 2 0 % in [125 j] iodocyanopindolol binding as compared to 
T15- cells. Therefore, the reduction in stimulated cyclic AMP levels seen in 
p 2 1  N-ras overexpressing cells may be due to the downregulation of p 
adrenergic receptors in these cells. Levitzki et al (1986) have demonstrated 
that NIH3T3 cells which express the Ha-ras proto-oncogene and the Ha-ras 
oncogene have a reduced number of iodocyanopindolol binding sites and 
this reduction in the number of p adrenergic receptors is associated with the 
relative tumouregenicity of the transfected Ha-ras oncogenes.
The results discussed so far have suggested that p21 N-ras 
overexpression causes a decrease in the number of p adrenergic receptors in
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T15+/24 hour and T15+ cells leading to decreased stimulated cyclic AMP 
production. This modification of the cyclic AMP signalling pathway at the 
receptor level cannot, however, explain the inhibition of forskolin stimulated 
cyclic AMP levels in T15+ cells and the inhibition of both basal and agonist 
stimulated cyclic AMP levels in N 8 6 6  cells. As forskolin acts as a ligand 
for the catalytic subunit of the adenylate cyclase enzyme (Gilman, 1984) the 
stimulation of cyclic AMP production by forskolin is a post-receptor event. 
If forskolin stimulation of cyclic AMP production is reduced, then this result 
suggests that this modification of the adenylate cyclase signalling pathway 
by p21 N-ras js at the enzyme level as p21 N-ras has been shown not to 
interact with or act as Gf ( Refer to figure 6.4). Therefore, it is possible that 
the expression of p21 N-ras jn NIH3T3 cells can modify the interaction 
between adenylate cyclase and forskolin resulting in inhibition of the 
forskolin stimulated cyclic AMP levels in these cells. However, the fact that 
the basal production of cyclic AMP is unchanged while forskolin stimulated 
cyclic AMP levels are reduced in T15+ cells, although both the basal and 
forskolin stimulated cyclic AMP levels are reduced in N 8 6 6  cells suggests 
that p21 N-ras expression may have a limited effect on the adenylate cyclase 
enzyme. p21 N-ras overexpression may result in the modification of 
adenylate cyclase only to the extent that forskolin stimulated adenylate 
cyclase activity is inhibited while the basal rate of adenylate cyclase activity 
is unchanged. Only when there is prolonged and constitutive expression of 
p21 N-ras doeS this modification of the adenylate cyclase enzyme affect 
basal levels of cyclic AMP production. This effect of p21 N-ras expression 
may be due to secondary effects of p21 N-ras anc] to the possible co­
expression of the c-sis proto-oncogene and is probably a cell proliferation 
related event. There is no plausible mechanism(s) for this effect of p21 N-ras 
on adenylate cyclase as yet.
Therefore, the results in this chapter have shown that progressive 
p21 N-ras overexpression can lead to an inhibition of P adrenergic agonist 
and forskolion stimulation of cyclic AMP production. Furthermore,
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constitutive expression of p21 N-ras leads to an inhibition of basal cyclic 
AMP production and almost complete inhibition of stimulated cyclic AMP 
production. These effects seem specific to the expression of p21 N-ras anc[ 
are not a consequence of non-specific effects of dexamethasone on T15 
cells. Also, it is probable that the ras oncogene specifically exerts these 
effects on the cyclic AMP signalling pathway via several mechanisms 
although some of these effects are possibly mediated through c-sis co­
expression. Firstly, it is possible that p21 N-ras overexpression results in a 
downregulation or a modifiction of P adrenergic receptors such that there is 
an inhibition of agonist stimulated cyclic AMP levels. This occurs without a 
change in the receptor affinity for (3 adrenergic ligands but may be due to the 
transformation effects of p21 N-ras^ Secondly, prolonged overexpression of 
p21 N-ras ^  the T15+ cell line and the constitutive overexpression of p21 
N-ras ^  jq 8 6 6  cells seems to modify the adenylate cyclase enzyme such that 
forskolin stimulated cyclic AMP levels and basal cyclic AMP levels are 
reduced. This modification does not appear to involve the stimulatory or 
inhibitory G proteins for the adenylate cyclase system from our data and the 
data of other workers.
Downregulation of p  adrenergic receptors or the modification of 
ligand binding to these receptors may be a consequence of receptor 
phoshorylation. Bouvier et al (1987) have shown that p adrenergic receptors 
are substrates for both protein kinase C and cyclic AMP dependent protein 
kinase. Therefore, one of the consequences of p21 N^as overexpression 
may be the activation of protein kinase C which results in phosphorylation of 
the p  adrenergic receptors in T15+ and N 8 6 6  cells. As the basal levels of 
cyclic AMP are similar in T15-, T15+/24 hour and T15+ cells, it is unlikely 
that phosphorylation of P adrenergic receptors occurs as a consequence of 
cyclic AMP dependent protein kinase A activation upon p21 N-ras 
overexpression. Therefore, the inhibition of p  adrenergic stimulated cyclic 
AMP levels in T15+/24 hour, T15+ and N 8 6 6  cells may be due to the 
phosphorylation and possible downregulation of p  adrenergic receptors as a
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result of protein kinase C activation.
The effects of prolonged p21 N-ras overexpression on forskolin 
stimulated cyclic AMP levels may be due to either phosphorylation of the 
adenylate cyclase enzyme itself or the inhibition of forskolin binding to the 
catalytic subunit of adenylate cyclase. However, Yoshimasa ef al (1987) 
have demonstrated that protein kinase C catalysed phosphorylation of 
adenylate cyclase results in a potentiation of isoproterenol, GTP and sodium 
fluoride stimulation of adenylate cyclase purified from frog erythrocytes. 
Unless different cell or tissue specific forms of adenylate cyclase exist, the 
phosphorylation of adenylate cyclase in T15+ and N 8 6 6  cells is therefore 
unlikely. Thus, the inhibition of forskolin stimulated cyclic AMP levels in 
T15+ and N 8 6 6  cells may be due to a yet unknown modification of 
adenylate cyclase resulting in an inhibition of forskolin binding or may be 
due to a decrease in adenylate cyclase synthesis at the transcriptional level. 
Although these effects are detected in T15+ and N 8 6 6  cells, the inhibition of 
forskolin stimulated cyclic AMP levels also occurs in sis 771 cells although 
to a lesser extent. Therefore, in T15+ and N 8 6 6  cells, these effects may in 
part be due to the co-expression of the c-sis oncogene. The implications and 
consequences of these modifications of the cyclic AMP signalling pathway 
as a result of p21 N-ras induced transformation of NIH3T3 cells will be 
discussed in the following final chapter.
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Chapter 7: General Discussion
The results described in this thesis are from experiments to investigate 
the role of of p21 N-ras jn t^e proliferation and transformtion of NIH3T3 
cells. The results in chapter 3 indicate clearly that p21 N-ras overexpression in 
T15 cells is associated with increased cell proliferation and transformation. 
This effect of p21 expression has been shown to be associated with almost 
all cell types investigated (Barbacid, 1987). Interestingly, this result of p21 
expression only occurs when there are very high levels of normal, cellular 
p21 ££§ expressed. For example, in T15+ cells , the cellular concentration of 
p21 N-ras js approximately 50 times that of normal NIH3T3 cells. To achieve 
similar effects with p2 1  v"fas or a mutant cellular ms oncogene, a lower 
concentration of the gene product is required than the normal proto-oncogene 
(See McKay et d , 1986 ; Trahey and McCormick, 1987). Also, mutant ras 
proteins microinjected into fibroblasts cause cellular changes which persist for 
a much longer length of time than those induced by normal ras proteins (Bar- 
Sagi and Feramisco, 1986). In addition, mutant Ha-ras when microinjected 
into quiscent cells causes very rapid effects whereas normal cellular Ha-ras is 
without effect when injected at the same concentration (Feramisco et al, 1984).
Modulation of p21 f^  transforming ability bv GAP associated GTPase 
activity.
Cell proliferation and transformation associated with the expression of 
p2 1  Bis is associated with the guanine nucleotide binding properties of the ras 
protein, determined by the association of p21 with the GAP protein. 
Mutant ras protein GTPase activities are not regulated by GAP (See 
Introduction) resulting in a p21 molecule which is permanantly in a GTP 
bound and thus biologically active state.
However, if mutant p21 !£§ proteins have a reduced ability to bind 
GTP, there is a loss of transforming ability in most cases (Clanton et al,
1987). Furthermore, the construction of a mutant Ha-ras oncogene with an
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asparagine residue substituted for serine at position 17 results in p21 Ha-ras 
with a preferential affinity for GDP. Expression of this oncogene in NIH3T3 
cells results in an inhibition of cell proliferation which can be reversed by the 
coexpression of an activated ras oncogene (Feig and Cooper, 1988). 
Therefore, these observations suggest that the biological function of p21£25 
relies on the relative binding of GDP/GTP as a consequence of GAP 
association. Furthermore, the relative amount of GTP or GDP bound will 
determine the transforming capacity of these ras oncogenes. It appears that 
normal p21 fits proteins exist in a preferentially GDP bound state whilst 
transforming mutant ras proteins are in a GTP bound state (Trahey and 
McCormick, 1987). This this may partly explain why a lower concentration 
of mutant p2 1  £25 is required for the stimulation of cell proliferation and 
transformtion than normal p21125 i.e. the relative amount of GDP/GTP 
bound will be one of the factors that determine the transforming potential of 
any one p21 £2 S protein. Therefore, GTP binding can thus be considered to 
be the 'limiting factor' and may affect the concentration of different ras 
proteins required for transformtion.
This data strengthens the possibility that p21 £25 can act as a G protein 
in signal transduction pathways which results in cell proliferation and 
transformtion. The identity(ies) of these pathway(s) is a contentious issue. 
However, The RAS proteins in yeast have been shown to stimulate adenylate 
cyclase activity (Broek et al, 1985) and there has been a report that RAS 
encoded proteins are invoved in glucose-stimulated inositol phospholipid 
turnover in S. Cerevisiae (Kaibuchi si, 1986). In yeast therefore, the RAS 
proteins seem to be involved in the stimulation of 2  major second messenger 
pathways.
p21 N-ras involvement in the inositol phospholipid signal transduction 
system.
The results presented in this thesis have suggested that p21 N-ras can 
act at a post-receptor level to enhance growth factor stimulated inositol
199
phospholipid turnover. In chapter 3, it was demonstrated that p2 1  N-ras 
overexpression resulted in increased bombesin stimulated total inositol 
phosphate production in T15+ cells. Furthermore, the results in chapter 4 
demonstrated that this increase was due to the enhanced production of Ins 
1,4,5 P3  and its dephosphorylated derivatives as a result of phosphoinositide- 
specific phospholipase C activation (Lloyd et al, submitted for publication). 
The other second messenger produced as a consequence of phospholipase C 
activation is DAG, which induces the activation of protein kinase C. This 
effect is due specifically to the expression of p21 N-ras can ^  correlated 
with the amount of cellular p21 N-ras (Wakelam et al, 1987). Although these 
results clearly demonstrate that transformation of NIH3T3 cells by p21 N-ras 
may be due in part to enhancement of agonist stimulated phosphoinositide 
specific phospholipase C and the generation of Ins 1,4,5 P3  with an 
associated increase in intracellular C a2+. However, the proposed role of p21 
N-ras as a coupling protein between growth factor receptors at the cell surface 
and phosphoinositide specific phospholipase C must be questioned.
Firstly, although bombesin and GRP stimulated the largest increase in 
inositol phosphate production in T15+ cells, p21 N-ras overexpression also 
resulted in increased bradykinin and calf serum induced inositol phosphate 
production. It has been demonstrated that Ha- and Ki-ras transformation of 
NIH3T3 cells results in an increased number of bradykinin receptors (Parries 
et al, 1987). Also, a recent study of Ha-, Ki- and N-ras transformation of 
NIH3T3 cells has demonstrated that enhanced bradykinin stimulated inositol 
phosphate production in these transformed cells is associated with an 
increased number of bradykinin receptors (Downward et al, 1988). It is 
possible that an increase in the number of bradykinin receptors also occurs in 
T15+ cells but this hypotheses has yet to be tested. If the amplification of 
bradykinin and calf serum stimulated inositol phosphate production in T15+ 
cells is not due to an increase in receptor number, then the role of p21 N-ras 
as a specific coupling protein between the bombesin receptor and the 
phosphoinositide specific phospholipase C remains in doubt.
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Secondly, in chapter 3, it was clearly shown that detectable bombesin 
stimulated inositol phosphate production occured at 6  hours after 
dexamethasone treatment. In addition, the time course of dexamethasone 
induced enhanced bombesin stimulated inositol phosphate production was 
closely correlated to the time course of dexamethasone induced p21 N-ras 
expression quantitated by immunoprecipitation of p21 N-ras with an anti-ras 
antibody ( Marshall, C. unpublished observation). Although the 
immunoprecipitation of p21 N-ras was performed on whole cell lysates from 
T15+ cells, the p21 N-ras protein detected was the acylated form. It has been 
shown that p2 1  needs to be inserted into the membrane to have any 
biological function. However, McKay et a! (1986) have shown that it takes 
twenty hours after dexamethasone treatment of T15- cells for p21 N-ras t0  be 
inserted into the membrane. If this figure is accurate, then the increase in 
bombesin stimulated inositol phosphate production seen after 6  hours of 
dexamethasone treatment cannot be due to the action of membrane bound 
p21 N-ras # Thjs suggests firstly, that there is an obvious discrepancy 
between the two sets of results described and secondly, that p21 N-ras may 
exert these effects on the phosphoinositide signalling pathway from the 
cytoplasm. However, Lacal et al (1987a) microinjected non-acylated p21 
protein into Xenopus oocytes, resulting in a very rapid increase in DAG levels 
and in the generation of inositol phosphates. This suggests that either p21 ^  
can be acylated and inserted into the membrane very rapidly, or can cause 
these effects from within the cytoplasm. If the latter were the case, then this 
is inconsistent with the hypotheses that p2 1  ras can function as a conventional 
G protein in signal transduction.
The involvement of other oncogenes in stimulated inositol phosphate 
turnover cannot be ignored. Lacal et al (1987b) have shown that v-sis 
transformed NIH3T3 cells exhibit elevated basal levels of inositol phosphates 
as has been demonstrated in pLHT-511 cells which overexpress p21 N-ras 
(Wakelam et al, 1987; Hancock et al, 1988). Owen and Owstroski (1987)
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have shown that dexanethasone induction of Ha-ras transfected into NIH3T3 
cells also induces c-sis expression. This implies that coexpression of other 
oncogenes with the ras proto-oncogene is a possibility in our cell system and 
may be modulating the bombesin response. However, overnight treatment of 
T15+ cells with suramin does not affect the bombesin stimulated inositol 
phosphate response (Wakelam, M.J.O., unpublished observation).
Therefore, this suggests that PDGF-like molecules may not have a role in 
bombesin stimulated inositol phosphate production in the T15 cell line.
Smith et al (1986) have demonstrated that growth factor-like 
oncogenes require c-ras expression in NIH3T3 cells whereas cytoplasmic 
oncogenes do not, in order to transform cells. This suggests that there is a 
role for p2 1 in growth factor stimulated cell proliferation and 
transformation in rodent cells but having discussed the results above, this role 
may not be as direct as previously thought. It is probable that the ras 
oncogene plays a crucial role in mediating cell proliferation and transformation 
in conjunction with other coexpressed oncogenes and that this effect of ras 
oncogene expression is an early and necessary step in this process.
The role of the ras oncogene family in the amplification of the 
phosphoinositide signalling pathway has been investigated by other workers. 
Fleischman et al (1986) have shown that transformation of NIH3T3 and NRK 
cells with N-, Ha- and Ki-ras genes results in elevated basal levels of inositol 
phosphates and DAG compared to non-transformed cells. Hancock et al 
(1988) have demonstrated that mutant Ha- and N-ras transformed NIH3T3 
and COS-1 cells exhibit an enhanced basal rate of inositol phospholipid 
turnover. By site directed mutagenesis of these ras genes, these workers have 
shown that there is a correlation between increased basal rates of inositol 
phospholipid turnover and transforming ability of the ras genes. Also, it has 
been shown that microinjection of p21 Ha-ras jn t0  Xenopus oocytes results 
in a stimulation of inositol phosphates and DAG production (Lacal et al, 
1987a). Chiarugi et al (1986) demonstrated that transfection of EJ/T24/ Ha­
ras oncogene into Balb c/3T3 cells caused an amplification of muscarinic
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stimulation of phosphoinositide hydrolysis and an increase in intracellular 
Ca^+ levels in NIH3T3 cells. Kamata and Kung (1988) have shown that 
normal Ha-ras transformation of NRK cells causes an increase in both GTPyS 
and PDGF stimulated inositol trisphosphate production in membranes 
prepared from these cells as compared to normal NRK cell membranes. 
However, this effect of p 2 1 e x p r e s s i o n  may be confined to certain 
fibroblast cell lines and Xenopus oocytes as other workers have presented 
evidence contrary to the reports described above.
Seuwen et al (1988a) have demonstrated that mutant Ha- and Ki-ras 
transformed CCL39 cells do not exhibit increased phospholipase C activity 
but rather, have reduced levels of stimulated inositol phosphates compared to 
non-transformed cells. However, this desensitisation is apparently at the 
receptor level and was also observed in polyoma virus transformed CCL39 
cells i.e. these effects were not specific to the ras oncogenes. Rat-1 
fibroblasts transformed with the Ha- and Ki-ras oncogenes exhibited a 
decrease in PDGF stimulated inositol phosphate production compared to non­
transformed cells with no effect on receptor number (Parries et al, 1987). 
Benjamin et al (1988) have also demonstrated that EJ-ras oncogene 
transformed NIH3T3 cells have decreased PDGF stimulated Ins 1,4,5 P3  and 
Ca2+ levels compared to control cells. Finally, Alonso et al (1988) have 
shown that Ha- and Ki- ras transformtion of rat-1 and NIH3T3 cells results in 
uncoupling of receptor-mediated growth factor stimulation of 
phosphoinositide specific phospholipase C activity. These workers suggest 
that these alterations in cellular signalling are not confined to ras transformed 
cells but occur in src, met, trk. mos and raf transformed cells. However, the 
use of lithium chloride to measure the inositol phosphate content in these 
transformed cells remained unclear. Also, comparisons between different 
inositol phosphate levels in the different cell lines were based on inositol 
monophosphate only and may not be an accurate reflection of inositol 
phosphate levels in these cell lines.
Inhibition of PGF2a stimulated inositol phosphate production has
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been observed in ras transformed cells when compared to control NIH3T3 
cells. This may be due to receptor phosphorylation as a consequence of p21 
expression in these cell types (Black, F.and Wakelam, M J.O., submitted 
for publication). The inhibition of PDGF stimulated inositol phosphate 
production described above could also be a consequence of PDGF receptor 
phosphorylation in ra$ transformed cells as a consequence of DAG 
production and subsequent protein kinase C activity. However, it has been 
demonstrated that PDGF binding with subsequent stimulation of the PDGF 
receptor tyrosine kinase and stimulated phosphatidylinositol hydrolysis are 
not sufficient for mitogenesis to occur (Escobedo and Williams, 1988). 
Benjamin et al (1988) have shown that ras transformed cells which have 
decreased PDGF stimulated inositol phosphate levels still respond 
mitogenically to PDGF. This could imply that the stimulation of inositol 
phosphate production is an initial signal in the mitogenic cascade and it is 
possible that this response is downregulated in rapidly proliferating cells once 
this cascade is activated. This may explain why the inhibition of PDGF 
stimulated inositol phosphate production occurs in the constitutive ras 
transformed cell types cited in the referances above.
There is a growing body of evidence that ras transformation results in 
elevated basal and/or stimulated levels of DAG which would suggest that ras 
transformation results in the activation of protein kinase C. Hagag et al
(1987) have demonstrated a rise in intracellular pH when p 2 1 i s  
microinjected into NIH3T3 cells. This is due to the activation of the Na+/H+ 
antiporter by protein kinase C and is an indication that p2 1  expression 
results in increased protein kinase C activity. Furthermore, Ha-ras 
transformed NIH3T3 cells have been shown to exhibit elevated levels of DAG 
but this occurs without a corresponding increase in inositol phosphates (Lacal 
et al, 1987b). This suggests that other phospholipids are hydrolysed to 
generate diacylglycerol. It is possible that this process takes place in ras 
transformed cells i.e.the initial production of inositol phosphates in response 
to growth factors is downregulated and the breakdown of another
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phospholipid is activated. This would result in persistent high levels of DAG 
with associated increased protein kinase C activity which precedes the onset 
of cell proliferation.
Therefore, the effects of the ras oncogene on the inositol phospholipid 
signal transduction system vary depending on the cell type and the particular 
ras (proto)-oncogene employed. It has been demonstrated, for example, that 
different clones of NIH3T3 cells respond differently to the same growth 
factors (Black, F. and Wakelam, M.J.O., manuscript in preparation) and this 
could be a reflection of the relative 'age' of the particular clone used or the 
relative spontaneous transformed state of the cells. Furthermore, murine 
fibroblasts spontaneously transform in culture at a high frequency. This 
spontaneous transformation is often associated with amplification of cellular 
genes. For example, the met oncogene is amplified 4-8 fold and 
overexpressed 20 fold in spontaneously transformed NIH3T3 cells (Cooper et 
al, 1986). Therefore, this is a possible occurance in and an additional 
difference between apparently similar cell lines utilised in studies to determine 
the effects of p2 1  I&S transformation on cellular signalling.
The varying effects of the ras oncogene on signal transduction in 
different cell types may be due to the different ras proteins which may couple 
to different growth factor receptors, different species of Gp and of 
phospholipase C activated by p21 and the fact that there are cellular 
sources of DAG other than inositol phospholipid breakdown. Differing 
species of Gp and/or phospholipase C in different cell types is suggested by 
the different pertussis toxin sensitivities of the growth factor stimulated 
inositol phosphate response. The data presented in this thesis clearly shows 
that pertussis toxin had no effect on inositol phosphate production in T15 
cells. Similarly, in GH3  cells, pancreatic acinar cells, liver cells and 
adipocytes, the inositol phosphate response is not pertussis toxin sensitive. 
However, in other cell types, for example CCL39 fibroblasts, mast cells and 
neutrophils, stimulated inositol phosphate production is inhibited by pertussi 
toxin (Cockcroft, 1987). If pertussis toxin sensitivity is used as a criterion
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for Gp activity, then there must be at least two different Gp species and 
possibly two separate phospholipase Cs in different cell lines which have 
distinct pertussis toxin sensitivities. The use of pertussis toxin in experiments 
to determine p2 1  l^s function will only determine if p2 1  ESS can act as or 
interact with, Gi, to mediate its effects. The data in this thesis suggests that 
p2 1  N-ras cannot act as Gi but the possibility remains that p21 N-ras can 
interact with or act as Gp in NIH3T3 fibroblasts. In addition, bombesin has 
been shown to couple to a pertussis toxin insensitive G protein in four 
different cell types including Swiss 3T3 fibroblasts and GH4 C 1 pituitary cells 
(Fischer and Schonbrun, 1988).
Therefore, the role of p21 N-ras jn amplified mitogen stimulated 
inositol phosphate production in T15+ cells is at present not clearly defined. It 
is certain that p21 N-ras acts at a post-receptor level and that the modulation of 
this second messenger pathway in this cell line does not involve Gi. Also, it 
has been demonstrated that dexamethasone induction of p21 N-ras expression 
in T15 cells does not result in changes in the levels of Gi, G0  or Gs ( Milligan 
et al, manuscript in preparation). This indicates that bombesin stimulated 
inositol phosphate production is not mediated through these G proteins in this 
cell line.lt has been demonstrated that a non-hydrolysable analogue o f GTP, 
GTPyS, can stimulate inositol phosphate production in a broken T15+ cell 
preparation. The bombesin stimulated inositol phosphate production in this 
cell-free system was partly abolished with an anti-ras antibody (Wakelam, 
unpublished observation). However, these experimental results are difficult to 
reproduce and therefore remain inconclusive. Alternatively, experiments 
using a temperature sensitive mutant of p21 N-ras transfected into NEH3T3 
cells could be used to provide more conclusive data to investigate if 
p2 1  N-ras does act as a g  protein in phosphoinositide signal transduction. 
Such an experimental system would reduce the possibility of the involvement 
of co-expressed oncogenes or oncogenes expressed as a consequence of p2 1  
N-ras expression in signal transduction pathways as de novo synthesis of 
p21 E£S does not occur (Durkin, J.P., personal communication). Finally, a
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conclusive experimental approach would be the reconstitution of the bombesin 
receptor, phosphoinositide specific phospholipase C, Ptd Ins 4,5 P2  and p21 
N-ras ^  ^  artificial membrane preparation . The question would be : will 
bombesin stimulated inositol 1,4,5 trisphosphate production occur in this 
reconstituted cell system in the presence of membrane bound p21 N-ras ?
The effects of p21 N-ras overexpression on the cyclic AMP signal 
transduction pathway.
In addition to its effects on the inositol phospholipid signalling 
pathway, p21 N-ras overexpression in T15 cells results in an associated 
decrease in cyclic AMP levels. As discussed in chapter 6 , these results are 
consistent with the data of other workers using different transfected ras 
oncogenes to investigate the effects of ras transformtion on adenylate cyclase 
activity and cyclic AMP levels in the cell. However, there are a few 
exceptions to the general 'rule' that p2 1 expression results in a decrease in 
intracellular cyclic AMP levels. Franks et al (1987) have demonstrated that a 
temperature sensitive oncogenic viral Ki-ras in NRK cells causes an increase 
in cyclic AMP levels in response to cholera toxin treatment. The authors have 
suggested that this effect is due to the inactivation of the Gi component of the 
adenylate cyclase system, possibly by the action of stimulated protein kinase 
C on Gi. Also, it has been demonstrated that v-Ha-ras and v-Ki-ras infected 
rat thyroid epithelial cells exhibit increased adenylate cyclase activity and an 
associated increase in intracellular cyclic AMP content (Spina et al, 1987). It 
was suggested that the activity of the adenylate cyclase enzyme or Gs itself 
could be modified by the presence of p2 1  ISS in the membrane.
It is possible that increased protein kinase C activity as a consequence 
of p21 ££§ expression results in an increase in adenylate cyclase activity. It has 
been demonstrated that the a  subunit of certain G proteins can be 
phosphorylated by protein kinase C, for example, transducin (Zick et al,1986) 
and Gj (Katada et al, 1985). Also, the phosphorylation of adenylate cyclase 
by protein kinase C results in an increase in agonist stimulated activity
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(Yoshimasa et al, 1987). However, this does not explain why there is an 
increase in cyclic AMP levels in some cell lines that express viral Ha- and Ki­
ras but a decrease in other cell types studied transfected with different ras 
oncogenes (See Discussion chapter 6 ). These differences could be a result of 
cell type variation.
It is possible, however, that in all these cell lines transfected with ras 
oncogenes, protein kinase C phosphorylation of in vivo substrates as a 
consequence of p2 1  ESS expression affects intracellular cyclic AMP levels. It 
has been shown that protein kinase C can phosphorylate (3 adrenergic 
receptors in vitro (Sibley et al, 1987). Such a modification of P adrenergic 
receptors by protein kinase C in T15+ cells may result in an inhibition of 
ligand binding and therefore of reduced stimulated cyclic AMP levels. 
Alternatively, protein kinase C catalysed phosphorylation may lead to an 
increase in receptor internalisation and thus a down-regulation of cell surface 
receptor number. Thus, the effect of p21 N-ras overexpression on the 
adenylate cyclase system may be via the activation of protein kinase C by 
DAG and is therefore an indirect effect of ras expression and is a 
transformation-associated phenomenon.
Production of cyclic AMP in ras transformed cells may be further • 
downregulated by modification of either the amount of adenylate cyclase 
synthesised in the cells, or of the catalytic subunit of adenylate cyclase by 
unknown mechanisms. This may explain the inhibition of forskolin stimulated 
cyclic AMP production in T15+ and N 8 6 6  cells (see chapter 6 ). However, 
this effect may be mediated by the sis-oncogene as a similar observation was 
made in sis-771 cells. It should be noted that c-sis expression may lead to an 
increase in protein kinase C activity as PDGF has been shown to stimulate the 
activity of this kinase in some cell types (Benidge, 1987a). The data suggests 
therefore, that the c-sis oncogene may play a cooperative role in the process of 
p21 N-ras transformation resulting in an inhibition of cyclic AMP production 
via several mechanisms.
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What are the main effects of decreased intracellular levels of cyclic 
AMP upon ras induced transformation? Smets and Van Rooy (1987) have 
shown that high intracellular cyclic AMP levels are associated with cells in the 
Go-Gi transition but inhibit cell progression through the G i-G s phase. 
Therefore, this suggests that proliferating cells do not require high cyclic 
AMP levels and that perhaps these increased levels of cyclic AMP will inhibit 
cell growth. Indeed, Katsaros et al (1987) have demonstrated that site- 
selective cyclic AMP analogues which bind to type 1 or type 2 cyclic AMP 
dependent protein kinases inhibit the proliferation of human cancer cell lines, 
including a ras expressing cell line. Inhibition of cell growth was associated 
with a change in cell morphology, a decrease in p2 1  ^  levels and an increase 
in the type 2 cyclic AMP dependent protein kinase. Furthermore, Tagliaferri 
et al (1988) have shown that growth inhibition and a reversal of 
transformation of v-Ha-ras transformed NIH3T3 cells occured as a 
consequence of the addition of cyclic AMP analogues to the growth medium 
of these cells. Results from this laboratory have shown that the addition of 
ImM dibutyryl cyclic AMP to the growth medium of p21 N-ras transformed 
T15 cells inhibits the growth of these cells (Davies et al, in preparation).This 
suggests that the concentration of cyclic AMP in the cell is an important factor 
in the process of cell proliferation and transformation. It is probable that one 
effect o fp 2 im s  expression is to decrease adenylate cyclase activity by 
reducing growth factor stimulation of this signalling pathway, via protein 
kinase C phosphorylation of the receptor and also by a further modification of 
the adenylate cyclase system at a post-recptor level.
Conclusions and future prospects.
It appears therefore, that the modulation of two major signal 
transduction systems is necessary for cell proliferation to occur as a 
consequence of p21 expression. As protein kinase C is dependent upon 
DAG and Ca2+ for its activation, it is possible that an early effect o f p2 1
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transformation is to increase levels of DAG. Protein kinase C mediated 
phosphorylation of the Na+/H+ antiporter and of various components of the 
adenylate cyclase system results in the entry of cells into the S phase and cell 
proliferation occurs. p2 1  could initially cause the amplified breakdown of 
Ptdlns 4,5 P2  to release DAG and Ins 1,4,5 P3 thus raising the intracellular 
concentration of Ca^+. However, since protein kinase C desensitisation of 
Ptdlns 4,5 P2  breakdown has been observed in many cell types (Berridge, 
1987b), this initial event may be downregulated. DAG production could be 
maintained at levels sufficient for cell proliferation to occur by hydrolysis of 
other phospholipids, for example, from phosphatidylcholine, the increased 
turnover of which has been observed in some ras transformed cells (Lacal et 
al, 1987b). This may explain why in some constitutive ras expressing cell 
types, there is no detectable increase in Ins 1,4,5 P3  as a consequence of 
growth factor stimulation. For example, the N 8 6 6  cell line exhibits very low 
levels of cyclic AMP compared to T15+ cells (Chapter 6 ) but there is no . 
detectable bombesin stimulated inositol phosphate production (Lloyd et al, 
submitted for publication). It may be that for yet unknown reasons, the 
downregulation of inositol phosphate production that occurs in other ras 
transformed cell lines does not occur in the T15 cell line.
The stimulation of DAG production and the inhibition of cyclic AMP 
production seems to be an important permissive event for cell growth and 
subsequent cell transformtion. Seuwen et al (1988b) have shown that 
serotonin stimulates DNA synthesis in CCL39 fibroblasts by activating 
phospholipase C and inhibiting adenylate cyclase. These events are pertussis 
toxin sensitive and the authors have suggested that Gi is involved in this 
process. Furthermore, Chiarugi et al (1985) have shown that Balbc/3T3 
fibroblasts transformed with transfected EJ/T24 ra§ oncogene have lower 
stimulated cyclic AMP levels compared to control cells but exhibit increased 
muscarinic induced inositol phosphate production. Similarly, data presented 
in this thesis also show that p21 transformation of T15 cells resulted in 
increased growth factor stimulated inositol phosphate production and an
2 1 0
associated decrease in cyclic AMP levels. This dual effect of p21 US on both 
the major signal transduction pathways suggests that p2 1  ESS does act to 
modulate second messenger production in its capacity as a membrane bound 
oncogene, but the precise mechanisms are still undefined.
In any type of experiment that utilises a cell line which expresses a 
particular oncogene in an inducible or constitutive manner, the expression of ' 
other, possibly cooperative, oncogenes cannot be ruled out. As cancer 
development does occur as a muti-stage process, it is probable that the 
expression of a particular oncogene will have a ’knock-on’ or relay effect on 
other oncogenes in different cellular locations. Whilst the process of 
transformation can be ascribed to the expression of a particular oncogene, the 
biochemical events invoved are a combination of different second messenger 
pathways and of different (proto)-oncogene actions. It is possible to inhibit 
cancer cell growth by the administration of antagonists to various growth 
factor receptors (Heldin et al, 1987). However, it is clear that this approach is 
not always successful. It may be that once an initial growth signal is 
transmitted from the cell surface, the presence of activated (proto)-oncogenes 
is sufficient to enable the cell to proliferate and become transformed under 
appropriate conditions. Thus, the inhibition of growth factor binding may not 
always be an effective anti-proliferative factor. Therefore, until there are 
experimental systems to assess the role of a particular oncogene on various 
biochemical pathways without the possible ’interference’ of other (proto)- 
oncogenes, investigations into the bichemical role of (proto)-oncogenes in 
normal cell growth and in transformed cells will be inconclusive. This 
especially applies to investigations into ras (proto)-oncogene function as this 
gene product plays an important role in maintaining cell growth under normal 
conditions and, under different circumstances, can cause malignant tumour 
growth. A diagrammatic summary of possible events associated with 
p21 N-ras overexpression in T15+ cells is shown overleaf.
In conclusion, the role of the ras oncogene in cell proliferation and 
transformation is still undefined although there is growing evidence to suggest
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Diagrammatic summary of possible intracellular events on p21 N-ras overexpression.
The diagram on page 211 illustrates the intracellular events that may occur on p21 N-ras 
overexpression in T15 cells.lt has been shown that p21 N-ras overexpression in the T15 cell 
line directly results in an amplification of receptor mediated Ins 1,4,5 P3  production which then 
acts as a second messenger to release intracellular stores of Ca^+. It remains a possibility that 
p2 1  Nzias may interact with or act as Gp this cell line (See Discussion). One consequence of 
increased intracellular Ca^+ as a result of receptor mediated Ins 1,4,5 P3 production will be 
increased nuclear oncogene expression, for example, c-mvc and c-fos, which are involved in 
the initiation of S phase.
Another consequence of increased receptor mediated Ptdlns 4,5 P2  hydrolysis in 
T15+ cells is the increased production of DAG. Increased levels of DAG in the cell will result in 
activation of PK C. The activation of PK C can result in increased nuclear oncogene expression 
resulting in the onset of DNA synthesis. Also, PK C induced phosphorylation of intracellular 
substrates include the phosphorylation of the Na+/H+ antiporter resulting in intracellular 
alkalinisation (See Introduction). An increase in intracellular pH as a result of mitogenic 
stimulation of T15+ cells will result in the initiation of DNA synthesis, which can only occur at 
this permissive intracellular pH. The production of DAG in mitogen stimulated T15+ cells may 
also be a consequence of phospholipase C or phospholipase D catalysed hydrolysis of other 
phospholipids distinct from Ptdlns 4,5 P2 . Phosphatidylcholine or phosphatidylethanolamine 
may be the substrates for phospholipase C or D action in T15+ cells as a result o f mitogen 
stimulation.
Finally, it has been demonstratedthat p21 N-ras overexpression in the T15 cell line 
results in a decrease in intracellular cyclic AMP levels as a consequence of p adrenergic receptor 
downregulation and a possible direct inhibition of adenylate cyclase enzyme activity, p 
adrenergic receptor downregulation may occur as a result of PK C phosphorylation, thus 
reducing intracellular cyclic AMP levels. It has been shown in ras transformed cells that reduced 
intracellular cyclic AMP levels are associated with the entry of cells into S phase. Also, 
decreased intracellular cyclic AMP levels result in the inhibition of cyclic AMP dependent 
protein kinase which, at high levels of enzyme activity, can inhibit cell proliferation. Therefore, 
the overexpression of p21 N-ras in NIH3T3 cells can result in increased cellular proliferation 
due to the activation and inhibition of at least two second messenger systems.
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that p2 1 -I&£ may interact with major signal transduction pathways in a still 
controversial manner. It appears that the ras oncogene, like many other 
oncogenes, causes tumour cell growth by utilising signalling pathways 
already active in a normally proliferating cell. 'Subversion' of these 
pathways, by mechanisms that may include the constitutive activation of 
particular components of these signal transduction cascades, can result in 
uncontrolled proliferation followed by cell transformation. Furthermore, it is 
probable that ras oncogene expression causes the expression of other 
cooperative oncogenes. The 'cure' for cancer, then, cannot be a single drug 
aimed at a single cellular target as from clinical, molecular biological and 
biochemical data, the process of cell proliferation and transformation is a 
multistep, cooperative process which still largely eludes us.
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